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SUMMARY OF THESIS
Breast caner is the commonest malignancy in women and a major cause of morbidity and
;
mortality in the western World. Well established risk factors for breast cancer are mostly
related to women’s reproductive history such as early menarche, late first pregnancy and 
late menopause. In recent years, survival is improving due to a combination of better f
health education with efficient large-scale use of screening mammography and earlier 
detection of breast cancer, as well as, improved surgical techniques and, in particular, 
widespread use of adjuvant therapy.
3
.Conventional clinico-pathologic foatures of the patient and primary tumour at initial
'Ipresentation such as age, tumour size and grade, nodal status and hormonal receptor 
status, are considered to be the key prognostic factors for predicting recurrence and 
survival and are used as a guide for appropriate therapy. However, the clinical course of
breast cancer may vary from an indolent slowly progressive one to that of rapid 
progression and metastatic spread, and with highly variable outcomes even when these 
factors are taken into account. Therefore, new prognostic and predictive indicators are
required to enable accurate assessment of outcomes and direct therapy towards those most
1
likely to benefit.
It is increasingly recognised that variations in outcome in cancer patients are not solely 
determined by the characteristics of the tumour but also by the host-response factors.
Cancer development and progression is dependent on a complex interaction of the tumour Iand the host inflammatory response. The local immune response with cell-mediated 
immune response and, in particular, the local environment of cytokines, proteases,
12
In patients with metastatic breast cancer, the prognosis is generally poor and prediction of 
outcome remains problematical. This prognostic uncertainty has driven the search for
i
.angiogenic and growth factors, and its subsequent systemic inflammatory response, may,
,in turn, stimulate tumour growth and metastasis. Recently, the systemic inflammatory
,
response, as evidenced by elevated circulating concentrations of C-reactive protein and/ 
or lowered albumin concentrations, has been shown to be stage independent prognostic
.factors in patients with a variety of cancers, including advanced systemic diseases, as well 
.as, following a potentially curative resection of primary operable tumours. However, this 
complex tumour-host interaction in patients with different staged breast cancer and its
: /L t  
:
prognostic value remains unclear.
well standardised laboratory-based parameters which have prognostic value in systemic
:
disease. Therefore, the value of systemic inflammation-based score (Glasgow Prognostic |
Score, GPS) was evaluated in patients with metastatic breast cancer (n=96). The GPS was 
constructed as follows; patients with both an elevated C-reactive protein (>10 mg/1) and 
hypoalbuminaemia (<35g/l) were allocated a score of 2. Patients in whom only one or 
none of these biochemical abnormalities was present were allocated a score of 1 or 0, 
respectively. The minimum fbllow-up was 7 months and the median fbllow-up of the
survivors was 16 months. During this period 51 patients died of their cancer. On I
multivariate analysis, only the GPS (HR 2.26, 95% Cl 1.45-3.52, P<0.001) remained |
significantly associated with cancer-specific survival. The median survival in these 
patients was 24 months, 13 months and 1 month for a GPS of 0, 1 and 2, respectively. 
Therefore, the presence of a systemic inflammatory response, the GPS that based on 
simple routinely available and well-standardised measurements, appeal's to be a useful 
independent indicator of poor outcome in patients with metastatic breast cancer. Y j
13
I|i
I
In patients with early-staged invasive disease, the prognostic value of the relationship 
between the systemic inflammatory response; as evidenced by elevated C-reactive protein 
and lowered albumin concentrations that were measured prior to surgery, standard 
clinico-pathologic factors and cancer outcome was examined in 300 patients with 
operable primary cancer. The median follow-up of the survivors was 46 months. During 
this period, 37 patients relapsed and 25 died of their cancer. On multivariate analysis only 
tumour size (P<0.05), albumin (P<0.01), and systemic treatment (P<0.0001) were 
significant independent predictors of relapse-free, cancer-specific and overall survival. 
Lower serum albumin concentrations (<43g/l) were associated with deprivation (P<0.05), 
hormonal-receptor negative tumours (P<0.01) and significantly poorer 3-year relapse-free 
(85% vs 93%, f=0.001), cancer-specific (87% vs 97%, P<0.0001) and overall survival 
(84% vs 94%, P=0.001) rates. Therefore, these results suggest that lower pre-operative 
albumin concentrations, but not elevated C-reactive protein concentrations, predict 
relapse-free, cancer-specific and overall survival, independent of clinico-pathologic status 
and treatment in patients undergoing potentially curative surgery for primary operable 
breast cancer.
The host-tumour interaction was further extended to examine the cell-mediated immune 
response, as evidenced by T-lymphocytic and macrophage infiltration, within the tumour 
microenvironment in association with tumour proliferative activity and micro vessel 
density, in a subset of 168 patients, to clarify then relationship with cancer outcome 
following potentially curative resection for primary operable breast cancer. Tumour 
CD4+ and CD8+ T-lymphocyte infiltration, CD68+ macrophage infiltration and CD34+ 
microvessel density were assessed using immunohistochemistry and slide counting 
techniques. The median follow-up of the suiwivors was 60 months. During this period, 20
14
patients relapsed and 15 died of their cancer. On univariate analysis, increased lymph 
node involvement (P<0.01), negative hormonal-receptor status (P<0.05), lower albumin 
concentrations (P<0.01), increased tumour Ki-67 labelling index (P<0.05), increased 
tumour microvessel density (P<0.05), the extent of loco-regional control (P<0.0001) and 
limited systemic treatment (P<0.01) were associated with both relapse-free and cancer- 
specific survival. Increased tumour grade and Ki-67 proliferative activity were associated 
with greater tumour infiltration of CD4+ and CD8+ T-lymphocytes (P<0.05), CD68+ 
macrophages (P<0.05) and CD34+ microvessel density (P<0.01) but not lowered albumin 
concentrations. On multivariate analysis, only pre-operative albumin (P<0.05), loco- 
regional treatment (P<0.01) and systemic treatment (P<0.05) were significant 
independent predictors of relapse-firee and cancer-specific survival.
In conclusion, the results of these studies suggest that tlie systemic inflammatory 
response, as measured by GPS, may be a useful tool in the assessment of survival in 
patients with systemic metastatic breast cancer. Moreover, the host inflammatory 
responses are closely related to poor tumour differentiation and hormone-negativity, and 
malignant disease progression in patients with early-staged invasive breast cancer. 
Furthennore, that the tumour-based cell mediated immune response and pathological 
factors are subordinate to the systemic factors, such as albumin, in determining survival in 
patients with primary loco-regional operable disease. Future prognostic studies should be 
large enough and over adequate follow-up time and should include all potential 
prognostic factors in the multivariate survival analysis.
15
CHAPTER 1: INTRODUCTION
16
■/I?
1.1 Epidemiology of breast cancer
1.1.1 Incidence and mortality L
Breast cancer is the most common malignancy in women and a major cause of mortality 
and morbidity. Worldwide, it accounts for more than a fifth of all cancers, with an 
estimated recent incidence of more than a million new patients per year, resulting in 
almost 373,000 deaths (Parkin et al., 2001 ; Boyle et al., 2003).
«
The incidence and mortality of breast cancer varies widely around the world, with North 
European countries. North American and Australia having the highest rates, and Asian Iand African countries the lowest (Key et al., 2001; Sasco, 2001; Boyle et al., 2003). In recent years, breast cancer incidence has been increasing in most countries, particularly in
several Asian and African countries (Sasco, 2001). Recent mortality rates have levelled
’Ioff or started to decline in many western countries, such as UK, United States, Canada
. ■ ; 4and Australia. Analysis of age-specific mortality rates shows that the change in mortality L
■shas occurred primarily in middle-age women and, to a lesser extent, in older women.
These trends are, at least in part, attributable to large-scale use of mammograghic 
screening, early detection of breast cancer and, in particular, to the widespread use of 
adjuvant therapy (Peto et al., 2000; Sasco, 2001; Jatoi and Miller, 2003).
In the UK, breast cancer continues to be the commonest cancer to affect women, with a
' Vrecent annual incidence of nearly 41,000 new patients per year, accounting for ahnost 30
' Îper cent of all new cancer cases in women, and with estimated lifetime risk of one in nine.
4 !
However, despite the increase in incidence, mortality rates have being falling steadily 
since 1990, probably due to a combination of factors including earlier diagnosis and 
improved treatment. In the year 2001, there were 12,994 breast cancer deaths compared to 
around 15,186 breast cancer deaths in 1992. It has been overtaken by lung cancer as tlie 
most common cause of death from malignancy in women (Cancer Research UK, 2003). I
■4 .
3
In Scotland, breast cancer is by far the most frequent cancer among women, accounting 
for 27% of cancer in women and with approximately 3,533 cases in 2001, Over the last 
decade, a substantial improvement in breast cancer survival has been observed with an 
obvious increase from 60% for patients diagnosed in 1977-1981 to 77% in 1997-2001.
%
This improvement is likely to be due to a combination of new treatments, particularly
4
hormonal therapy, earlier diagnosis of cancers in women participating in Scottish Breast 3
XèScreening Programme, and better organization and delivery of care for patients. Around f1.2% of women are living with breast cancer and the prevalence of breast cancer is
■'Iincreasing due to improvements in prognosis and increasing incidence (Scottish Cancer 
Registry, ISD, NHS National Seiwices Scotland; www.isdscotland.org.).
i
■I
s
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1.1.2 Aetiology and risk factors
(Spicer and Pike, 1999; McPherson et at., 2000; Key et ah, 2001; Sainsbury, 2001).
1.1.2.2 Age
,34
The search for specific breast cancer risk factors has been stimulated by the large 
difference in rates of breast cancer among countries worldwide, within countries over 
time, and by changes in rates among migrating population. In general, the causes of breast 
cancer are not fully understood, but epidemiological researches have clearly identified 
important factors that influence breast cancer risk (Table: 1.1). Known and suspected risk 
factors include the following:
1.1.2.1 Geographical variation
Marked geographical variation in the age-adjusted incidence and mortality of breast 
cancers is observed between countries. The difference between Far Eastern and Western
countries is diminishing, but the relative-risk difference is still around five-fold. Studies 
of immigrants from countries with a low-risk of breast cancer (eastern Asia) to one of 
higher-risk (United States) show that immigrants experience an increase in incidence of 
breast cancer, with a doubling of incidence rates within 10 years of arrival, and assume 
levels just below that of their adopted country within one or two generations, indicating 
that lifestyle and environmental factors are of greater importance than genetic factors
The incidence of breast cancer increases rapidly with age during the reproductive years, |  
being rare before the age of 25 and doubling about every 10 years until the menopause 
(about 50 years of age), when there is a slight levelling off before the incidence again 
rises, although at a reduced rate compared with the premenopausal years (McPherson et
18
menopause (McPherson et al., 2000; Sainsbury, 2001).
1.1.2.4 Childbearing
1
ah, 2000; Sainsbury, 2001). The cumulative incidence of breast cancer among women in 
Europe and North America is about 2.7% by age 55, about 5% by age 65, and about 7.7% 
by age 75 (Key et al., 2001).
1.1.2.3 Age at menarche and menopause
Women who have more menstrual cycles witli an early onset menarche (imder 12 years of 
age) and late menopause (over 55 years of age) have an increased risk of developing
breast cancer, resulting from increasing the time of exposure to the mitogenic effect of
ovarian hormones, in particular oestrogens (Gendy and Rainsbury, 2001a; Sasco, 2001; 
Cuzick, 2003). For each one-year delay in menarche, the risk decreases by around 5%, 
and for one-each year older at menopause, the risk increases by about 3% (Key et al., 
2001; Cuzick, 2003). Women who have a natural menopause after the age of 55 are twice 
as likely to develop breast cancer compared with those whose menopause occurs before
the age of 45. And those women who have had bilateral oophorectomy under the age of 
35 years have only 40% of the risk of breast cancer of women who have a natural
Childbearing appears to have a dual effect on the risk of breast cancer. Although, the risk 
is increased in the immediate period following childbirth; possibly reflecting the effects 
of oestrogen in pregnancy in causing extensive terminal ducts differentiation and their 
subsequent involution, this excess risk gradually diminishes and then, for the rest of 
women’s life, the effect of birth is rather to protect against the disease (Key et al., 2001; 
Cuzick, 2003). Late age at first full-term pregnancy and nulliparity increase the lifetime
19
risk of developing breast cancer. With an increase of around 3% for each one-year delay, 
the risk of breast cancer in women who have their first child after the age of 30 years is 
about twice that of women who have their first child before the age of 20 years. The
autosomal dominant gene with limited penetrance, which may be transmitted through 
either maternal or paternal lines (McPherson et al., 2000; Sainsbury, 2001). Two breast
I
liighest risk is for those who have their first child after the age of 35; these women seem 
to have even a higher risk than that associated with nulliparous women. An increasing %
protection against breast cancer is also observed with increasing the numbers of full-term 
pregnancies; with a decrease of around 7% per birth. Furthermore, an early age at birth of 
a second child further reduces the risk of breast cancer (McPherson et aL, 2000; Key et 
a l, 2001 ; Cuzick, 2003). î
1.1.2.5 Breast feeding |
The effect of breastfeeding on the risk of breast cancer has been examined. Studies fi'om 
Asian and less developed countries, where the duration of breastfeeding is substantially 
longer, have reported a protective association between breast-feeding and breast cancer.
Also, some studies from more developed countries have found that women who had 
breastfed for a total of 25 months or more had a 33% lower risk compared to those who
1 .Yi ■b:::
1
had never breastfed (Key et al., 2001).
1.1.2.6 Family history of breast cancer
Hereditary breast cancer accounts for approximately 5-10% of overall breast cancer in 
Western countries. It includes mutations in the genes BRCAl, BRCA2, p53, PTEN and
i'ATM  (Key et al., 2001). Breast cancer susceptibility is generally inherited as an |
..'■44
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cancer genes, BRCAl and BRCA2, have been responsible for a substantial proportion of 
very high-risk families, with a considerable life-time risk of developing breast cancer 
estimated as high as 50-80% among mutation carriers compared to the general population 
(Sasco, 2001; Cuzick, 2003). Inherited mutations in other rare genes, such as p53 and 
PTEN, are associated with familial syndromes (Li-Fraumeni cancer syndrome and 
Cowden’s disease, respectively) that include a high risk of breast cancer (McPherson el 
aL, 2000; Key et aL, 2001). Breast cancer risk increases with the number of relative 
affected (at least two different affected first-degree relatives), younger age at diagnosis, 
presence of bilateral breast cancer disease, male breast cancer or multiple primaries in the 
same women such as ovarian cancer and BRCAl and BRCA2 gene mutations (Table 1,2; 
McPherson et aL, 2000; Gendy and Rainsbury, 2001a; Sainsbury, 2001; Cuzick, 2003).
1.1.2.7 Previous benign breast disease and mammographie parenchymal patterns
History of prior breast biopsy for benign breast disease of specific epithelial abnormality 
increases the risk of breast cancer. Non-proliferative lesions are generally associated with 
little or no increase in breast cancer risk. Proliferative lesions without atypia confer an 
increase in the risk of about two-fold. While atypical hyperplasia is associated with an 
approximately four to five-fold increase in breast cancer risk, women with this change 
and also a family history of breast cancer (first degree relative) have a nine-fold increase 
in the risk (McPherson et aL, 2000; Key et aL, 2001).
The extent of mammographie opaque areas have been shown to be an important measure 
of the risk of developing breast cancer. Women with a large proportion of the breast 
consisting of radiodense tissue are at a higher risk of breast cancer than women with more
21
radiolucent breasts. Although, breast density decreases after the menopause, the risk is 
apparent for both pre- and post- menopausal women (Key et aL, 2001; Cuzick, 2003).
1.1.2.8 Radiation
Ionising radiation is the most well established environmental risk factor for increasing 
breast cancer later in life, particularly when exposure is during rapid breast foimation. A 
doubling of breast cancer risk was observed among teenage girls exposed to radiation 
during the Second World War (McPherson et aL, 2000). The relative risk for women 
exposed to ionising radiation before the age of 40 years ranges between 1.1 -  2.7 at 1 Gy 
(Key et aL, 2001).
1.1.2.9 Oral contraceptive
There is a small increase in the relative risk of developing breast cancer among women 
while taking oral contraceptive and for 10 years after stopping these agents. The use of 
oral contraceptives late in a women’s reproductive life will result in an increase of the 
relative risk at a time when the background risk is becoming appreciable. However, at 
young ages and when the use of oral contraceptives is common, the absolute risk is low 
(Key et aL, 2001; Cuzick, 2003). Cancers diagnosed in women taking oral contraceptive 
are less likely to be clinically advanced than those diagnosed in women who have never 
used these agent, with a relative risk of 0.88 (0.81-0.95) (McPherson et aL, 2000).
1.1.2.10 Hormonal replacement therapy
The use of hormonal replacement therapy for the menopause occurs during the prime risk 
period for breast cancer. Among current and recent users of hormonal replacement
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therapy, the relative risk of breast cancer increases with increasing the duration of use, but 
this excess diminishes after cessation of use. Long-term users (> 5 years) of oestrogen 
replacement therapy were observed to have a 35% increase in the risk of breast cancer; 
this risk appears to be higher with combined oestrogen and progestin preparations 
(Brewster and Helzlsouer, 2001; Key et al.  ^ 2001). The increase in breast cancer risk is 
consistent with the effect of delay in the menopause (McPherson et al., 2000). Current 
evidence, however, suggests that women taking hormonal replacement therapy do not 
develop poorer prognosis tumours (Stallard et al., 2000).
1.1.2.11 Weight
Postmenopausal obesity is associated with an increase in the risk of breast cancer; about 
50% higher among obese women (body-mass index > 3 0  kg/m^) compared with lean 
women (body-mass index 20 kgW ). But during the premenopausal years, it actually 
reduces the risk (McPherson et al., 2000; Key et al., 2001). This inverse relationship can 
be explained in terms of the differential effects of premenopausal and postmenopausal 
obesity on endogenous hormone levels. Premenopausal obesity decreases sex hormone 
binding globulin and minimally increases exposure to oestrogen, but decreases breast 
exposure to progesterone. Postmenopausally, the decrease in risk is gradually eliminated, 
and eventually, the increased bioavailable oestrogen levels associated with 
postmenopausal obesity, and which are determined by the conversion of fat in adipose 
tissue to oestrogen via aromatisation, produce an increase in the risk of breast cancer 
(Spicer and Pike, 1999; Cuzick, 2003).
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1.1.2,12 Life style and other environmental factors
Breast cancer is more common among women of higher socio-economic status than those 
of lower socio-economic status (Sainsbury, 2001).
Diet and nutrition are controversial factors in the risk of breast cancer. Although there is a 
close correlation between the incidence of breast cancer and dietary fat intake in 
populations, the true relation between fat intake and breast cancer does not appear to be 
particularly strong or consistent. Also, the evidences for the protective roles of fruits, 
vegetables, specific antioxident micronutrients, and dietary vitamins, such as vitamin C 
and E, have been inconclusive (McPherson et ah, 2000; Brewster and Helzlsouer, 2001; 
Key ah, 2001).
Alcohol consumption is associated with a moderate increase in the risk of breast cancer. 
Within the range of light to moderate alcohol intake, and with an increase risk in the order 
of 10% for each lOg alcohol (1 unit) / day, breast cancer seems to increase linearly. So, an 
intake of around 30g (3 units) per day is associated with an increased risk of around 30%. 
The basis for the increased risk associated with alcohol consumption is unclear, but may 
be caused by the influence of alcohol on the liver and so on hormone profiles (Brewster 
and Helzlsouer, 2001; Key et ah, 2001; Boyle et ah, 2003; Cuzick, 2003).
The possible role of cigarette smoking as a risk factor for breast cancer has remained 
controversial (Key et ah, 2001; Sasco, 2001).
Moderate physical activity has been reported to be associated with a lower risk of breast 
cancer, which seems to be stronger for premenopausal women than for postmenopausal
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women (Key et al., 2001). The risk reduction may result from the differences in 
endogenous sex steroid levels. In premenarcheal girls, strenuous exercise can delay the 
onset of menarche. And moderate exercise increases the probability of anovulatory cycles 
(Spicer and Pike, 1999).
m
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Table 1.1: Established and probable risk factors for breast cancer (from McPherson 
et aL, 2000).
Factor Relative risk Hish risk eroun
Age >10 Women aged over 50 years
Geographical location 5 Developed country
Age at menarche 3 Menarche before age 11
Age at menopause 2 Menopause after age 54
Age at first full pregnancy 3 First child in early 40s
Family history > 2 Breast cancer in first degree 
relative when young (before 
age 50)
4-6 Breast cancer in two first 
degree relatives (one before 
age 50)
Previous benign breast disease 4-5 Atypical hyperplasia
Cancer in other breast > 4
Socio-economic group 2 Group I and II
Diet 1.5 Fligh intake of saturated fat
Body weight:
- Premenopausal 0.7 Body mass index >35
- Post menopausal 2 Body mass index >35
Alcohol consumption 1.3 Excessive intake
Exposure to ionising radiation 3 Abnormal exposure in 
young females after age 10
Taking exogenous hormones: 
- Oral contraceptives 1.24 Current use
- Hormone replacement therapy 1.35 Use for > 10 years
- Diethylstilbestrol 2 Use during pregnancy
ii
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Table 1.2: Familial breast cancer (from McPherson et «/., 2000). 
Criteria for identifying women at substantial increased risk:
The following categories identify women who have three or more times the population 
risk of developing breast cancer.
A women who has:
- One first degree relative with bilateral breast cancer or breast and ovarian cancer or
- One first degree relative with breast cancer diagnosed under the age of 40 years or 
one first degree male relative with breast cancer diagnosed at any age or
- Two first or second degree relatives with breast cancer diagnosed under the age of 
60 years or ovarian cancer at any age on the same side of the family or
- Three first or second relatives with breast and ovarian cancer on the same side of 
the family.
First degree relative is mother, sister, or daughter.
Second degree female relative is grandmother, granddaughter, aunt, or niece.
Criteria for identifying women at very high risk in whom gene testing might be 
appropriate:
- Families with four or more relatives affected with either breast cancer or ovarian 
cancer in three generations and one alive affected relative.
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1.2 Anatomy of the breast
The basic structural unit of the mammary gland is the duct-lobular unit, which vary 
enormously in their number and size, from about 10 to over 100 lobules that empty via 
ductules in to a lactiferous duct; of which there are around 15-20 ducts. The glandular 
tissue, with its various relative amounts of supporting connective tissue and fat, lies 
within a superficial fasica, in which fibrous processes (Cooper’s ligaments) attach firmly 
to the deep and superficial layers of this fasica, and thereby to the overlying breast skin. 
The main bulk of the breast tissue is usually localized to its upper outer-quadrant (Figure: 
1.1; Ellis, 2004; Sainsbury, 2004).
Pectoralis minor muscle 
 ^ Pectoralis major muscle 
Adipose tissue
Areola
/ ■ /
^Lactiferous duct 
Lobules
Figure 1.1: Cross-section of the breast (from McCready, 2003).
28
The blood supply of the breast is a rich anastomotic network which is derived from 
internal thoracic artery (internal mammary), intercostals artery, and axillary artery that 
branches into superior thoracic, pectoral branch of the acromiothoracic, lateral thoracic.
2004).
supraclavicular nodes and drain into the subclavian lymph trunk, which enters the great 
veins directly, or via thoracic duct or jugular trunk. The internal thoracic (internal
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The adult female breast extends from the second rib above to the sixth rib below, and
'
from the lateral border of the sternum medially to the mid-axillary line laterally; with its 
superiolateral extremity extending into the axilla as the axillary tail. On its deep aspect, iabout two-thirds of the breast lies on the pectoralis major. It overlaps the serratus anterior i
IIlaterally and the upper part of rectus sheath inferiorly (Ellis, 2004; Sainsbury, 2004).
-iThe nipple with its surrounding areola is usually situated at the level of the fourth 
intercostals space in nulliparous women, but this position tends to be variable with
pendulous breasts. The nipple contains about 15-20 lactiferous ducts openings, and the
■Ê,areola contains numerous sweat and sebaceous glands (Ellis, 2004; Sainsbury, 2004). y |
I
:»rand subscapular. These arteries are accompanied by their corresponding veins (Ellis,
■ ' « V
The lymphatics of the breast drain predominantly into the axillary lymph nodes, which
receive nearly 75-85% of the breast drainage, and into the internal thoracic (internal
■;mammary) lymph nodes (Figure: 1.2). The axillary lymph nodes vary in number from 20-
■30 nodes, and often defined by clinicians and pathologists into three levels; as level I
(nodes inferior to pectoralis minor), level II (nodes behind pectoralis minor) and level III
.(nodes above pectoralis minor). The apical nodes are also in continuity with the
1
:■
mammary) lymph nodes are small, few (3-5 nodes) and lie along the internal thoracic 
vessels, deep to the plane of the costal cartilage (Figure: 1.2; Ellis, 2004; Sainsbury, 
2004).
^ ^ illa ry  vein
Level III n o d e s
Level 11 n odes
Internal
m am m ary
n o d e s
Pectoralis
m inor
Figure 1.2: Levels of axillary lymph nodes (from Bundred etaL, 2000).
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1,3 Pathology of breast cancer
Breast cancers arise from the epithelial cells that line the terminal duct-lobular unit 
(Sainsbury et al., 2000). The transition from a normal breast-epithelial cell into cancer 
cell is assumed to proceed in a stepwise fashion in the multi-step phenomenon of breast 
carcinogenesis (Figure: 1.3; Sakorafas and Tsiotou, 2000; Burstein et ah, 2004).
Breast cancer can be classified into pre-invasive {in situ carcinoma) and invasive cancer 
as follows:
1.3.1 In situ carcinomas of the breast
In situ carcinoma is the proliferation of epithelial cells that have undergone malignant 
transformation but remain confined within the basement membrane at their site of origin 
within the terminal duct-lobular unit and draining duct. As there are no lymphatics or 
blood vessels in the epithelial layer, in situ carcinoma offers no risk of metastasis until 
malignant cells cross the basement membrane (Sainsbury et a i, 2000; Sakorafas and 
Tsiotou, 2000).
Two types of in situ carcinoma of the breast have been described and comprise ductal 
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). Both arise from the 
terminal duct-lobular unit. However, there are significant clinical, morphological, and 
biological behavioural differences between the two types (Table: 1.3; Lagios and Page, 
1998; Finder, 2001).
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^^ommnEpithdSu^
Ductal Hyperplasiai
Atypical Ductal Hyperplasia
Ductal Carcinoma In Situ
Invasive Ductal Carcinoma
Metastasis
-S'
Figure 1.3: Multi-step breast carcinogenesis (from Sakorafas and Tsiotou, 2000; 
Burstein et aL, 2004).
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invasive malignancy relatively rapidly within 3-5 years. Whereas, low-grade DCIS may 
take 10-15 years to progress to invasive carcinoma. Also, previous autopsy studies 
suggest that latent DCIS is relatively common, however, not all DCIS progress to 
invasive breast cancer (Sakorafas and Tsiotou, 2000; Finder, 2001).
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1.3.1.1 Ductal carcinoma in situ (DCIS)
Ductal carcinoma in situ of the breast is a heterogeneous group of non-invasive 
neoplastic proliferations of the ductal epithelium that have several morphological 
variants, which differ markedly in gross and histological appearance, in molecular and 
cellular characteristics, and in their clinical behavioui*. DCIS appeal’s to behave as 
premalignant lesion in the process of multi-step breast carcinogenesis (Figure: 1.3). 
However, the biology of the process is relatively poorly understood. Because previous )'d':M
studies, which based on small series of patients with missed lesions or disease for which 
patients refused excision, indicate that about 50% of high-grade DCIS progresses to
Îi
i
The frequency of DCIS in symptomatic series of breast cancer is 2-5%, often presenting Ias a palpable mass. However, DCIS is increasingly identified in asymptomatic women at
'}breast-screening mammography as microcalcification, and in such series the frequency 1accounts for around 20-25% of all breast cancers (Finder, 2001 ; Foller, 2001).
■ f ;
DCIS may extend to the nipple along the major ducts and produce the characteristic Ieczematous appearance of Faget’s disease of the nipple. Faget’s disease is always 
accompanied by DCIS in the underlying subareolar ducts, although invasive carcinoma i*
may also be present (Finder, 2001).
I
Traditionally, DCIS has been subclassified on the basis of architectural and growth 
patterns into: comedo, cribriform, papillaiy, solid and micropapillary. However, this 
system has been superseded by a pathological classification that includes the nuclear 
grade of the tumour cells and the presence or absence of necrosis (Figure: 1.4), as these 
two features have been shown to be prognostically important, as well as, having high 
interobserver reproducibility among pathologists. Based on such criteria, tumour size and 
tumour- free margin, local treatment options include either: local excision alone, local 
excision plus radiotherapy, or mastectomy (Finder, 2001; Foller, 2001; Silverstein and 
Buchanan, 2003; Burstein et ah, 2004).
DCIS
Non- high grade
T V
Without necrosis With necrosis
Group 1 Group 2
High grade 
Group 3
Figure 1.4: Illustration of Scheme for the Van Nuys ductal carcinoma in situ (DCIS) 
Classification (from Poller, 2001).
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1.3.1.2 Lobular carcinoma in situ (LCIS)
Lobular carcinoma in situ is less common than DCIS. It is usually an incidental finding in 
breast tissue that has been removed for another disease process, such as fibrocystic 
change. LCIS is often multifocal and bilateral involvement occurs in up to 30% of cases. 
Follow-up studies have shovm that LCIS is generally considered to be a marker of 
increased risk (about tenfold) of future invasive malignancy rather than a true anatomic 
precursor lesion of invasive disease; any subsequent malignancy does not necessarily 
occur at the site of LCIS (Sakorafas and Tsiotou, 2000; Finder, 2001).
Table 1.3: Comparative features of ductal and lobular carcinoma in situ (from 
Lagios and Page, 1998).
DCIS LCIS
Average age Late 50s Late 40s
Menopausal status 70% Postmenopausal 70% Premenopausal
Clinical signs - Breast mass
- Fagef s disease
- Nipple discharge
None
Mammographie signs Microcalcification None
Risk of subsequent carcinoma 30% to 50% at 10 to 23% to 30% at 15 to
18 years 20 years
Site of subsequent invasive carcinoma
- Same breast 99% 50% to 60%
- Other breast 1% 40% to 50%
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ductal cai’cinoma does not necessarily arise from the duct (Schnitt and Guidi, 2000;
1.3,2.1 Invasive ductal carcinoma
■
11.3.2 Invasive carcinomas of the breast
Invasive breast carcinoma is defined as a malignant neoplasm of the mammary epithelial 
cells that have invaded beyond the native basement membrane at their site of origin of the ;'.:ÿ
terminal duct-lobular unit into the surrounding stroma. Invasive tumour cells may access 
lymphatic and blood vessels within the siurounding adjacent normal tissue through which
;it may metastasis to both regional lymph nodes and distant sites (Mizrachi, 1999). | |
II
Invasive breast cancers constitute a heterogeneous group of lesions that differ with regard <
■ .4A
classified on the basis of the cytologic-morphology features and growth pattern of the 
invasive tumour cells rather than structure of origin within the mammary duct system, as
f l
to their morphological types, pathological features and biological potential. They are
IÏ
Sainsbury et al., 2000; Finder, 2001). The main types are as follow; ' i
, s
Invasive ductal carcinoma is the most common histological type of invasive breast cancer, 
accounting for more than 50-70% of cases (Finder, 2001; Sainsbury, 2001). It includes
tumours with a range of histological appearance; from those with well-formed glands to | |
l |those that have little or no evidence of specific differentiation, alternatively known as - I'I“carcinoma of no special type (NST)” and “carcinoma not otherwise specified (NOS)”, in
.51which they are further categorised according to histological grade that takes into account 
the variation in appearance (Mizrachi, 1999). Histologically, it is often composed of cords 
and sheets of large pleomorphic malignant epithelial cells that penetrate the stromal I
ifibrous tissue haphazardly (Figure; 1.3; Finder, 2001).
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1.3.2.2 Invasive lobular carcinoma
Invasive lobular carcinoma is the second most frequent form, accounting for about 10- 
15% of all invasive breast cancer (Finder, 2001). It is characterized by multifocaiity in the 
ipsilateral breast and more frequently bilateral (Schnitt and Guidi, 2000). Histologically, 
it is formed from moderately sized, regular malignant cells often arranged in linear cords 
that diffusely infiltrate within fine collagen bands, giving the “Indian file” appearance 
pattern (Finder, 2001).
1.3.2.3 Invasive tubular carcinoma
Invasive tubular carcinoma is a special type cancer that is typically associated with 
limited metastatic potential and excellent prognosis (Schnitt and Guidi, 2000). It is 
uncommon in routine symptomatic practice, accounting for about 2% of invasive 
carcinomas. However, in screen-detected populations it comprises about 15% of invasive 
carcinoma. Histologically, there is central elastosis and elongated tubular structures 
radiated through a fibroblastic stroma. The tubules are lined by a single layer of malignant 
cells that form central lumina (Finder, 2001).
1.3.2.4 Other invasive breast cancers
Other special histological types of invasive breast carcinomas such as mucinous, 
medullary, papillary and invasive cribriform are usually have a better prognosis (Gendy 
and Rainsbury, 2001a). Other rare cancers may include adenoid cystic carcinoma, spindle 
cell/ metaplastic and squamous cancers (Schnitt and Guidi, 2000; Finder, 2001).
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1.3.3 Spread of breast cancer
The spread of primary breast cancer occurs by:
1.3.3.1 Local invasion
Local spread of malignant cells through the breast parenchyma occurs along mammary 
ducts, and as the tumour increases in size, by direct infiltration into other portions of the 
breast, and by the breast lymphatics. In advanced and untreated cases, it tends to involve 
the overlying skin and to penetrate deep to the pectoral muscles, and even the chest wall 
(Heilman and Harris, 2000; Sainsbury, 2004).
1.3.3.2 Lymphatic spread
The most common regional lymphatic node involvements in breast cancer occur primarily 
to the axillary lymph nodes and to the internal mammary lymph nodes chain. The site of 
the primary tumour within the breast does not dictate which nodes will be involved, 
because medial tumours spread to the axillary nodes just as readily as lateral tumours. In 
advanced disease, the supraclavicular nodes and any contralateral lymph nodes may also 
be involved by cancer spread (Heilman and Harris, 2000; Sainsbury, 2004).
1.3.3.3 Haematogenous spread
Tumour cells may disseminate, by the lymphatic and blood vascular systems, to a variety 
of organs, including most commonly bone, lung, liver, and brain. Skeletal metastasis 
occurs in the lumbar vertebrae, femur, thoracic vertebrae, ribs and skull; they are 
generally osteolytic. Occasional sites of metastasis may also occur in the adrenal glands 
and ovaries (Heilman and Harris, 2000; Singletary et ah, 2002a,b; Sainsbury, 2004).
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1.3.4 Histological grading of breast cancer
Because of the histological diversity of breast cancer, histological grading is considered 
as an essential component of the pathological assessment of breast cancer. The grading 
system measures the degree of differentiation of a carcinoma by microscopic 
examination, and based on a combination of scores for glandular (tubule) formation, 
nuclear grade; nuclear size/ degree of pleomorphism, and on mitotic rate (Table: 1.4; 
Elston and Ellis, 1991; Schnitt and Guidi, 2000).
1.3.5 Staging of breast cancer
The prognosis of breast cancer is related to the stage of the disease at presentation 
(Sainsbury et al., 2000). The staging system for breast carcinoma applies to both in situ 
and invasive (including microinvasive) carcinoma (Singletary et al., 2002a,b). The 
clinical staging that depends on the size of the primary tumour (T) along with regional 
lymph nodes status (N) and the presence or absence of distant métastasés (M) is a clinical 
assessment and hence may be inaccurate. Therefore, a separate pathological classification 
has been added which allows tumour size and lymph nodes status, as assessed by 
pathologist, to be taken into account. Patients with certain additional features, such as 
peau d’orange, skin involvement by tumour or inflammatory cancer (i.e., advanced local 
breast cancer), have a worse prognosis (Tables: 1.5 & 1.6; Sainsbury et ah, 2000; 
Bundred, 2001; Singletary et ah, 2002a,b).
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Table 1.4: Histological grading system of invasive breast cancer; Elston and Ellis 
modification of Bloom and Richardson grading system (from Elston and Ellis, 1991; 
Schnitt and Guidi, 2000).
Comnonents of grading Score
- Tubules
> 75% of tumour composed of tubules 1 point
10-75% of tumoui" composed of tubules 2 points
< 10% of tumour composed of tubules 3 points
- Nuclear grade
Nuclei small and uniform 1 point
Moderate variation in nuclear size and shape 2 points
Marked nuclear' pleomorphism 3 points
- Mitotic rate
Dependent on microscopic field ai'ea 1-3 points
Histological grade Total points
1 (Well differentiated) 3-5
2 (Moderately differentiated) 6-7
3 (Poorly differentiated) 8-9
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Table 1.5: TNM Staging system for breast cancer (from Singletary et aL, 2002a,b). 
Primary tumor (T):
TX Primary tumor cannot be assessed.
TO No evidence of primary tumor.
Tis Carcinoma in situ:
Tis (DCIS) Ductal carcinoma in situ.
Tis (LCIS) Lobular carcinoma in situ.
Tis (Paget) Paget’s disease of the nipple with no tumor.
Note: Paget’s disease associated with a tumor is classified according to the 
size of the tumor.
T 1 Tumor < 2 cm in greatest dimension:
Tlmic Microinvasion < 0.1 cm in greatest dimension.
T la Tumor >0.1 cm but not > 0.5 cm in greatest dimension.
Tib Tumor > 0.5 cm but not > 1 cm in greatest dimension.
T ic Tumor > 1 cm but not > 2 cm in greatest dimension.
T2 Tumor > 2 cm but not > 5 cm in greatest dimension.
T3 Tumor > 5 cm in greatest dimension
T4 Tumor of any size with direct extension to (a) chest wall or (b) skin, only
as described below:
T4a Extension to chest wall, not including pectoralis muscle.
T4b Oedema (including peau d’orange) or ulceration of the skin of the breast,
or satellite skin nodules confined to the same breast.
T4c Both T4a and T4b.
T4d Inflammatory carcinoma.
Regional lymph nodes (N):
NX Regional lymph nodes cannot be assessed (eg, previously removed).
NO No regional lymph node metastasis.
N 1 Metastasis in movable ipsilateral axillary lymph node(s).
N2 Métastasés in ipsilateral axillary lymph nodes fixed or matted, or in
clinically apparent* ipsilateral internal mammary nodes in the absence of 
clinically evident axillary lymph node metastasis:
N2a Metastasis in ipsilateral axillary lymph nodes fixed to one anotlier (matted)
or to other structures.
N2b Metastasis only in clinically apparent* ipsilateral internal mammary nodes
and in the absence of clinically evident axillary lymph node metastasis.
N3 Metastasis in ipsilateral inlfaclavicular lymph node(s), or in clinically
apparent* ipsilateral internal mammary lymph node(s) and in the presence 
of clinically evident axillary lymph node metastasis; or metastasis in 
ipsilateral supraclavicular lymph node(s) with or without axillary or 
internal mammary lymph node involvement:
N3a Metastasis in ipsilateral inffaclavicular lymph node(s) and axillary lymph
node(s).
N3b Metastasis in ipsilateral internal mammary lymph node(s) and axillary
lymph node(s).
N3c Metastasis in ipsilateral supraclavicular lymph node(s).
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Continuation of table 1.5: TNM Staging system for breast cancer (from Singletary et
al., 2002a,b).
Regional lymph nodes- Pathologic (pN)f:
pNX Regional lymph nodes cannot be assessed (eg, previously removed or not
removed for pathologic study). 
pNO No regional lymph node metastasis histologically, no additional
examination for isolated tumor cells J: 
pNO(i-) No regional lymph node metastasis histologically, negative IHC,
pNO(i+) No regional lymph node metastasis histologically, positive IHC, no IHC
cluster >0.2 mm.
pNO(mol-) No regional lymph node metastasis histologically, negative molecular
findings (RT-PCR).
pNO(mol+) No regional lymph node metastasis histologically, positive molecular 
findings (RT-PCR). 
pNlmi Micrometastasis (> 0.2 mm, none > 2.0 mm).
pNl Metastasis in one to three axillary lymph nodes and/or in internal
mammary nodes with microscopic disease detected by sentinel lymph node 
dissection but not clinically apparent §: 
pNla Metastasis in one to tliree axillary lymph nodes.
pNlb Metastasis in internal mammary nodes with microscopic disease detected
by sentinel lymph node dissection but not clinically apparent §. 
pNlc Metastasis in one to three axillary lymph nodes and in internal mammary
lymph nodes with microscopic disease detected by sentinel lymph node 
dissection but not clinically apparent §, II. 
pN2 Metastasis in four to nine axillary lymph nodes, or in clinically apparent*
internal mammary lymph nodes in the absence of axillary lymph node 
metastasis:
pN2a Metastasis in four to nine axillary lymph nodes (at least one tirnior deposit
> 2.0 mm).
pN2b Metastasis m clinically apparent* internal mammary lymph nodes in the
absence of axillary lymph node metastasis. 
pN3 Metastasis in 10 or more axillary lymph nodes, or in infraclavicular lymph
nodes, or in clinically apparent* ipsilateral internal mammary lymph nodes 
in the presence of one or more positive axillary lymph nodes; or in more 
than three axillary lymph nodes with clinically negative microscopic 
metastasis in internal mammary lymph nodes; or in ipsilateral 
supraclavicular lymph nodes: 
pN3a Metastasis in 10 or more axillary lymph nodes (at least one tumor deposit
> 2.0 mm), or metastasis to the infraclavicular lymph nodes.
pN3b Metastasis in clinically apparent* ipsilateral internal mammary lymph
nodes in the presence of one or more positive axillary lymph nodes; or in 
more than three axillary lymph nodes and in internal mammary lymph 
nodes with microscopic disease detected by sentinel lymph node dissection 
but not clinically apparent §. 
pN3c Metastasis in ipsilateral supraclavicular lymph nodes.
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Continuation of table 1.5: TNM Staging system for breast cancer (from Singletary et
aL, 2002a,b).
Distant metastasis (M):
MX Distant metastasis cannot be assessed,
MO No distant metastasis.
Ml Distant metastasis.
Abbreviations:
IHC, immunohistochemistry; RT-PCR, reverse transcriptase polymerase chain reaction.
* “Clinically apparent” is defined as detected by imaging studies (excluding 
lymphoscintigraphy) or by clinical examination.
t  Classification is based on axillary lymph node dissection with or without sentinel 
lymph node dissection. Classification based solely on sentinel lymph node dissection 
without subsequent axillary lymph node dissection is designated (sn) for “sentinel node” 
(eg, pNO(i+)(sn)).
X Isolated tumor cells are defined as single tumor cells or small cell clusters not greater 
than 0.2 mm, usually detected only by immunohistochemical or molecular methods but 
which may be verified on hematoxylin and eosin stains. Isolated tumor cells do not 
usually show evidence of metastatic activity (eg, proliferation or stromal reaction).
§ “Not clinically apparent” is defined as not detected by imaging studies (excluding 
lymphoscintigraphy) or by clinical examination.
II If associated with more than three positive axillary lymph nodes, the internal 
mammary nodes are classified as pN3b to reflect increased tumor burden.
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Table 1.6: TNM Stage grouping for breast cancer (from Singletary et al.^  2002a,b).
Stage Grouping TNM classification
0 Tis NO MO
I Tl* NO MO
IIA TO NI MO
Tl* NI MO
T2 NO MO
IIB T2 NI MO
T3 NO MO
IIIA TO N2 MO
Tl* N2 MO
T2 N2 MO
T3 NI MO
T3 N2 MO
IIIB T4 NO MO
T4 NI MO
T4 N2 MO
IIIC Any T N3 MO
IV Any T Any N Ml
*T1 includes Tlmic.
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1.3.6 Prognostic and predictive factors in breast cancer
The clinical course of breast cancer may vary from indolent slowly progressive one to a 
course associated with rapid progression and metastatic spread. Therefore, assessment of 
certain prognostic and predictive ‘markers’ or ‘factors’ in the pathological examination of 
breast tumours, in order to predict disease outcome, is becoming increasingly important in 
understandmg the natural history of breast cancer, planning treatment strategies and 
counselling patients (Henderson and Patek, 1998; Clark, 2000; Slooten ei al., 2001; 
Morabito et al., 2003; Cianfrocca and Goldstein, 2004; Esteva and Hortobagyi, 2004).
A prognostic factor is defined as any measurement or feature of the patient or tumoui* 
available at the time of diagnosis or surgery that is associated with outcomes, such as 
disease-free or overall survival, in the absence and independent of systemic therapy. 
Wliereas, a predictive factor is any measurement or feature in which its presence or 
absence signals resistance or sensitivity to a particular therapy independent of prognosis; 
it may or may not have prognostic value as well (Henderson and Patek, 1998; Clark, 
2000; Bundred, 2001; Slooten et al., 2001; Cianfrocca and Goldstein, 2004; Esteva and 
Hortobagyi, 2004).
Several established prognostic factors and a few predictive factors aie used routinely in 
the clinical management of breast cancer. Through the increased understanding of breast 
cancer biology, numerous other novel markers have been identified in recent years. These 
are in general either chronological; indicators of how long the cancer has been present, or 
biological; indicators of the metastatic potential behaviour of a tumour (Bundred, 2001;
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Cianfrocca and Goldstein, 2004; Esteva and Hortobagyi, 2004), and include the 
following:
1.3.6.1 Age
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'ABreast cancer tends to be more aggressive with poor prognosis in younger patients than in
:
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older. Recent studies have suggested that a young age of less than 35-40 years is 
associated with the worst prognostic pattern such as excess of high-grade tumour and 
axillary lymph-node metastasis, with the highest rates of necrosis, vascular invasion and 
proliferation, and lower ER expression levels, and subsequently, a poorer survival rate.
This poor outcome improves as age increases and is best in patients over 75 years of age.
In addition, patient age is important for predicting response to chemotherapy and 
hormonal therapy, as menopausal status is an age-dependent fector (Kroman et a l, 2000; 
Zavagno et al., 2000a; Bundred, 2001; Sundquist et al., 2002; Morabito et al., 2003).
I
1.3,6.2 Tumour size
f iTumour size is a time-dependent prognostic factor that correlates directly with survival.
The best measure of tumour size is maximum pathological size assessment since Ïradiological and clinical assessments may be inaccurate (Bundred, 2001; Finder, 2001). | |
Patients with small tumours have a better prognosis with a better long-term survival than 
those with larger tumours. The 20-year relapse-fiee survival rates for patients with 
tumours <10 mm in diameter have been reported to be around 88%; falling to 72% and 
59% for lesions measuring 11-30 mm and 31-50 mm in diameter, respectively. 
Nevertheless, 15-20% of tumours of < 10 mm in size have nodal metastasis, compared
Î
with 40% for lesions of more than 15 mm (Carter et ah, 1989; Bundred, 2001; Finder, 
2001; Rampaul et al., 2001a; Mirza et al., 2002; Cianfrocca and Goldstein, 2004).
1.3.6.3 Histological type/ grade
The liistopathological characteristics of the breast tumour have prognostic significance. 
Favourable prognosis of certain histological subtypes of invasive breast carcinoma, which 
based on architectural pattern of the tumour, is well established. Tubular, mucinous, 
papillary carcinomas, invasive cribriform, medullaiy, infiltrating lobular and tubulo- 
lobular types, together with rare tumours such as; adenoid cystic carcinoma, 
adenomyoepithelioma and low-grade adenosquamous carcinoma have all been reported to 
have a better prognosis than carcinoma of no special type (ductal NST) (Bundred, 2001; 
Rampaul et al., 2001a; Cianfrocca and Goldstein, 2004).
The histological grading of breast cancer, as determined by the combination of glandular 
(tubule) formation, nuclear grade and mitotic rate (Table: 1.4), correlates strongly with 
prognosis. Patients with grade I breast cancer have the best survival rate with 85% 10- 
year survival, compare with less than 45% for those patients with grade III tumours. This 
histological grading potentially provides an overview of a number of molecular events 
that are reflected in histological morphology, which includes detail of cell morphology 
(nuclear pleomorhism), with a measurement of differentiation (tubule formation), and an 
assessment of proliferation (mitotic frequency) (Elston and Ellis, 1991; Finder, 2001; 
Rampaul et al., 2001a; Mirza et al., 2002).
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1.3.6.4 Axillaiy lymph node status
The presence or absence of axillary nodal métastasés is the single most important 
prognostic factor for the disease-free and overall survival in breast cancer. It is a time- 
dependent factor and has a direct correlation with survival from breast cancer. Clinical 
assessment of nodal status is unreliable; as palpable nodes may be enlar ged because of 
benign reactive changes or secondary to biopsy whilst nodes bearing tumour deposit may 
be impalpable. Thus, careful histological examination should be carried out for all excised 
axillary lymph nodes (Finder, 2001; Rampaul et a/., 2001a). A large number of studies 
with histologically confirmed lymph-node involvement have shown that on average 10- 
year survival is reduced from 75% for patients with no nodal involvement to 25-30% for 
those with metastatic disease in the locoregional nodes. Prognosis worsens the greater the 
number of lymph nodes involved and metastasis to the higher axillary lymph nodes level, 
particularly those at the apex, carries a worsened outcome (Carter et a/., 1989; Bundred, 
2001; Finder, 2001; Rampaul et ah, 2001a; Cianfrocca and Goldstein, 2004). Node 
positivity is reasonably taken as a maiker of metastatic potential. However, this is only a 
qualitative, not a quantitative difference, as many patients with positive lymph nodes 
never develop distant métastasés, while many with negative nodes do. Axillaiy lymph 
nodes status has no predictive value for response to therapy (Henderson and Fatek, 1998; 
Morabito et aZ., 2003).
1.3.6.5 Lymphatic/ vascular invasion
Lymph-vascular invasion has been shown to be a significant prognostic factor in invasive 
breast cancer, particularly with respect to local recurrence and systemic relapse, and 
hence poorer overall survival (Finder et ah, 1994; Finder, 2001; Rampaul et ah, 2001a;
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Mirza et ah, 2002; Cianfrocca and Goldstein, 2004). The presence of lymph-vascnlar 
invasion, also, correlates closely with loco-regional lymph-node involvement, tumour 
grade, and size (Finder et ah, 1994).
1.3.6.6 Hormonal receptors
In breast cancer, the degree of oestrogen (ER) and progesterone (FR) hormone receptors 
expressions are considered prognostic and predictive factors (Henderson and Fatek, 1998; 
Cianfrocca and Goldstein, 2004).
The oestrogen and progesterone receptors are steroid receptors located in the cell nucleus. 
Hormone is believed to diffuse into or be transported to the nucleus where a steroid- 
receptor complex is formed with receptor dimerization. Some of the genes regulated by 
steroid receptors are involved in cell-growth control, and currently, it is believed that 
these effects are the most relevant to oestrogen receptor, which influence the behaviour 
and treatment of breast cancer (Rampaul et ah, 2001a).
As prognostic factor, it has been reported that survival of women with ER-positive 
cancers is longer, and with node negative breast cancer, ER status was a significant 
predictor of longer survival (Bundred, 2001). Nevertheless, oestrogen receptors are of 
limited value in predicting long-term survival, and any survival advantage of ER-FR- 
positivity is lost after 8-10 years of follow-up (Fichon et ah, 1996; Leinster, 1998). This is 
due to its close relationship with histological grade (Rampaul et ah, 2001a), and largely 
because women tend to survive longer after first relapse, following a better response to 
hormone therapy (Bundred, 2001).
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The value of these steroid receptors as a predictive factor for response to systemic 
endocrine therapy is well established. Approximately 30% of unselected patients with 
breast cancer will respond to endocrine therapy. However, with ER-positive tumours, a 
response in about 50-60% of patients is seen compared with less than 10% in patients 
with ER-negative tumours. Also, it has been suggested that the prediction of hormonal 
manipulation can be further refined by combining ER and PR assay, and that ER-PR- 
positive tumours carry a 78% response rates compared to less than 10% in patient with 
ER-PR-negative tumours, whilst ER-positive/PR-negative tumours have an intermediate 
respond rate of about 40% (Bundred, 2001; Rampaul et al., 2001a).
1.3.6.7 Human epidermal growth factor receptor-2
The presence of human epidermal growth factor receptor-2 (HER-2) gene amplification 
and/or protein overexpression have been shown to have both prognostic and predictive 
value in human breast cancer (Henderson and Fatek, 1998; Winston et al., 2004)
The HER-2 proto-oncogene (also known as c-erbB2 or neu) is located on chromosome 
17q21 and encodes a 185-kD transmembrane glycoprotein receptor (plSS™*^) that shares 
intrinsic tyrosine kinase activity homologous to type I subfamily of the epidermal growth 
factor receptors (Ross et al., 2003; Cianfrocca and Goldstein, 2004; Esteva and 
Flortobagyi, 2004). Immunohistochemistry (IHC) analysis and Fluorescent in situ 
hybridisation (FISH) are the most widely assays used to detect and measure HER-2 
protein expression and gene amplification, respectively (Winston et al., 2004).
HER-2 plays an important role in the pathogenesis of breast cancer and is associated with 
adverse prognostic significance, independent of all other prognostic variables. FIER-2/ncw
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gene amplification and/or protein over-expression has been identified in 40 to 60% of 
ductal carcinoma in situ that associated with more aggressive forms, and in 20-30% of 
invasive breast cancers, with most studies linking this to worse prognosis, both in axillary 
node positive and negative breast cancer, and poorer disease free and overall survival 
(Henderson and Patek, 1998; Walker, 2000; Bundred, 2001; Ross et aL, 2003; Cianfrocca 
and Goldstein, 2004; Esteva and Hortobagyi, 2004; Winston et al., 2004). Also, it has 
been associated consistently with high tumour grade, DNA aneuploidy, high cell 
proliferation, negative oestrogen and progesterone receptors, p5 3 mutation, topoisomerase 
Ila amplification, and alternations in a variety of other molecular biomarkers related to 
invasiveness and metastasis in breast cancer (Ross et al., 2003; Winston et al., 2004).
HER-2 status has attracted great interest as a potential predictor of endocrine and 
chemotherapeutic response, and more directly for the selective use of trastuzumab 
therapy; a humanized monoclonal antibody against HER-2 oncoprotein (Cianfrocca and 
Goldstein, 2004; Esteva and Hortobagyi, 2004; Winston et al., 2004).
Previous trials have shown HER-2 tumours to be inversely related to ER status and to 
predict resistance to hormonal therapy, specifically to the common antiestrogen agent 
tamoxifen. For example, women with HER-2 positive cancer, who were treated with a 
single agent tamoxifen adjuvant therapy, had a worse outcome than untreated control 
women. However, in others studies HER-2 status failed to predict tamoxifen resistance in 
oestrogen receptor positive cases (Bundred, 2001; Rampaul et al., 2001b; Ross et al., 
2003; Cianfrocca and Goldstein, 2004; Esteva and Hortobagyi, 2004).
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In addition, HER-2- positive tunionrs appeared to be resistance to alkylator-based 
chemotherapy (cyclophosphamide/ methotrexate/ 5-fluouracil; CMF), but sensitive to 
anthracycline-containing chemotherapy regimens. Compared to adjuvant CMF regimens, 
the addition of doxombicin to the chemotherapy regimens improved the clinical outcome 
of patients with HER-2 positive tumours sufficiently to render their prognosis similai’ to 
that of the more favourable prognosis FIER-2 negative group. Patients with HER-2 
positive tumours who did not receive doxorubicin had a significantly worse prognosis. 
(Walker, 2000; Bundred, 2001; Ross et al., 2003; Cianfrocca and Goldstein, 2004; Esteva 
and Hortobagyi, 2004). The predictive value of HER-2- positivity on response to taxane- 
based chemotherapy regimens has been controversial, with some studies suggesting 
increased response to paclitaxil rather than resistance (Ross et al., 2003; Cianfrocca and 
Goldstein, 2004).
The optimal use of HER-2 status, as a predictive factor, is for the selection of the 
humanized monoclonal anti-HER-2 antibody (trastuzumab or Herceptin®) as a direct 
target therapy against HER-2 positive tumours. Trastuzumab-based therapies either in 
combination with chemotherapy or as a single agent therapy, offered significant benefit 
and survival advantage, over chemotherapy alone, in advanced metastatic disease and 
relapsed-cases following conventional chemotherapy, respectively. In early-stage breast 
cancer, clinical trials are ongoing to determine its efficacy and safety in the adjuvant 
setting (Bundred, 2001; Ross et a l, 2003; Cianfrocca and Goldstein, 2004; Esteva and 
Hortobagyi, 2004).
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1.3.6.8 Tumour proliferation markers
Tumour proliferation plays an important role in the clinical behaviour of breast cancer,
and many of prognostic factors are directly or indirectly related to proliferation, such as I
cell-cycle regulators and growth factors or angiogenesis, respectively (Diest et ah, 2004).
Cellular proliferation takes place through a defined process, in which several phases can 
be recognised. From the resting (GO) phase, and after appropriate stimuli, cells join the 
active cycling population that enter die first gap (Gl) phase. Both phases have a highly 
variable duration. In G l, the cell prepares for the synthesis (S) phase, in which DNA 
synthesis and doubling of the genome take place. The S phase is then followed by a 
period of apparent inactivity, the second gap (G2) phase, in which die cell prepares for 
further separation of chromatids during the mitotic (M) phase. After the M phase, each 
daughter cell may enter GO phase or move on to the G1 phase to repeat the cell cycle. The 
inter-phase, including G l, S, and G2 phases, forms die largest part of the cell cycle, but 
cells in these phases cannot be morphologically recognised. However, cells in the mitotic 
phase can easily be identified because of die typical appearance of the chromosome sets
during the different sub-phase of the M phase (Diest et a i, 2004).
I
In invasive breast cancer, the prognostic values of various proliferation assays, including 
the S-phase fraction (SPF), thymidine labelling index (TLI), mitotic rate and Ki-67/ MIBl 
index, have been shown to be associated with prognosis in the majority of studies. 
However, teclinical difficulties and lack of standardization in measurements, have limited 
their clinical usefulness. Nevertheless, mitosis counting and the Ki-67/MIB-l 
proliferation index are considered to be the most practical methods to assess proliferation 
(Bundred, 2001 ; Cianfrocca and Goldstein, 2004; Diest et al., 2004).
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Mitosis counting, the oldest form of assessing proliferation, provides the most 
reproducible and independent prognostic value. It is the most well established component 
of the histological grading system in breast cancer (Morabito et a l, 2003; Diest et al., 
2004). Patients with tumour of increased mitotic index had a significant poor prognosis 
for overall and disease-free survival (Mirza et ah, 2002; Diest et al., 2004).
Ki-67 protein expression is strictly correlated to cell proliferation and to the active phases 
of the cell cycle (Gl, S, G2 and mitosis), but absent from the resting cells (GO), which 
makes it an excellent marker for assessing the growth fraction of a given tumour cell 
population, and in which the Ki-67/ MIBl monoclonal antibodies have been widely used 
for its immunohistochemical staining (Querzoli et al., 1996; Scholzen and Gerdes, 2000; 
Bundred, 2001; Mirza et al., 2002; Morabito et al., 2003).
The Ki-67 labelling index (Ki-67- positive tumours cells) has been shown to have strong 
correlations with other biological and histopathological markers of invasive breast cancer, 
and also, with the clinical course and outcome of the disease (Querzoli et ah, 1996; 
Scholzen and Gerdes, 2000; Bundred, 2001).
The Ki-67 proliferation indices have been found to coiTelate directly with histological 
grade, tumour size, axillary lymph node status, vascular invasion, p53 and HER-2 
overexpression, DNA and Thymidine labelling index score; and inversely with oestrogen 
and progesterone receptor status (Elston and Ellis, 1991; Querzoli et al., 1996; Morabito 
et a i, 2003.). Tumours with liigh Ki-67 proliferation index (>20%) were associated with a 
higher probability of disease-relapse and death, when compared with tumours of low 
proliferation rates (Veronese et al., 1993). Similarly, in patients with early-stage pTl
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tumour or node negative breast cancer, increased Ki-67 was a significant prognostic 
factor for overall survival and/or disease-free survival (Querzoli et aL, 1996; Mirza et al.,
2002). Therefore, Ki-67 labelling index is a promising prognostic marker of cell-cycle
I
proliferation in breast cancer.
1.3.6.9 Other markers
A number of other potential prognostic and predictive features, related to different tumour 
characteristics or indicative of the biological processes of cancer cells such as cell-cycle 
regulators (p53, c-myc, cyclins), proteases (urokinase, cathepsin D), and metastasis 
proteins (laminin 67 kDa receptor, nm23), have shown promising results in breast cancer, 
yet their role in patient management is at present not entirely clear (Bundred, 2001).
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1.3.7 The Nottingham Prognostic Index
The value of prognostic factors lies in a better quantifying of risk of recurrence and in 
defining low-risk patients, for whom adjuvant therapy is not indicated, and high-risk 
groups, who would most benefit from treatment. Currently, the Nottingham Prognostic 
Index (NPI; Table 1.7); based on tumour size, histological grade, and lymph node status, 
is the most practical integral measure available to assess individual patient’s prognosis, 
and thereby, stratify appropriate adjuvant therapy for patients with invasive primary 
operable breast cancer. In several independent prospective studies, the Nottingham 
Prognostic Index has been found to give valuable prognostic information, and due to its 
simplicity, it is suitable for routine clinical use (Haybittle et al, 1982; Todd et ah, 1987; 
Galea et a l, 1992; Brown et ah, 1993; Fisher et al., 2001 ; Rampaul et al., 2001a).
Table 1.7: Nottingham Prognostic Index (NPI) (from Galea et al,, 1992, Gendy and 
Rainsbury, 2001a).
Nottingham Prognostic Index (NPI):
NPI = (0.2 X tumour size /cm) + lymph node stage + tumour grade
Factor:
Involved nodes
0
1-3
>3
Tumour grade
I
II
III
Score /factor
1
2
3
NPI
<3.4
3.4-54
>5.4
Prognosis
Good
Moderate
Poor
Survival (15 vearsi
80%
42%
13%
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1.4 Management of breast cancer
Breast cancer management is a rapidly evolving field. Optimal management with 
improved outcomes of patients with breast cancer have been achieved through a co­
ordinated multimodality approach that require inputs from surgeons, radiologists, 
pathologists, oncologists, radiotherapist and psychologists with special interest in breast 
diseases, as well as, general practitioners, breast-care nurses and the women herself. 
Several studies have shown a better outcome with such multidisciplinary specialist 
treatment, which may relate to sufficient workloads and more frequent use of appropriate 
systemic therapy (Sainsbury et al., 1995; Gillis and Hole, 1996; Blichert-tofr et ah, 1997; 
Golledge et ah, 2000).
The purpose of the multidisciplinary approach is to design appropriate individualized 
treatment plans for all patients who require coordinated multi-specialty care. It lies in 
having a clear appreciation of the objectives of treatment and knowing its limitations and 
unwanted effects, in the context of individual patient. The objectives that need to be 
considered include cure, local control, survival, and cosmetic, social and psychological 
consequences of the diagnosis and treatment of breast cancer (Webster, 2001),
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1.4.1 Clinical presentation and assessment of breast cancer
In the UK, about 5 % of patients with breast cancers will present with either locally 
advanced disease or with symptoms of metastatic disease, but in developing World this 
figure is near 20% (Sainsbury, 2004). The widespread use of screening mammography, 
which started as UK NHS Breast Screening Programme (NHSBSP) in the late 1980s, has '.:U '
enable the diagnosis of small impalpable breast cancer and ductal carcinoma in situ 
(Pinder, 2001).
The preoperative diagnosis of breast cancer can be established using the ‘triple 
assessment’, which is a combination of clinical assessment that include both history and 
physical examination, imaging with mammography and/or ultrasonography, and cyto- 
histologicai conformation using fine-needle aspiration cytology (FNAC) and/or core 
biopsy. The diagnostic accuracy, when all three methods agree, exceeds 99%. But when
doubt exists after the triple assessment, then an open biopsy is indicated (Gendy and 
Rainsbury, 2001b).
A comprehensive history and review of systems are required to reveal the extent and 
characters of the breast lesions (such as hard painless palpable lumps, nipple discharge, 
retraction and rash) and help identifying patients with advanced and metastatic diseases
" I
(such as axillary mass, peau d’orange, ulceration or fungating breast mass, symptoms of
■ ! ■metastasis, such as skeletal pain), as well as, to reveal aetiological and risk factors (such
".Ias previous history of breast disease and management, family history of breast and a
ovarian cancer) and current co-morbidities and medications that may influence treatment " 
decisions (Cliianakwalam and Bates, 2001; Gendy and Rainsbury, 2001b).
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Breast cancers develop most frequently in the upper outer quadrants, but any portion of 
the breast, including the axillary tail, may be involved (Sainsbury, 2004). Physical signs 
suggestive of malignancy include firm breast mass with poorly defined margins, skin 
nodules, tethering, distortion and ulceration, nipple retraction, fixation to underlying 
structures, and palpable axillary or supraclavicular nodes. Any other symptomatic regions 
should be examined as required to identify or exclude metastatic spread. In a specialist 
breast clinic, clinical examination has an overall sensitivity for cancers of over 80%, but 
this value tends to be much lower in premenopausal women with nodular breast 
(Chianakwalam and Bates, 2001; Gendy and Rainsbuiy, 2001b).
Mammographie examination is one of the most effective methods for the detection of 
breast cancer, with a sensitivity of about 90% and a specificity of about 87%. Standard 
mammography comprises a craniocaudal and mediolateral oblique views of the breast, 
which may be augmented by coned compression and magnification views in certain cases. 
Suggestive mammographie appearance of malignancy includes; a speculated mass, 
isolated density, asymmetry, architectural distortion, stellate lesions and calcification 
(Blarney et a l, 2000; Chianakwalam and Bates, 2001; Gendy and Rainsbury, 2001b). 
Despite the recent controversy on the value of mammographie screening, as a result of 
suboptimal randomisation or inadequate methodology in some previous trials, regular 
screening has been shown to reduce breast cancer mortality, for example, by 
approximately 27% in the “UK Trial of Early Detection of Breast Cancer”, with the 
greatest reduction of about 33% observed in women aged 60-69 years (Alexander et al., 
1999; UK Trial of Early Detection of Breast Cancer group, 1999; Gotzsche and Olsen, 
2000; Nystrom et al., 2002; Tabar et al., 2003; Freedman et al., 2004). Screen-detected 
cancers are significantly smaller, more likely to be non- invasive {in situ) tumours, and
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any invasive cancers are more likely to be of better histological grade and type, and are 
less likely to be node positive than symptomatic cancers (Nisbet and Borthwick-Clarke, 
1999; Blamey et ah, 2000; Sainsbmy, 2001). Mammography is required before planning 
surgery to identify extensive tumours or any additional cancers in either breast. Also, it is 
used for localization of impalpable lesion for FNAC, core biopsy or surgical excision, in 
addition, as surveillance of breast-cancer survivors post-treatment, and for other Ingh-risk 
patients (Gendy and Rainsbury, 2001b).
The use of ultrasound as an adjunct to mammography in the diagnosis of breast cancer is 
well established. It may be the only modality to suggest malignancy in about 3% of 
patients with palpable breast lumps when mammography and FNAC are normal. It has a 
sensitivity of about 75% and a specificity of about 90% for the diagnosis of malignancy. 
On ultrasound, malignant tumours are usually of mixed echogenicity with irregular 
outline and cast distal hypoechoic shadows. Ultrasonograhy is a more valuable diagnostic 
tool in young women of less than 35 years of age, where mammography is less sensitive. 
It can be used for localizing impalpable breast lesions, for accurate measurement of breast 
cancer before selecting appropriate surgical procedure or for monitoring tumour response 
to primary systemic therapy (Chianakwalam and Bates, 2001; Gendy and Rainsbury, 
2001b).
A preoperative tissue-diagnosis can be obtained in the majority of patients using 
alternative biopsy techniques that include fine-needle aspiration cytology and/ or core­
needle biopsy, rather than excisional biopsy. Fine-needle aspiration cytology and core 
biopsy are both fast and simple techniques, requiring only local anaesthesia and leave 
minimal scarring compared with excisional biopsy. These techniques can accurately
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diagnose the breast lesions in more than 90% of patients with palpable breast tumours 
(Singletary, 2001).
Routine preoperative investigations include a full blood count, liver function test, with 
alkaline phosphatase and calcium levels, in addition to, chest radiography. Extensive 
imaging and other special testing such as liver ultrasonography and isotope bone scanning 
are not required in a clinically negative history and physical examination, which are 
sufficient to designate a case as MO. However, appropriate specific tests are indicated for 
patients with symptoms suggestive of metastatic disease or as a follow-up to the first 
round of tests if they are abnormal (Gendy and Rainsbury, 2001b; Webster, 2001; 
Singletary et a l, 2002a,b).
At present, there are no reliable semm tumour markers for breast cancer. CA 15-3 shows 
some promise in a few specific circumstances, but it is of limited value in clinical 
practice. It is raised in 70-80% of metastatic breast cancer, but only in 30% of early 
disease that confined to the breast. However, CA 15-3 is occasionally of value in 
assessing response and monitoring treatment of patients with metastatic disease and in 
lesions that are otherwise not evaluable. CA27-29 and carcinoembryonic antigen (CEA) 
may also be used to monitor response to treatment and detect relapse in breast cancer 
(Petersen et al., 2001; Webster, 2001; Emens and Davidson, 2003).
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1.4.2 Surgical treatment
In patients with early-stage breast cancer, surgery remains the first treatment modality to 
achieve local control, and in locally advanced breast cancer with fimgating tumoui', ‘toilet 
mastectomy’ may be required to control symptoms such as bleeding, discomfort, and 
pain.
In the elderly, breast cancer has been considered to be a more indolent disease compared 
to younger women. However, the omission of primary surgery in those elderly patients 
with operable breast cancer who were fit for the procedure has been shown to result in 
earlier subsequent therapeutic intervention and increased mortality (Bates et al., 2001).
The surgical treatment of breast cancer has evolved into two methods; either mastectomy 
or breast conservation, with or without reconstruction. Both should be combined with an 
axillary procedure.
1.4.2.1 Mastectomy
Mastectomy, removing all breast tissue, is considered to be the standard surgical 
treatment to which other treatments need to be compared. It is indicated for large tumours 
in relation to the breast size, multifocal primary tumours, central tumours beneath or 
involving the nipple in a small breast, following local recurrence in patients with previous 
breast conservation surgery, for lack of patient’s commitment to undergo radiotherapy 
after breast conservation, or for patient preference. Other clinical and pathological factors 
that may influence the selection of mastectomy over wide local excision, due to their 
impact on loco-regional recurrence following breast conservation surgery, include
62
incomplete initial excision, presence of extensive in situ component or lymph-vascular 
invasion, poor histological grade and younger age (Table: 1.8; Sainsbury et aL, 2000).
The radical Halsted mastectomy, that excises the breast, axillary lymph nodes, and both 
pectoralis major and pectoralis minor muscles, is no longer indicated as it causes 
excessive morbidity with no smwival advantages. Modified radical (Tatey’) mastectomy 
is the procedure more commonly performed. It dissects the whole breast and associated 
structures including a large portion of skin, the centre of which overlies the tumours and 
also the nipple, and all axillary fat, fascia and lymph nodes bloc\ with the pectoralis 
minor muscle either divided or retracted to access the axilla. Simple mastectomy involves 
only the removal of the breast tissue, with no dissection of the axilla, except for the region 
of axillary tail tliat usually has few lymph nodes of the low anterior group attached to it. 
Simple mastectomy is often followed by radiotherapy to axilla, because no pathological 
staging of the axillary lymph nodes is performed with this procedure (Sainsbury, 2004).
Following mastectomy, common immediate complications include haematoma and 
seroma formation, infection and flap necrosis. Factors associated with increased long­
term risk of loco-regional recurrence in the skin flap include large tumour > 4cm in 
pathological examination, grade III carcinoma, axillary lymph nodes involvement and 
lymphatic-vascular invasion (Sainsbury et aL, 2000; Sainsbury, 2004),
1.4.2.2 Breast conservation surgery
Breast conserving surgery with breast radiotherapy is now the preferred method of local 
treatment for most women with early-stage breast cancer and, to some extent, for those 
patients with larger tumours that have been downstaged through neoadjuvant therapy.
63
Many randomised controlled studies have shown no significant differences in disease-free 
survival or overall survival after breast conservation surgery combined with radiotherapy 
compared to mastectomy, when both included axillary dissection (Blichert-Toft, 1992; 
Calais et aL, 1994; Fisher et aL, 1995; Van Dongen et aL, 2000; Veronesi et aL, 2002; 
Poggi et aL, 2003; Kroman et al., 2004).
Breast conserving surgery is suitable for clinically and mammographically unifocal 
tumours of < 4cm in diameter, or of > 4cm in large breast, and with no sign of local 
advancement (i.e., Ti, < 4cm) or extensive nodal involvement (i.e., No, Ni) or 
métastasés. There is no age limit for breast conservation therapy. However, patients who 
have had prior radiotherapy that have included the breasts in its field are not suitable for 
breast conservation, as well as, those with collagen vascular diseases who could be 
negatively affected by combined radiotherapy (Sainsbury et aL, 2000; Singletary, 2001).
Breast conservation surgery can be achieved with wide local excision, which consist of 
excision of the tumour with about 1 cm of the surrounding normal tissue and skin if 
necessary, or quadrantectomy, which is a more extensive resection of a whole quadrant of 
the breast. The aim is to excise all tumour tissue, preferably in one piece, with adequate 
margins, while maintaining acceptable cosmetic results, and to confirm histologically that 
the margins are free of tumour. Otherwise, a higher incidence of local recurrence is 
anticipated. Any margin < 5mm should be regarded with suspicion and any clearance < 
1mm should be regarded as incomplete. Further local re-excision, if feasible, or 
mastectomy is indicated for margins with incomplete excision. Other risk factors for loco- 
regional recurrence of breast cancer following breast conserving surgery are shown in 
Table 1.8 (Sainsbury et aL, 2000; Singletary, 2001; Webster, 2001).
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Table 1.8: Risk factors for local recurrence of breast cancer after breast 
conservation (from Sainsbury et aL, 2000).
Factor Relative risk
- Involved resection margins x3-4
- Extensive in situ component X 3
- Patient’s age < 35(versus age >50) X 3
- Lymphatic or vascular invasion X 2
- Histological grade II or III (versus grade I) X 1.5
1.4.2.3 Breast reconstruction
Breast reconstmction after breast cancer surgery is a safe and acceptable procedure. It 
aims to restore the normal shape and, to some extent, consistency of the breast after 
excisional surgery (quadrantectomy or large wide local excision) or after mastectomy. 
Evidences on psychological and cosmetic benefits and on cost advantages are well 
documented, particularly, for immediate reconstruction. Moreover, breast reconstruction 
does not appear to interfere with subsequent oncological adjuvant therapy or detection of 
loco-regional recurrence and, also, does not compromise survival (Johnson et ah, 1989; 
Sandelin et ah, 1998; Malata et aL, 2000; Sainsbury, 2001; Singletary, 2001; Grotting et 
al,, 2003; Langstein et aL, 2003).
Breast reconstruction can be performed either as an immediate procedure at the time of 
initial breast surgery or as a delayed procedure. It can be achieved using either implant- 
based reconstruction (with silicone-gel or saline-filled implant) or autologous tissue
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1.4.2.4 Axillaiy management
':sreconstruction (such as the latissimus dorsi or transverse rectus abdominis myocutaneous 
flaps; either with ‘pedicle’ or ‘free’ flap), or a combination of both techniques. In 
addition, skin-sparing mastectomy, which preserves the original breast skin envelope and #
natural peripheral landmarks including the inframammary fold, may be considered for 
women with noimal-size breasts and minimal ptosis that have small primaiy tumours 
situated deep in breast parenchyma without skin involvement. It can provide superior 
cosmetic result, with reduced breast scarring and preserved breast sensation, without 
compromising oncological safety and outcome. The nipple-areolar complex can be ;f; 
created, under local anaesthesia, using a small skin flaps that have been raised from the 
surrounding breast mound, and aided with medical-grade pigments tattooing. Implant-
■
based breast reconstructions, however, are not recommended for women who have 
.received or will receive radiotherapy. Many women may also need surgery to the contra-
: ïlateral breast such as reduction mammoplasty, mastopexy or augmentation to achieve |;
symmetry (Malata et aL, 2000; Sainsbury, 2001 ; Singletary, 2001 ; Grotting et aL, 2003). | |
"External prosthesis could be worn or attached to the chest wall under bra. Artificial 
nipple-areolar complex may, also, be created using colour-matched silastic prosthesis. 
However, they may feel unnatural and may associate with patient unsatisfaction
(Sainsbury, 2001).
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In breast cancer, axillary node status is crucial for staging, prognosis, and frequently 
directs the use of adjuvant systemic therapy in the management of eaiiy disease. It ranges 
from sampling; which should probably have four or more lymph nodes, to a level III
clearance; which should yield an average of 20 or more lymph nodes. It aims for the
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with primary breast cancer and a possible survival advantage (Kjaergaard et aL, 1985; 
Steele et aL, 1985; O’Dwyer, 1991; Cabanes et aL, 1992; Kutiyanawala et aL, 1998;
disease is demonstrated in about 40%-46% of patients, but in tumours less than 1 cm in 
size, the incidence of axillary metastasis falls to 22%; the remaining patients receive no 
benefit from axillary dissection and are exposed to the morbidity associated with axillary 
dissection. Without any axillary treatment, only 21% of patients will develop axillary 
metastatic tumour in their lifetime (Carpenter, 2001; Humzah, 2001).
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f
histological assessment of nodal metastasis, and the additional clearance allows regional ;S.
control to minimize the risk of axillary recurrence, reduces the incidence of long-term | |
complications, when compared with axillary node sampling and radiotherapy, in patients | |
Carpenter, 2001 ; Webster, 2001 ). ; |='.|:I
11
Axillary lymph node dissection remains the gold standard for both staging and prognosis.
It is a major operation that requires general anaesthesia, and is either performed in 
continuity with a mastectomy or through a separate incision with a wide local excision.
■ ;
This procedure, however, has several sequelae and complications, including seroma, 
wound infection, pain, numbness or paraesthesia, reduced shoulder movements, chronic 
lymphoedema, in addition to, the emotional distress that associate with these short and 
long-term complications (O’Dwyer, 1991; Chetty et aL, 2000; Webster, 2001; Posther et 
aL, 2004). The acute complication rate can be as high as 20- 30%, and long-term ■'1morbidities such as chronic lymphoedema can reach 20% to 30%. Recurrence rates II 
following axillary clearance are 1-3% (Boolbol and Borgen, 2001; Carpenter, 2001). |
The high morbidity has been accepted as a necessary consequence of the need to obtain
■ iïï 
. -À,;;axillary node status and to achieve regional disease control. However, metastatic nodal "J-!:
i
The improvement in early diagnosis has led to an increasing number of axillary dissection 
cases in which axillary nodes are found to be negative (Zavagno et aL, 2000b). It has been 
suggested that axillary lymph node dissection could be avoided in group of patients with 
clinically negative axillary node for whom the risk of nodal involvement is so low.
S'*’
including patients with pure tubular or mucinous carcinoma of < 15 mm, tumour of <
5mm, or with negative lymphovasculai' invasion (Chua et aL, 2001). Nodal metastasis are 
seen in less than 1% of cases with pure tubular carcinoma < 1cm in diameter, and in about 
3% of patients with microinvasive carcinoma (Singletary, 2001). Therefore, a selective
policy for the management of the axilla in patients with operable breast cancer has also 
been found to be associated with no increase in axillary recurrence or mortality rate 
compared with routine axillary clearance. Patients who are node negative after axillary 
sampling can avoid axillary clearance or radiotherapy (Chetty et aL, 2000).
i
Sentinel lymph node biopsy, a major development in the field of surgical oncology, has IIrapidly emerged within the last decade as an alternative staging method to axillary lymph node dissection to detect occult lymph-node métastasés in patients with clinically node­
negative invasive breast cancer (Boolbol and Borgen, 2001; Humzah, 2001; Kelley et aL, 
2004). It is based on the observation that specific areas of the breast drain by way of
I
i
efferent lymphatics to a specific lymph node (sentinel lymph node), and then to other
lymph nodes in the basin. As the sentinel node is the first node to receive the lymphatic
flow from the primary tumour, it is assumed that if the sentinel node is correctly
identified and is free of neoplastic cells, then the other axillary nodes ai e also negative. It 
..........................................is a minimally invasive technique that avoids the morbidity associated with formal
'Îaxillary clearance, by excluding negative axillae fi*om unnecessary dissection (Zavagno et 
aL, 2000b; Carpenter, 2001; Humzah, 2001; Singletary, 2001; Kelley et aL, 2004).
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The sentinel lymph node can be located by injecting a tracer material, such as blue dye or 
radiolabelled particles, deep into or around the primary tumour (peritumoural), or 
superficial into the skin over the tumour site (subdermal, intradermal) or into the 
subareolar tissue. The blue dye allows the direct visualization of the lymphatic channels 
that lead to the marked lymph node in the axilla, whereas, the radioactive tracer facilitates 
the detection of the radioactive nodes prior to the surgical exposure of tissues by a hand­
held gamma probe (Singletary, 2001; Krag and Harlow, 2003; Kelley et aL, 2004; 
Noguchi, 2004). The identification rates have been demonstrated to be superior with a 
combination of both techniques, rather than either method alone (Carpenter, 2001; Kelley 
et al,, 2004; Posther et aL, 2004). In addition, preoperative lymphoscintigraphy may be 
performed to visualize the sentinel lymph node before surgery. However, its value is still 
a matter of debate (Singletary, 2001; Kelley et aL, 2004; Noguchi, 2004).
In North America and Europe, the sentinel lymph node biopsy has become a 
commonplace in the management of patients with clinically node-negative breast cancer, 
and published data on its efficacy are promising (Flett et aL, 1998; Zavagno et aL, 2000b; 
Humzah, 2001; Kelley et aL, 2004; Posther ei aL, 2004). In a recent meta-analysis using 
variety of techniques, and where sentinel node biopsies were followed by axillary 
dissections, 84% of sentinel nodes were identified with a false negative rate of 5%, but 
other series reported 100% accuracy for tumours less than 1cm. The identification rates 
were also liigher with injection around intact tumours (96%), with invasive cancer (95%), 
and in clinically negative axilla (96%; Carpenter, 2001).
The histological assessment of the sentinel nodes can be more detailed when compared 
with an axillaiy clearance specimen, allowing understaging such as with micrometastases
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to be corrected (Zavagno et aL, 2000b). This is usually carried out using techniques of 
serial sectioning of the retrieved lymph-node specimen, with Haematoxylin-Eosin and 
immunohistochemical staining (Carpenter, 2001). Molecular detection technique, based 
on reverse transcriptase-polymerase chain reaction, has also been incorporated at some 
centres. However, the clinical significance of micrometastases identified by such 
techniques remains to be determined (Posther et aL, 2004).
The internal mammary sentinel node biopsy has also been found to be feasible without 
serious additional complications. It improves nodal staging by identifying higher-risk 
subgroups of patients with internal mammary nodal métastasés, that occurs in 
approximately 20% of patients and which has been shown to have an adverse effect on 
survival. Such patients might benefit from altered adjuvant treatment regimens (Van der 
Ent et aL, 2001). However, the practicability of this procedure is still in the investigation 
stage (Kelley et aL, 2004; Noguchi, 2004).
Factors that could affect the identification of sentinel node and associate with high false- 
negative rates include large tumour, previous surgery, palpable lymph nodes, increasing 
patient age and the surgeon’s sentinel lymph node biopsy experience. Other problems that 
need to be resolved are the potential adverse outcomes relating, for example, to regional 
recurrence and survival following its use (Carpenter, 2001; Singletary, 2001; Krag and 
Harlow, 2003; Kelley et aL, 2004; Posther et aL, 2004). Wlien strict criteria are used, the 
sentinel node biopsy, without further axillary dissection after a negative histological 
investigation, is believed to be a safe accurate predictor of nodal status. Therefore, it may 
considered to be the standard of care for the management of patients with early-stage 
diseases (Carpenter, 2001; Roumen et aL, 2001; Smillie et aL, 2001; Posther et aL, 2004).
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1.4,3 Radiotherapy in breast cancer
. . .Radiation therapy is an essential pait of the management of breast cancer. It is indicated 
as a part of the primary treatment if breast conserving surgery has been performed, and in 
selective cases following mastectomy. It may be given to the breast, axilla, chest wall, 
and supra- and infra-clavicular fossa and internal mammary node chain. In patients with 
advanced disease, local radiotherapy may also be used as a palliative therapy to relief 
symptoms such as painful bone métastasés (Webster, 2001; Kurtz, 2002).
Breast conservation surgery, as an alternative to mastectomy, is only made possible by the 
use of adjuvant radiotherapy. Disease-free and overall survival after breast conserving 
surgery, combined with radiotherapy, was equivalent to that following mastectomy 
(Blichert-Toft, 1992; Fisher et aL, 1995; Van Dongen et aL, 2000; Veronesi et aL, 2002; 
Poggi et aL, 2003; Kroman et aL, 2004). In addition, recent studies have demonstrated a 
significant benefit of adjuvant radiotherapy in reducing locoregional recurrence following 
conserving surgery, as well as, mastectomy by approximately one to two-thirds. 
Moreover, post-mastectomy locoregional radiotherapy in high-risk patients, combined 
with appropriate systemic therapy, significantly reduced breast cancer recurrence and 
mortality and improved overall survival. The observed 20% absolute reduction in 
locoregional relapse was associated with an absolute improvement of 5% in long-term 
breast cancer-specific survival. This was offset in the older trials by an increased inter­
current mortality, caused by excess cardiovascular deaths. However, recent results with 
newer radiotherapy techniques have demonstrated a clear overall survival improvement, 
without excess cardiovascular morbidity (Fisher et aL, 1995; Overgaai’d et aL, 1997;
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Ragaz et al., 1997; Overgaard et ah, 1999; Early Breast Cancer Trialists, 2000; Julien et 
al., 2000; Holli et al., 2001; Fisher et ah, 2002a; Fisher et al., 2002b; Kurtz, 2002).
In general, a dose of 40-50 Gy (in 25 2-Gy fractions over 5-6 weeks, starting within 8 
weeks following surgery in patients not receiving chemotherapy, or after completion of 
chemotherapy) has been recommended as the standard adjuvant radiotherapy of large 
volumes including the whole breast after breast conservation, chest wall and nodal areas. 
Additional radiation boost of 10-20 Gy to smaller volumes may be required to the tumour 
bed site, either by fractionated external beam irradiation or by means of radioactive 
implants; using electrons or iridium wire implant, in cases with higher risk of loco­
regional recurrence such as close resection margins (< 1cm), extensive in situ disease, 
lymph-vascular invasion, and high grade tumour (Sainsbury et al., 2000; Henry and Ash, 
2001; Kurtz, 2002).
After mastectomy, adjuvant radiotherapy to the chest wall and nodal groups is also 
recommended in women considered to be at higher risk of locoregional recurrence of > 
20% at 10 years, including node-positive patients with large tumours (> 5cm) or with 
chest wall, deep margin, or skin involvement, and all patients with four or more positive 
axillary lymph nodes. Whereas, patients witli Tl-2 tumours and 1-3 positive nodes aie 
generally associated with < 15% risk of locoregional recurrence. Other risk factors, in 
addition, include lymph-vascular invasion, high histological grade, extension of cancer 
cells beyond lymph node capsule, or gross tumour multicentricity (Sainsbury et a l, 2000; 
Henry and Ash, 2001; Kurtz, 2002).
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Radiotherapy to the axilla is avoided after axillary lymph node cleai'anee, but may be used 
in patients with known residual disease after axillary sampling or in patients with large 
number of involved nodes and with gross extranodal disease. In these circumstances, 
adjuvant chemotherapy will also have an important role in preventing local recurrence, as 
well as, distant metastasis (Dawson and Taylor, 1996; Kurtz, 2002),
Radiation therapy is associated with both early and late complications. Immediate skin 
reactions normally resolve within a few weeks, but occasionally, severe skin reaetion with 
subsequent cutaneous radionecrosis, skin telangiectasia, thickening of the skin of the 
breast or chest wall, and cosmetic deformity of the residual breast tissue may develop 
later. Other less common or rare complications include lymphoedema, brachial 
plexopathy, shoulder stiffiiess, osteoradionecrosis of the ribs, radiation pneumonitis with 
pulmonary fibrosis, increased cardiovascular deaths, due to cardiac and great vessels 
damage particularly in women with left-sided breast tumour s, and secondary malignancy 
and sarcoma of the chest wall. Recent developments in radiation tecliniques, by using 
modem linear accelerators with reduced radiotherapy portals and doses, may minimize 
these side effects (Dawson and Taylor, 1996; Sainsbury et al., 2000; Sainsbury, 2001; 
Webster, 2001; Kurtz, 2002).
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Ovarian ablation in premenopausal women was associated with a positive effect on both 
disease-free and overall survival in patients with node-positive as well as node-negative
I
1.4.4 Hormonal therapy in breast cancer g
1
The aim of endocrine therapy is to decrease the hormonal growth stimulation of hormone- ;sensitive breast cancer cells. It is indicated as adjuvant therapy or as treatment for 
advanced systemic disease, and occasionally, as sole treatment in patients who are unfit or 
unwilling to have surgery (Webster, 2001; Stokes and Chan, 2003; Sweetland, 2004).
The current options for hormonal manipulation include anti-oestrogens such as tamoxifen, 
aromatase inhibitors, progestogens such as megestrol acetate, in addition to, suppression 
or ablation of ovarian function, medically by luteinizing hormone releasing hormone 
analogues, or surgically by laparoscopic or open surgery, or by radiation therapy 
(Webster, 2001; Stokes and Chan, 2003; Sweetland, 2004).
%
The selection of hormonal therapy depends on the patient’s menopausal status which in 
turn determines the source of oestrogen production; in premenopausal women by the #ovaries, and in postmenopausal women via the peripheral aromatase enzyme that is 
required for the peripheral conversion of adrenal androgens into oestrogens in the muscle, 
liver and fat tissue including the breast (Stokes and Chan, 2003; Pritchard, 2003). a
fItumours (Pritchard, 2003). The Early Breast Cancer Trialists’ Collaboration Group
i |(EBCTCG, 1992) showed a reduction in the annual rates of recurrence by 26% and death 
by 25% in patients less than 50-years of age, with further highly significant 15-years 
recurrence-free and overall survival improvements among those patients allocated to 
ovarian ablation (EBCTCG, 1996). Medical castration with luteinizing hormone
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releasing hormone analogues goserelin (Zoladex), as well, produced significant reduction 
in recurrence with a trend toward improvement in breast cancer survival and/ or overall 
survival, irrespective of the additional adjuvant tamoxifen therapy or chemotherapy 
(Pritchard, 2003). Ablation therapy precipitates the menopause, whereas, the reversible 
effect of luteinizing hormone releasing hormone analogues makes them suitable for 
women who want to remain fertile (Sweetland, 2004).
Tamoxifen, a non-steroidal anti-oestrogen, has been the gold standard for nearly 30 years. 
It is recommended for both premenopausal and postmenopausal women in the adjuvant 
and advanced metastatic treatment of hormone-receptor positive tumours (Stokes and 
Chan, 2003). It has a demonstrable effect on both recurrence-free and overall survival 
with an overall reduction in the death rate, which is higher in women over 50 years. In the 
Early Breast Cancer Trialists’ Collaboration Group (EBCTCG), adjuvant tamoxifen 
reduced the annual rates of recurrence by 25% and death by 17% (EBCTCG, 1992). In 
the 1998 EBCTCG overview, the proportions of reductions in recurrence and mortality 
during 10 years of follow-up for the 5 years adjuvant tamoxifen were 47% and 26%, 
respectively. The greatest benefit is achieved in patients who are oestrogen positive with 
involved nodes. Patients who are oestrogen receptor negative obtain no similar benefit. 
The proportional reduction in the contralateral breast cancer was 47% for the 5 years 
adjuvant tamoxifen (EBCTCG, 1998a).
The aromatase inhibitors have recently become established in the management of 
postmenopausal women with locally advanced and metastatic breast cancer; as a first-line 
therapy with a superior antitumour activity compared to tamoxifen and as a second-line 
therapy in patients whose disease has progressed during tamoxifen therapy. The third-
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generation aromatase inhibitors anastrozole, letrozole (reversible non-steroidal) and 
exemestane (irreversible steroidal) have been shown to have a favourable impact on 
survival with better safety profile compared to megestrol acetate therapy as a second-line 
therapy (Stokes and Chan, 2003; Buzdar, 2004; Campos; 2004; Clemons et al., 2004).
In current practice, postmenopausal women with hormone-sensitive disease typically 
receive 5 years of anti-oestrogens adjuvant treatment in the form of tamoxifen. 
Alternatively, anastrozole is considered in patients whom they have a relative or absolute 
contraindication to the use of tamoxifen. Although more recent emerging evidence on 
anastrozole, as initial adjuvant endocrine treatment of postmenopausal women with ER 
positive breast cancer, has shown its superiority over standard tamoxifen therapy for 5 
years in terms of disease-free survival, as well as, a better tolerability and safety profiles, 
the data so far regarding the overall survival benefit, however, has not yet been reported. 
Moreover, impressive reductions in risk of recurrence have been demonstrated in trials 
evaluating the switch fiom tamoxifen to aromatase inhibitors; either letrozole after 5 
years or exemestane after 2-3 years of tamoxifen, respectively (Pritchard, 2003; Campos; 
2004; Clemons et ah, 2004).
The third-generation aromatase inhibitors have shown lower incidences of hot flashes and 
endometrial side-effects such as vaginal discharge and bleeding or endometrial cancer, as 
well as, deep vein thrombosis, ischemic cerebro-vascular and thrombo-embolic evejits, 
with a better tolerability and fewer withdrawals from treatment compared to standard 
tamoxifen or megestrol acetate. However, musculo-skeletal side-effects, reduced bone 
density and fractures were more common in women treated with aromatase inhibitors 
(Pritchard, 2003; Buzdar, 2004; Campos; 2004; Clemons et ah, 2004).
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1.4.5 Chemotherapy in breast cancer
Systemic chemotherapy is indicated as adjuvant therapy, as a treatment for advanced 
metastatic disease, and to some extent, it is considered in patients with large non-operable 
breast cancer as preoperative primary (neoadjuvant) therapy to improve operability with 
breast-conserving surgery (Webster, 2001).
Commonly used chemotherapeutic agents in breast cancer include alkylating agents 
(cyclophosphamide), antimetabolites (5-fluorouracil, methotrexate, capecitabine, 
gemcitabine), anthracycline cytotoxic antibiotics (doxorubicin, epirubicin), taxanes 
(paclitaxel and docetaxel), and vinca alkaloids (vinorelbine). Polychemotherapy is 
significantly better than single-agent chemotherapy. However, in endocrine-resistance 
metastatic disease the optimal schedule of chemotherapeutic agents as concurrent versus 
sequential remains controversial, and decision must be individualized (Aapro, 2001; 
Webster, 2001; Cardoso and Piccart, 2003; Goldhirsch et al., 2003; Bernard-Marty et a l, 
2004; Nowak et ah, 2004).
The aim of adjuvant chemotherapy is to increase the cure rate after the primary loco- 
regional surgery. It is most frequently used in premenopausal patients, in patients with 
aggressive disease and with hormonal-receptor negative tumours (Webster, 2001). Four to 
six courses (3-6 months) of adjuvant systemic polychemotherapy (>2 agents) provide the 
optimal benefits and substantially improve disease-free and overall survival, irrespective 
of lymph node, hormone receptor or menopausal status up to age of 70 years, thought the 
data are inconclusive for those over the age of 70 years, and in most tumour subsets, 
except for small node negative tumours of less than 1 cm in diameter (Aapro, 2001).
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node-negative disease, the absolute advantage of anthracycline over CMF is smaller (1.7
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In the Early Breast Cancer Trialists’ Collaboration Group (EBCTCG), polychemotherapy 
reduced the amiual rates of recurrence by 28% and death by 16%. The greatest benefits of 
chemotherapy were for women with node positive disease and for younger women. But in 
women aged 50-69, it also reduced the rates of recurrence and mortality when combined 
with tamoxifen, being better than chemotherapy alone or tamoxifen alone (EBCTCG, 
1992). In the 1998 EBCTCG update, polychemotherapy with a combination of 
cyclophosphamide, methotrexate and 5-fluorouracil (CMF) or with an antliracycline- 
based regimen for 3 to 6 months produced significant proportional reductions in 
recurrence and mortality, both among women aged less than 50 years and those aged 50- 
69 years (35% and 20% reduction in recurrence, with 27% and 11% reduction in 
mortality for both age groups, respectively). The anthracycline-containing regimens, 
compared with CMF alone, produced somewhat greater effects on recurrence and 
mortality (72% vs 69% 5-year survival). Long-term treatment for more than six months, 
however, did not provide any additional benefit (EBCTCG, 1998b).
The reduction in recurrence with adjuvant polychemotherapy emerged chiefly during the 
first 5 years, whereas the difference in survival increased throughout the first 10 years; 
typically producing an absolute improvement in 10-years survival for young women (<50 
years) with early breast cancer of about 7% in node-negative and 11% in node-positive 
disease, and to a lesser extent, for postmenopausal women of about 2% in node-negative 
and 3% in node-positive early breast cancer, regardless of the added use of tamoxifen. 
Moreover, after 10 years follow-up, the anthracycline-based chemotherapy was associated 
with a 4% absolute risk reduction for recurrence and death above that seen with CMF 
(11% and 16% relative improvements in relapse and death, respectively). However, in
at 5 years). This advantage of anthracycline-based chemotherapy has been found almost 
exclusively when three-drug regimen was used; either epirubicin-containing (CEF) or 
doxorubicin-containing (CAF) regimen (EBCTCG, 1998b; Cardoso and Piccart, 2003).
In the adjuvant setting, currently used regimens include anthracycline-based 
chemotherapy such as four courses of AC, which have been shown to be equivalent to six 
cycles of classical CMF. The CEF, CAF regimen and to some extent FEC have yielded 
superior result. The CMF regimen is used less frequently but still valid for lower risk 
patients. The taxanes (paclitaxel and docetaxel) are being incorporated into adjuvant 
regimens on the basis of their antitumour activity in advanced breast cancer and the 
absence of cross-resistance with doxorubicin (Shapiro and Recht, 2001). Recent results 
support the use of taxanes as adjuvant chemotherapy for women with early breast cancer 
and involved lymph nodes, independent of hormone-receptor status. The docetaxel- 
containing regimen (TAC) proved to be superior to FAC in randomized clinical trials, and 
others trials have shown improvement in disease-free survival with or without significant 
improvement in overall survival in taxanes-treated patients (Aapro, 2001; Cardoso and 
Piccart, 2003; Goldhirsch et ah, 2003; Nowak et aL, 2004).
Primary systemic therapy, especially chemotherapy, is considered the standard of care for 
non-operable locoregional advanced breast cancer, and provides additional opportunity 
for breast-conserving surgery in patient presenting with large unifocal breast cancer. It 
allows clinical downstaging of the primary tumour, provides in-vivo chemo-sensitivity 
assessment of the tumour response to a specific chemotherapy regime and offers unique 
advantages in understanding the tumour biology, and has been shown to improve survival
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in patients with the best clinical response (Calais et aL, 1994; Kaufmann et aL, 2003; 
Garces and Cance, 2004).
Randomized controlled clinical trials in patients with operable breast cancer, which 
include stage Tl-3, NO, MO or Tl-3, N l, MO, have shown that primary 
polychemotherapy; using CMF, AC, FAC, or FEC regimes, increases the proportion of 
patients who subsequently shown to have metastatic-free axillary lymph nodes or who 
become candidates for breast-conserving surgery. The reported absolute differences in the 
rate of successful breast-conservation surgery between patients who received primary 
chemotherapy compared to those who received adjuvant chemotherapy range from 5% to 
36%. In addition, primary chemotherapy offers the same disease-free and overall survival 
benefits as adjuvant chemotherapy with the same drug combinations (Fisher et aL, 1997; 
Kaufrnann et aL, 2003). Recent trials with neoadjuvant taxanes-containing regimens have 
been shown to produce superior clinical and pathological response rates, compared to 
non-taxane containing group (Garces and Cance, 2004; Nowak et aL, 2004). However, 
despite the potential advantages, preoperative chemotherapy has not been advocated as 
being preferable over adjuvant chemotherapy in patients with early breast cancer, because 
of a lack of significant survival advantage (Goldhirsch et aL, 2003).
In patients with metastatic breast disease, chemotherapy is indicated as a palliative 
measure to ensure prolonged disease control without compromising quality of life. 
Treatment should be tailored according to patient and tumour characteristics, including 
patient’s performance status, tolerability, tumour burden and aggressiveness. The most 
active cytotoxic drugs include the anthracyclines and the taxanes, followed by alkylating 
agents, antimetabolites (capecitabine, gemcitabine), and vinca alkaloids. Unless
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symptoms or signs of life-threatening disease exist, the single used agents can produce 
objective response rates of 20%-80%. However, the rai'e complete responses are short 
lived and progression of disease is almost inevitable (Bernard-Marty et aL, 2004).
Side-effects of chemotherapy are significant. Doxorubicin and cyclophosphamide are
more likely to cause alopecia and vomiting, whereas cyclophosphamide, methotrexate,
and fluorouracil are more likely to cause nausea, myelosuppression, and ovarian failure,
with its subsequent menopausal symptoms including hot flashes, vaginal dryness,
depression, sleep disturbance, increased risk of osteoporosis. Doxorubicin directly
damages the myocardium and can cause cardiomyopathy. Both taxanes (paclitaxel and
docetaxel) can cause hypersensitivity reactions, peripheral neuropathy, myalgia, arthralgia
and fatigue. Peripheral neuropathy is seen, as well, with vinca alkaloids. The increased 
.incidence of secondary leukaemia, coimnonly of acute myeloid leukaemia, and 
myelodysplasia have been documented in patients treated with adjuvant alkylating and 
anthracyclines-based agents, and are dependent on the administered dose (dose intensity 
and cumulative dose) and the duration of treatment (Aapro, 2001; Shapiro and Recht,
2001; Webster, 2001; Cardoso and Piccart, 2003; Nowak etaL, 2004).
Most acute side-effects can be controlled or reduced by modern measures, including
drugs like corticosteroids and ondansetron for nausea and vomiting and scalp cooling for
alopecia, and resolve on completion of treatment (Sainsbury, 2001; Webster, 2001).
.Whereas, longer-term side-effects are to be carefully considered on individual patient 
basis. In the adjuvant setting, if both chemotherapy and hormonal therapy are
' î lrecommended, the chemotherapy is given first to minimize the toxicity and improve the 
efficacy of each therapeutic modality (Pritchard, 2003).
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1.4.6 Biological therapy in breast cancer
Trastuzumab (Herceptin(D) is a humanized monoclonal antibodies with anti-tumour 
activity targeted against the epidermal growth factor family oncogene (Her-2//?ew). It is a 
novel therapeutic option for patients with aggressive forms of advanced metastatic Her-2/ 
Mgw-positive breast cancer (Ross et aL, 2003; Vogel and Franco, 2003).
It suppresses tumour growth when used as a single agent or in combination with other 
chemotherapeutic agents. Single-agent trastuzumab therapy produces objective benefits in 
15-20% of patients with Her-2 positive tumours. Trastuzumab in combination with 
cytotoxic chemotherapy, either anthracycline plus cyclophosphamide or taxans, has been 
shown to improve overall survival, with a higher rate of objective response and a longer 
duration of response, as well as, to increase time to disease progression and time to 
treatment failure, in synergistic rather than an additive manner. Ongoing trials of 
trastuzumab in combination with various chemotherapy agents are encouraging and 
showing significant clinical activity over chemotherapeutic regimens alone (Leonard et 
aL, 2002; Ross et aL, 2003; Vogel and Franco, 2003).
Trastuzumab therapy is generally well tolerated. However, mild side-effects may include 
fever and chills; which are generally seen with first infusion dose, in addition to, 
diarrhoea, nausea, headache, rash and rhinitis. Other severe adverse events include 
cai’diac toxicity, especially occurring when used in combination with anthi'acycline-based 
chemotherapy regimens. In the absence of pre-existing cardiac disorders or prior 
anthracycline therapy, intrinsic cardiotoxicity with single-agent trastuzumab appears to be 
rare (Leonard et aL, 2002; Ross et aL, 2003; Vogel and Franco, 2003).
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1.4.7 Follow-up
Increased incidence of breast cancer together with improved management and reduced 
mortality have created a large population of breast-cancer survivors at risk of disease- 
relapse (local recurrence and/ or distant metastasis), or development of a second new 
primary breast tumours, in addition to, therapy-related complications, whom they require 
follow-up medical care and psychological support (Emens and Davidson, 2003; Flurria 
and Hudis, 2003).
Data suggest that screening for disease relapse is likely to be most useful in the first 5 
years after primary therapy, with more frequent evaluation during the first 2 years when 
relapse rates are highest. After mastectomy, local recurrence is most common in the first
2-3 years and decreases with time, but after breast conservation, it occurs at a fixed rate 
each year. Patients with carcinoma of one breast are also at high risk of cancer in the 
contralateral breast; about 0.6% a year develop second primary tumour (Sainsbury et aL, 
2000). In addition, late recurrence, metastatic relapse and death from breast cancer are 
well documented, even 20 years or more after initial diagnosis and primary tieatment 
(Louwman et aL, 2001; Emens and Davidson, 2003).
Therefore, all patients should be followed on regular basis for at least 5 years. The 
recommended strategy includes; history and physical examination (every 3-6 months for 
3 years, every 6-12 months for 2 years, and annually thereafter), monthly self-breast 
examination, annual mammography of the preserved and contralateral breast (Hurria and 
Hudis, 2003). Mammography may be difficult to interpret after breast conservation due to 
scarring, and in this situation, magnetic resonance imaging (MRI) is usefiil to differentiate
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it from cancer recuiTence (Sainsbury et aL, 2000). Patients on adjuvant tamoxifen, based 
on the recommended surveillance strategy, are also advised to have annual 
gynaecological examination, reserving specific test such as endometrial biopsy and/ or 
transvaginal ultrasound to those who developed abnormal vaginal bleeding or discharge 
(Emens and Davidson, 2003; Hurria and Hudis, 2003).
Although it is important to be aware of the potential short and long-term primary therapy- 
related complications of breast cancer including the psychological impact, the available 
data support a conservative approach with clinically directed follow-up, based on careful 
history and physical examination, in which further diagnostic-tests are to be guided by 
clinical information. Current data on early diagnosis of systemic-relapse, prior to the 
onset of clinical signs or symptoms, by aggressive or routine serological or radiological 
testing (with the exception of mammography) have failed to impact overall suivival, and 
so should not be conducted routinely. Instead, such women should be educated about the 
signs and symptoms of breast-cancer recurrence, and encouraged to report any new 
persistence symptoms when they develop to their medical personnel (Emens and 
Davidson, 2003; Hurria and Hudis, 2003).
I
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1.5 The systemic and local inflammatory response in breast cancer
Breast cancer is a heterogeneous disease with diverse biological and clinical 
manifestations, in which the clinical evolution is much less predictable. Established 
prognostic factors, which are used as a guide to decide appropriate adjuvant therapy, are 
mainly including tumour-associated characteristics such as the primary tumour size, 
histological grade, lymph-node status, hormone-receptor status and oncogene over­
expression. Nevertheless, outcome remains highly variable even when these factors are 
taken into account.
It has long been thought that disease variability in cancer patients, including breast 
cancer, is not solely determined by the characteristics of the tumour but also by the host- 
response factors (Hart and Saini, 1992).
The tumour-host interaction is a complex relationship that has yet to be fully understood 
(Figure 1.5). The host-immune responses can be divided into innate or adaptive immunity 
that can act within the local/regional microenvironment or systemically (Figure 1.6). The 
cellular mediators of the innate immunity include macrophages, granulocytes, natural 
killer cells, and non-MHC-restricted and gamma/delta T lymphocytes. In addition, soluble 
factors including natural antibodies, complement components and C reactive protein play 
a role in the innate immunity. The adaptive immune response is mediated by the tumour 
antigen-specific T- lymphocytes that include cytotoxic effector CD8+ and MHC class I 
restricted cells, as well as, helper CD4+ T- lymphocytes of MHC class II molecules 
(Figure 1,7; Whiteside, 2003).
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However, there is now increasing evidence that both the local inflammatory response, 
within the tumour microenvironment, and the systemic inflammatory response, as 
evidenced by increased circulating concentrations of acute phase proteins such as C- 
reactive protein, play pivotal roles in malignant disease development, progression and 
metastatic formation in a variety of common solid tumours (Figure 1.5 & 1.6; Witz, 2001; 
Coussens and Werb, 2002). The basis of the tumour-host response is not clear. However, 
it appears to be a driven response of the tumour behaving as “wound that does not heal” 
(Dvorak, 1986).
Local inflammatory 
response
Tumour inflammatory 
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T-lymphocytes, 
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Pro-inflammatory
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Systemic inflammatory 
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Circulating acute phase 
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Figure 1.5: The tumour-host relationship.
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Figure 1.7: Immune responses to cancer cells (B: B-cells, C: complements, DC: 
dendritic cells, G: granulocytes, M: macrophages, NK: natural killer cells, Tc: T 
cytotoxic lymphocytes, Th: T-helper lymphocytes; from Whiteside, 2003).
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1.5.1 Systemic inflammatory response
The systemic inflammatory response (acute-phase response) is the wide-ranging patho­
physiological disturbances in homoeostasis that result from tissue damage, infection, 
immunological disorders, or malignant disease. It involves a large number of systemic 
changes in the biosynthetic, metabolic and catabolic profiles of many organs, along with 
behavioural and nutritional changes, which is characterized clinically by the presence of 
fever, leucocytosis, anaemia, muscle wasting, anorexia and fatigue (Figure 1.6). The 
function of the acute-phase response is to restore the body’s homoeostasis by removing 
the cause of the initial disturbance. However, in certain conditions of chronic or recurring 
inflarmnation and cancer, the response can persist and may contribute to many deleterious 
consequences (Gabay and Kuslmer, 1999; Slaviero et aL, 2003).
A complex cascade of phagocyte-derived endogenous mediators, especially cytokines, 
induces the acute-phase reaction (Figure 1.8). These secreted pro-inflammatory cytokines, 
including interleukins 1 and 6 (IL-1 & IL-6) and tumour necrosis factor a (TNF-a), 
circulate from the initial site of disturbance to distant organs, such as the liver, resulting in 
the stimulation of expression of acute-phase proteins. Circulating concentrations of acute- 
phase proteins increase (positive acute-phase proteins), or decrease (negative acute-phase 
proteins), by at least 25% during inflammatory disorders (Figure 1.8; Gabay and Kushner, 
1999; Slaviero et aL, 2003).
Other gene products such as phospholipase-Az, cyclooxygenase-2, and inducible nitric 
oxide synthase are upregulated during tlie cytokine cascade to generate small mediator 
molecules, including platelet activating factor, leukotrienes, prostanoids, and nitric oxide, 
that contribute to the inflammatory response (Figure 1.6; Slaviero et aL, 2003).
The major pathway for the transcriptional activation of acute-phase proteins and other 
proteins, such as cyclooxygenase-2, by cytokines, involves Janus kinases (JAK) and 
signal transducers and activators of transcription (STATs, particularly STAT3). Another 
pathway involves the activation of mitogen-activated protein kinases, which in turn 
induce the expression of various nuclear factors including CCAAT enhancer binding 
proteins (C/EBP), such as Nuclear Factor-xB (Slaviero et aL, 2003).
C-reactive protein and albumin are the classical (positive and negative; respectively) 
acute-phase proteins in humans (Figure 1,8). These measurements may be a useful 
indicators in predicting the net effect of various local and systemic inflammatory response 
mediators, including cytokines (Gabay and Kuslmer, 1999).
30,100
^  30 , 000 -
700 -
C-reactive proteinCD 600 -§c<siCOCDQl.c:
500
S e ru m  a m y lo id  A
300 “
Haptoglobin
Fibrinogen200
CD
gCD
TransferrinAlbumin
O 7 14 21
Time after Inflammatory Stimulus (days)
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acute-phase proteins after a moderate inflammatory stimulus (from Gabay and 
Kushner, 1999).
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1.5.1.1 C-reactive protein
C-reactive protein is a non-specific positive acute-phase protein synthesized by 
hepatocytes in response to trauma, inflammation and malignant processes. Its semm 
concentrations are extensively used in routine clinical practice to monitor the systemic 
inflammatory response, and therefore the extent and activity, as ’well as, the prognosis of 
many underlying diseases (Kolb-Bachofen, 1991; Pepys, 1996).
C-reactive protein belongs to the pentraxin family of proteins and consists of five 
identical non-glycosylated subunits, encoded by a single gene on chromosome 1. The 
monomers, each of molecular mass 23 027, are non-covalently associated in a very stable 
disc-like configuration with cyclic pentameric symmetry, which is resistant to proteolysis. 
C-reactive protein is primarily upregulated by the local and systemic release of the pro- 
inflammatory cytokines, in particular interleukin-6. In tlie presence of calcium, C-reactive 
protein undergoes specific ligand-binding to phosphocholine in autologous phospholipids 
and microbial polysaccharides. Complexed or aggregated C-reactive protein efficiently 
activates the classical complement pathway and can thereby opsonize ligands for 
phagocytosis. C-reactive protein neutralizes the potent inflammatory mediator, platelet- 
activating factor, which contains phosphocholine and has down-regulatoiy effects on 
neutrophil function. C-reactive protein may thus contribute to host defence, modulation of 
inflammation and lipid metabolism (Pepys, 1996).
The plasma half-life and fractional catabolic rate of C- reactive protein appears to be 
constant under virtually all conditions. Therefore, its plasma concentration is determined 
primarily by its synthesis rate. In normal healthy individuals the serum C-reactive protein
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concentrations are barely detectable with a median level of 0.8 mg/1 and with 99% of 
apparently healthy individuals having C-reactive protein concentrations less than 10 mg/1. 
Higher values are abnormal and objectively reflect the presence, extent and activity of 
underlying organic diseases and disorders. The rapid increase in concentrations may 
exceed 200 mg/1 within 24 hours of an acute event. High serum concentration can be 
maintained for a prolonged period if the stimulus or underlying condition persists. After 
effective treatment or cessation of the stimulus the value can fall rapidly and almost to 
near-normal values within 2-3 days (Kolb-Bachofen, 1991; Pepys, 1996).
In recent years, there has been a considerable interest in the role of systemic inflammatory 
response, as evident by raised serum C-reactive protein concentration, in patients with 
malignant disease. Pro-inflammatory cytokines are usually produced by activated white 
blood cells (Gabay and Kushner, 1999; Whiteside, 2003), and may act as autocrine 
growth factors for tumours (Dunlop and Campbell, 2000). However, there is some 
evidence that cancer cells may also produce significant amounts of pro-inflammatory 
cytokines (Balkwill and Mantovani, 2001; Whiteside, 2003). Higher C-reactive protein 
concentration at presentation has been found to correlate with the overall tumour load and 
has been demonstrated to have stage independent prognostic value in a variety of cancers, 
notable of gastrointestinal carcinoma (McMillan et ah, 1995; Goransson et ah, 1996; 
Pepys, 1996; Nozoe et ah, 1998; Fujita et ah, 1999; Nielsen et ah, 2000; Nozoe et ah, 
2001).
In breast cancer, few studies have been conducted with conflicting results. However, the 
majority of studies were based on small number of patients (Coombes et ah, 1977a,b; Lee 
et ah, 1982), included patients with operable early-stage and inoperable advanced-stage
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diseases (Coombes et al., 1977a,b; Drahovsky et a l, 1981), were retrospective (Weinstein 
et aL, 1984), and used non-speeific assay techniques with limited sensitivity (Mortensen 
and Rudczynski, 1982) and limited follow-up.
Coombes and co-workers (1977 a,b) first showed, in a study of 51 patients with breast 
disease, that C-reactive protein was abnormally elevated (>10 mg/1) in 14 / 16 (87%) 
patients with overt metastatic breast cancer, but rare in patients with apparently localised 
disease. They reported that high pre-operative C-reactive protein concentrations, with 
other biochemical markers abnormalities such as carcinoembryonic antigen (CEA), can 
delineate patients with primary tumour that associated with poorer prognosis on 
histological ground or some other patients with no clinical or investigational evidence of 
metastasis but who have micrometastasises, in whom relapses might occurred sooner than 
others (3/7 patients in this study), suggesting that C-reactive protein with other 
biochemical markers could be of a value in the initial staging of patients, in the early 
detection of metastasis, in assessing prognosis and, therefore, could be used to select 
patients for adjuvant systemic therapy in addition to local therapy.
Similarly, Drahovsky and co-workers (1981) reported, in a study of 287 patients with 
different stages breast cancer, that there were 153 (53%) patients who had a positive C- 
reactive protein value of > 2 mg/1. A significant increase in the fi'equency of elevated C- 
reactive protein concentration was seen with advanced stages of disease (61.2% and 
72.3% in stage III and IV respectively vs. 45.1% and 47.2% in stage I and II). C-reactive 
protein concentrations were also significantly elevated in early stages with active disease. 
C-reactive protein appeared to reflect tumour mass with a clearly positive correlation to
92
tumour correlated with each other, neither measure was a useful in predicting the disease- 
free interval following surgery. C-reactive protein concentrations had no correlation with 
the size of the primary breast tumour, the histopathological grade or the lymph node 
involvement.
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TNM staging, as well as, tumour activity (recurrence and/or metastasis) at the time of 
determination; i.e. independent of TNM stages.
However, Hillyard and co-workers (1982), in their study of 53 patients with benign breast 
masses and 196 patients with breast cancer and which aimed to test whether the 
biochemical changes can aids the staging of breast cancer, showed a considerable overlap 
between the concentrations of fifteen plasma proteins, including C-reaetive protein, and 
the various clinical stages, and were often normal even in the metastatic disease. The 
mean C-reactive protein concentrations were raised in less than 50 % of patients with 
overt métastasés.
As a part of a major study to identify prognostic factors for breast cancer, Mortensen and
Rudczynski (1982) studied 297 patients with different stage breast cancer, and with a
clinical follow-up period of 3-48 months post-surgery, to evaluate the role of sei*um C-
reactive protein concentration and the extent of lymphocytic infiltration of the primary
tumour as prognostic markers. Elevated C-reactive protein concentrations (>10  mg/1) 
.were present in a higher proportion of patients with stage IV disease (24/57; 42%), when
compared to patients in stages I (23/106; 22%), II (25/115; 22%) and III (4/19; 21%). 
There was no difference in C-reactive protein concentrations among patients with stage I- 
III disease. Although the serum C-reactive protein concentrations at the time of initial
surgery and the presence of a localized lymphocytic infiltration within the primary breast
i
In the therapeutic monitoring of 179 patients with metastatic breast cancer, Williams and 
co-workers (1990) found a higlily significant association between the therapeutic
alterations in the serum concentration of C-reactive protein and other tumour-related 
markers, including carcinoembryonic antigen, ferritin, orosomucoid and the erythrocyte 
sedimentation rate, after bmonths of primary endocrine therapy. Suggesting that the 
design of an objective measurement of response, as a Therapeutic index’, that combined
subjective UICC criteria and so could be used to direct systemic endocrine therapy.
reactive protein concentration in the 65 patients who survived beyond 3 months showed 
no significant correlation with the International Union Against Cancer (UICC) criteria-
In another prospective study of 85 patients with newly diagnosed metastatic breast cancer, 
the pre-treatment serum concentrations of C-reactive protein and other tumour markers
:
:
■iresponse according to the International Union Against Cancer (UICC) criteria and the
these tumour-related markers had the potential to replace the existing and largely I
In a prospective study, C-reactive protein concentration with other tumour markers such
as CEA and erythrocyte sedimentation rate (ESR) were observed to have no significant
elevation in primary breast cancer (100 patients), compared to normal control (56 
.patients) or benign breast disease (100 patients). Therefore, appeared to have no role 
either in screening or in the differential diagnosis of breast cancer. On the other hand, C-
reactive protein concentration was significantly elevated (>10mg/l) in 43/85 (51%)
v | |
patients with systemic (metastatic) breast cancer. However, the sequential changes of C- il
1assessed therapeutic response; indicating that C-reactive protein would not appear to be of 
a clinical value in measuring response to therapy in advanced breast cancer (Roberston et 
al., 1991).
I
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did not predict therapeutic response. However, the pre-treatment serum concentrations of 
C-reactive protein, ferritin, human milk fat globule membrane 1 and 2 above the mean + 
2SD of the normal control group appeared to be prognostic and correlated significantly 
with longer post- métastasés survival (Albuquerque et ah, 1995).
More recently, in 77 patients with locally advanced non-metastatic breast cancer 
undergoing neo-adjuvant chemotherapy, Heys and co-workers (1998) demonstrated that 
pre-treatment concentrations of acute phase proteins did not indicate which patients will 
respond to chemotherapy, as assessed either by the clinical response or by the histological 
destruction of the tumour. C-reactive protein concentrations were not related to patient 
survival.
Zhang and Adachi (1999) in a study of 46 Japanese patients with metastatic breast cancer, 
observed a strong correlation between IL-6 concentrations and C-reactive protein 
concentrations. IL-6 concentrations correlated with the extent of métastasés 
dissemination, being significantly higher in liver and pleuml métastasés. In these patients, 
higher IL-6 serum concentrations were associated with a poorer response to 
chemotherapy or chemo-endocrine therapy and correlated with a shortened survival, and 
therefore, representing a poorer prognostic predictor in patients with metastatic breast 
carcinoma.
O’Hanlon and colleagues (2002) in a recent study of 92 patients with breast cancer and 31 
patients with benign breast disease, reported a significantly higher C-reactive protein 
concentration in patients with stage IV disease, T4 ulcerating tumouis, and during 
recurrence, but it was of no benefit in predicting recurrence.
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In conclusion, C-reactive protein concentration appears to reflect the presence of systemic 
metastatic disease. However, the majority of studies were small or included patients 
unlikely to progress (primary operable) and patients who had already progressed 
(metastatic).
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1.5.1.2 Albumin
Human albumin, the major negative acute-phase protein, is a single polypeptide 
consisting of 585 amino acids with a molecular weight of approximately 66 kDa. It is the 
most abundant of hepatic secretory proteins with a total albumin pool size of 4-5 g/kg of 
body weight, of which 40-45% is in the intravascular space and other 60% is in the 
interstitial space. The serum albumin concentration is normally around 40 g/1 (Margarson 
and Soni, 1998).
The main functions of albumin are maintenance of colloid osmotic pressui e, as a result of 
its relatively low molecular weight compared to the other major intravasular proteins such 
as immunoglobulin (accounting for 75-80% of the colloid osmotic pressure of human 
plasma), binding and transport, free radical scavenging, platelet function inhibition and 
antithrombotic effects, and its effects on capillary membrane permeability (Mai’garson 
and Soni, 1998).
The serum albumin level remains a traditional standard factor by which to assess a 
patient’s nutritional status. In disease status, a decrease in serum albumin concentration is 
almost an inevitable finding, with marked persisting changes generally associated with 
poor prognosis (Margarson and Soni, 1998). It appears to be primarily mediated in the 
acute phase response by the altered energy and protein metabolism, that associate with its 
increased demand for specific amino acids for mediator and acute-phase protein synthesis 
and immune and antioxidant defences, which promotes the degradation and progressive 
loss of the available body vital protein components, including albumin and body cell 
mass. The modest albumin pool-size, relative to that of body cell mass, may be reflected
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aiid/or elevated C-reactive protein concentrations were found more often in patients with
Similarly, low baseline serum albumin concentration of < 35 g/1 in 180 consecutive 
patients with different stage breast cancer was a powerful prognostic variable of overall
in its loss becoming noticeable at an earlier stage (Fearon et al., 1999; McMillan et al..
■I
The association between reduced serum albumin concentrations and/or elevated C- lisreactive protein concentrations with severity of illness and poor outcome has long been
%recognised. More recently, in malignant diseases, low albumin concentrations (<35 g/1)
■advanced inoperable/ metastatic cancers than in patients with early stage operable
cancers, most probably reflecting disseminated disease with more pro-inflammatory
cytokine-mediated metabolic events, and subsequent poorer prognosis (Goransson et ah,
.1996; Fiorenza et ah, 2000; McMillan et ah, 2001a).
In locally advanced non-metastatic breast cancer, Heys and co-workers (1998) in a study 
of 77 patients undergoing neo-adjuvant chemotherapy, reported that reduced pre­
treatment serum albumin concentration, progressive lymph node involvement, and 
advanced tumour stage were independent prognostic indicators for poor survival.
I
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survival, accounting for approximately 10% of the overall variation in patient survival 
time. In mid- and lower-stage breast cancer, the overall 5-year survival of patients with | |
hypoalbuminaemia was 60% compared with 85% in patients with a normal albumin. 
Whereas, patients with stage IV lesions who fell in the lowest quartile serum albumin 
concentration had a median survival of 14.8 months compared with 22 months for the rest Iof patients in this stage (Lis et ah, 2003).
,1:-
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In summary, there is some evidence that an elevated C-reactive protein and a low albumin 
concentration may identify patients with breast cancer at a higher risk of poor outcomes 
and premature death. However, there is little data on the relationship between these 
systemic acute-phase proteins and the local inflammatory response in patients with breast 
cancer.
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1.5.2 Immune-cellular infiltration
Locally, the immune-cellular infiltration within the tumour microenvironment of many 
human malignant neoplasms, including breast cancer, was observed as early as the middle 
of the nineteenth century, and since that time, discrepancies have been existing on the 
functional and prognostic significance of this phenomenon.
Breast cancer, among other solid tumours and their métastasés, have been documented to 
be largely orchestrated by a heterogeneous populations of immune cells, consisting of 
variable proportions of helper, suppressor, and cytotoxic T lymphocytes, B lymphocytes, 
natural killer (NK) cells, macrophages, eosinophils and mast cells. All of which are 
capable of producing an assorted array of cytokines, growth factors and proteases, and are 
believed to represent a marker of the host immune response to neoplastic growth (Chin et 
ah, 1993; O’Sullivan and Lewis, 1994; Goedegebuure and Ederlein, 1995; Wong et al., 
1998; Witz, 2001; Coussens and Werb, 2002; Yu and Rak, 2003).
In breast cancer, T- lymphocytes have been demonstrated to be a major component of the 
tumour-associated leucocytes (TALs) population, of which both the CD8+ (T 
suppressor/cytotoxic) and the CD4+ (T helper/inducer) subsets have been reported to 
predominate (Chin et aL, 1993; Ogmundsdottir, 2001; Georgiannos et a l, 2003). 
However, the relationship between patient’s prognosis and the extent of lymphocytic 
infiltrate and /or the degree of phenotypic difference remains the subject of considerable 
debate (Hadden, 1999).
Previous investigators have indicated that an intense lymphocytic infiltrate is associated 
with a favourable prognosis. The assumption for this was based on that lymphoid cells
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infiltration of breast cancer has often been interpreted as an indication of an active 
immune response against the tumour and, thus, a favourable prognostic sign 
(Ogmundsdottir, 2001). However, others studies found no relationship, or even, claim that 
patients with intensely infiltrated cancers had worse prognosis (Stewart and Tsai, 1993; 
Ogmundsdottir et ah, 1995). These contradictory results may be related to the small and 
limited number of tumours analysed or due to the differences in the type of analysis 
performed.
In general, each histological type differs in its biological properties and clinical 
progression, and the immime response between tumour-types may also vary. It is of 
interest that the medullary subtype of breast carcinomas is characterized by marked 
lymphoid infiltration, with increased numbers of activated cytotoxic lymphocytes 
(CD8+), and generally has a more favourable prognosis than other histological subtypes 
(Yakirevich et aL, 1999; Ogmundsdottir, 2001).
In contrast, primary breast cancers with markers of poor prognosis, such as high-grade 
tumour, tumour size of more than 2 cm, and with three or more positive lymph nodes, 
were found to exhibited increased lymphocytic infiltrate (Griffith et aL, 1990; 
Vgenopoulou et aL, 2003). It was suggested, in a significant subgroup of breast cancer 
patients, that a high degree tumour-infiltrating lymphocytes might create a favourable 
environment for the malignant cells and may even facilitate cancer development and 
growth and, therefore, correlated with poor prognosis (Stewart and Tsai, 1993).
A higher proportion of CD8+ (cytotoxic type) compare to CD4+ cells (T helper type) has 
been observed in some studies (Ogmundsdottir, 2001), with a significantly higher CD8+
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T cells in progesterone-positive tumoui' than that in progesterone-receptor negative 
tumours (Chin et ah, 1993). Also in patients with early disease stage or those who were 
alive with no residual disease compared with late stage or those dead of disease (Marrogi 
et aL, 1997). On the other hand, T helper/inducer lymphocyte subset predominated in 
other studies, especially in large tumours, and they usually increased with the size of the 
tumours. It has been reported that there is elevated CD4+ T cells with a declined CD8 
expression in oestrogen-receptor negative tumours, and increased CD4/CD8 ratio in 
lymph node métastasés (Griffith et aL, 1990; Chin et aL, 1992; Chin et al., 1993; Wong et 
aL, 1998). However, in patients with primary operable breast cancer (n = 77), neither the 
density of lymphocytic infiltration nor the ratio of helper to suppressor lymphocytes were 
related to the Nottingham Prognostic Index or with improved survival or reduced rates of 
cancer recurrence in the immediate 3-years period following tumour resection (Griffith et 
aL, 1990).
The relationship between the extent of lymphoid-cell infiltration within the primary 
tumour and the serum C- reactive protein concentration, as a systemic inflammatoiy 
response, has been evaluated in 297 breast cancer patients using radial immunodiffusion 
teclinique. Although, the presence of lymphoid-cell infiltration has found to be correlated 
with C- reactive protein concentration, neither measures showed any obvious association 
with the length of disease-fi-ee interval following surgery (Mortensen and Rudczynski, 
1982).
Tumour-associated macrophages, derived from the circulating monocytes, are another 
major component of the cellular leucocytic infiltrates within the breast tumour 
microenvironment (O’Sullivan and Lewis, 1994; Lewis et al, 1995; Lee et al, 1996; Leek
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and Harris, 2002). In breast cancer, recent studies have indicated that the pro-tumour role 
of tumour-associated macrophages is dominant over the anti-tumoui* activities, and the 
evidence from both experimental and clinical studies suggests, in most cases, that these 
cells can play an active role in enhancing tumour progression and metastasis. In addition 
to tumour cells, activated macrophages secret a wide range of growth factors, digestive 
enzymes, angiogenic cytokines and hypoxia inducible factors, such as epidermal growth 
factor (EGF), vascular endothelial growth factor (VEGF), tumour necrosis factor (TNFa), 
thymidine phosphorylase (TP), transforming growth factor-^ (TGF-p), platelet-derived 
growth factor, interleukin-6 (IL-6), urokinase plasminogen activator and tissue-type
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plasminogen activator (t-PA), which may promote tumour growth, facilitate tumour-cell 
invasion and migration, and enhance tumour angiogenesis (O’Sullivan and Lewis, 1994; 
Lewis et al, 1995; Leek et al, 1996; Leek and Harris, 2002).
A high tumour-associated macrophages density has been demonstrated to be associated 
with established prognostic factors indicating aggressive phenotype breast cancer. For 
example, in series of less than 80 patients with breast cancer, diffuse inflammation of 
macrophages, and to lesser extent T-lymphocytes, was most frequently associated with 
larger tumour size, higher tumour grade or mitotic activity index, tumour necrosis or/ and 
positive c-er^B-2 expression (Lee et al, 1996; Pupa et al, 1996; Lee et al, 1997; Jonjic et 
al, 1998).
Similarly, the prognostic significance of tumour-associated macrophages in breast cancer 
has been reported in association with increased tumour angiogenesis, as well as, poor 
prognosis (Steele et al, 1984; Leek et al, 1996). In a cohort of nearly 100 patients with 
breast cancer, increased tumour-associated macrophage density correlated significantly
:
with high vascular grade, as assessed by quantitative CD68+ and CD31+ iminuno- 
staining; respectively, and independently associated with reduced relapse- free and overall 
survival (Leek et al, 1996).
Other cellular infiltrates such as B-lymphocytes, natural killer cells, granulocytes, 
eosinophils, mast cells, or plasma cells are scarce in malignant breast tumours, and their 
involvement in cytotoxicity or tumour progression is limited (O’Sullivan and Lewis, 
1994).
In summary, the relationship between the tumour, cellular immune response, and outcome 
in patients with primary operable breast cancer remains unclear.
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1.5.3 Angiogenesis
Invasion and metastasis in breast cancer, as most of other solid tumours, depend on the 
activation of angiogenesis (or neovascularization); a multi-step process leading to the 
formation of new blood vessels from an existing vascular' endothelium in a growing 
tumour beyond 1-2 mm in size (Gasparini, 1995; Uzzan et aL, 2004).
Angiogenesis is an active process, derived by hypoxia and regulated by a large number of 
pro-angiogenic growth factors, cytokines and proteases, such as vascular endothelial 
growth factor, platelet-derived endothelial cell growth factor, and basic fibroblast growth 
factor, as well as, anti-angiogenic molecules, which are produced by tumour cells and 
stromal cells, including infiltrating inflammatory cells (Gasparini, 1995; Yu and Rak, 
2003; Coradini and Daidone, 2004; Esteva and Hortobagyr, 2004; Uzzan et aL, 2004). 
Either within the primary tumour or its métastasés, angiogenesis is a necessary process 
required both at the beginning and at the end of the development of distant metastasis. 
Furthermore, it has been implicated in the phenomenon of dormant micrometastases 
(Gasparini, 1995).
Within a given tumour type, the angiogenic activity is believed to be heterogeneous 
(Gasparini, 1995; Uzzan et aL, 2004). Nevertheless, intratumoural microvessel density 
(MVD) or vascular grading, a surrogate marker of tumour angiogenesis, which has been 
determined by panendothelial markers and immunohistochemical techniques in several 
studies, has been shown to have a prognostic value and associate with clinical outcome 
(Gasparini et aL, 1995; Hansen et aL, 2000a,b; Gasparini et al., 2001; Uzzan et aL, 2004).
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Angiogenesis correlates significantly with other clinico-pathologic factors, including 
axillary node metastasis, large tumour-size, high malignancy grade, histological type and 
oestrogen receptor-negative tumoui% It has, also, been shown to have independent 
prognostic value for both relapse-tfee survival and overall survival in all patients with 
breast cancer, including those with node-negative and node-positive disease (Gasparini et 
a l, 1995; Hansen et al., 2000a,b; Gasparini et al., 2001; Coradini and Daidone, 2004; 
Esteva and Hortobagyi, 2004; Uzzan et al., 2004). Patients with highly vascularized 
primary tumours are at high risk of early recurrence and metastasis, at any time 
(Gasparini et al., 2001).
Conflicting results, however, have been observed witli some other studies, most probably 
resulting fi’om the application of different methods, including different staining markers 
and assessment techniques (Uzzan et al., 2004).
With the standardization of intratumouial vascular profile, angiogenesis may prove to be 
a novel biological marker that can be added to other demonstrated prognostic and 
predictive factors in breast cancer.
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1.5.4 Interleukin-6
Cytokines and growth factors are powerful modulators of the immune response in cancer 
development and malignant disease progression, and have been the focus of numerous 
investigations.
Interleukin-6, as a key member of the interleukin family, is a multiflmctional pro- 
inflammatory cytokine, which plays a central role in regulating the immune and 
inflammatory responses, via the synthesis of most acute-phase proteins such as the C- 
reactive protein. Elevated serum interleukin-6 production is often seen in infectious 
diseases, chronic inflammatory diseases, and certain malignant diseases. It is produce by 
immune and immune-accessory cells, as well as, many non-immune cells including; 
polymorphonuclear neutrophils, monocytes / macrophages, B and T lymphocytes, mast 
cells, endothelial and mésothélial cells, fibroblasts, kératinocytes, some nerve cells and 
certain tumour cells (Gabay and Kushner, 1999; Ko vacs, 2001).
The biological activities of interleukin-6 are initiated by its binding to a specific receptor 
complex on the target cells. This is composed of an 80 kDa component receptor (IL-6R) 
that binds interleukin-6 with low affinity, and a signal-transducing component of the 130 
kDa (gpl30), which is required by the complex for the high-affinity binding of 
interleukin-6 (Kovacs, 2001; Corcoran and Costello, 2003).
The interleukin-6 receptor is present in two forms: a membrane-bound and a soluble 
form. The soluble receptors as ‘carrier’ protect cytokines from proteolytic activation and 
thereby increase their half-life in the blood. The soluble interleukin-6 receptor as an 
agonist enhances the biological effect of released interleukin-6. The soluble form of
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paracrine or autocrine mechanism (Qiu et a l, 1998; Chung and Chang, 2003).
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gpl30 is a common signal transducer not only for Interleukin-6 but also for other 
Interleukin-6 related cytokines. It is a potent endogenous antagonist that inhibits the 
effects of the interleukin-6/ soluble interleukin-6 receptor complex. This inhibitory 
activity of soluble gpl30 is enhanced by soluble interleukin-6 receptor (Kovacs, 2001).
About 70% of secreted interleukin-6 forms a complex with the soluble interleukin-6 
receptor in the blood and binds directly to membrane gpl30. The other 30% has only a 
transient existence in the blood, or binds to the membrane-bound receptor. Almost every 
cell expresses gpl30 on the membrane, in contrast to interleukin-6 receptor, which exists 
only on specific cells (Kovacs, 2001).
The interleukin-6 signalling complex can diversify its action by engaging other signalling 
pathways. Recent studies in prostate and breast cancer cells have shown that the 
interleukin-6 with its gpl30 subunit appear to induce activation of certain members of the 
epidermal growth factor receptor family, through the mitogen-activated protein kinase 
(MAPK) and the phosphatidylinositol 3 -kinase (PI3K) pathways (Qiu et a l, 1998; 
Badache and Hynes, 2001; Corcoran and Costello, 2003),
Elevated serum values of interleukin-6, soluble interleukin-6 receptor and soluble gpl30
have been reported in 20-40% of patients with certain malignant disease (Kovacs, 2001).
In patients with colorectal and prostate cancer, increased serum interleukin-6 levels have
■been shown to reflect tire disease’s status and significantly correlate with cancer stage. It 
is believed to be associated witli malignant transformation and tumour progression, by a
108
In the breast, limited numbers of studies, mostly with smaller series of selected patients, 
have shown paradoxical results on the significance of interleukin-6 and its related protein- 
receptors.
Breast tissue of normal, benign and neoplastic origin expresses a wide range of cytokines, 
including interleukin-6 (Green et aL, 1997; Kuang et aL, 1998).
In early-stage breast cancer, interleukin-6 has been correlated with good prognosis. 
Karczewska and his co-workers (2000), in a study of 75 patients with breast cancer, 
showed that the expression of interleukin-6 and its receptor subunits (interleukin-6 
receptor and gpl30) in breast cancer tissue and their cultured cells were associated with 
earlier stages of the disease in term of tumour size and lymph node involvement only 
(with no correlation to overall grade, nuclear grade, mitotic index, menopausal status, or 
oestrogen or progesterone receptor status), and proved to be a favourable prognostic 
factor for overall and disease free survival.
In another study of 149 patients with invasive breast cancer, who received no anti­
neoplastic treatments before surgery, the majority were found to express at least low 
levels of immunoreactive interleukin-6. The expression was directly related to oestrogen 
and progesterone receptor-positive cells, and inversely associated with the tumour 
histological grade and Ki67 positivity. However, no association was demonstrated 
between interleukin-6 and tumour size, nodal status, or p53 protein expression (Fontanini 
etaL, 1999).
However, contradictory results have been reported in patients with advanced breast 
cancer, in which higher serum interleukin-6 levels were demonstrated to correlate with
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the extent of metastatic dissemination and were associated with worse prognosis (Zhang 
and Adachi, 1999; Salgado et aL, 2003).
Serum interleukin-6 concentration was significantly higher in patients with metastatic 
breast cancer compared to those with loco-regional operable disease (Benoy et aL, 2002), 
and with a significant higher values detected in those patients with more metastatic 
deposits and with dominant metastatic visceral disease (such as liver metastasis or pleural 
effusion) than in those with one metastatic site or with dominant metastatic bone or soft 
tissue disease (Zhang and Adachi, 1999; Salgado et al., 2003).
Salgado and his colleagues (2003), in their study of 96 unselected consecutive patients 
with progressive metastatic breast cancer and before the initiation of systemic therapy, 
found no correlation between soluble interleukin-6 receptor and age, menopausal status, 
performance status, tumour grade, body-mass index, histology and hormone receptor 
status.
Serum interleukin-6 concentration was demonstrated to have a strong correlation with C- 
reactive protein concentrations and to be an independent prognostic factor for advanced 
and metastatic breast cancer, with significantly poorer survival rate in patients with higher 
interleukin-6 values than in patients with lower iiiterleukin-6 values (Zhang and Adachi, 
1999; Bachelot e taL, 2003; Salgado etaL, 2003).
Moreover, in recurrent and metastatic breast cancer, higher serum interleukin-6 
concentrations were found to predict a poorer response to chemo-endocrine therapy, and 
are now believed to be link to drug resistance (as with anthiacycline resistance). Patients 
unresponsive to chemo-endocrine therapy were shown to have significantly higher serum
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interleukin-6 levels than those who responded to chemo-endocrine therapy (Zhang and 
Adachi, 1999; Yokoe etaL, 2000).
A similar relationship has also been described for endocrine therapy with 
medroxyprogesterone acetate with low pre-treatment interleukin-6 levels and less 
increased interleukin-6 levels during treatment being associated with response to 
treatment (Nishimura et al., 2000).
Tumour-derived interleukin-6 may influence tumour-related angiogenesis, decrease cell 
adhesion, promote cell migration by activating the mitogen-dependent protein kinase 
pathway, and inliibit the activation of proteases involved in apoptosis and thereby 
increase chemotherapeutic resistance (Asgeirsson et aL, 1998; Benoy et aL, 2002; 
Bachelot et al., 2003).
It has been suggested that as tumours evolve toward a metastatic phenotype and interfere 
with other endogenous or exogenous factors, interleukin-6 activity on cancer cells and 
their environment might actually shift from growth inliibition and differentiation to 
proliferation and anti-apoptosis, this could explain the favourable prognosis associated 
with the presence of interleukin-6 in early-stage breast cancer and the poor survival 
associated with the high serum interleukin-6 in patients with metastatic breast cancer 
(Bachelot et al., 2003). However, the net effects of this prime pro-inflammatory mediator 
with respect to both local and systemic inflammatory responses and other pathological 
prognostic factors within the primary breast cancer have not been adequately investigated.
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1.5.5 Cyclo-oxygenase-2
The tumour microenvironment may include up-regulation of other mediators of the 
inflammatory response, which may impact tumour-cell growth and survival-signalling 
pathways (O’Byme and Dalgleish, 2001). A weight of epidemiological, phai'macological, 
genetic and expression studies suggested a key role for Cyclooxygenase-2 (COX-2) in the 
pathogenesis of a variety of epithelial human cancers, including breast cancer (Howe et 
al., 2001; Howe and Dannenberg, 2003).
The COX enzyme-system, the two isoenzymes COX-1 and COX-2, are prostaglandin 
synthases with intrinsic cyclooxygenase and peroxidase activities, which mediate the 
conversion of arachidonic acid into prostaglandins (Figure 1.9).
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Figure 1.9: Prostaglandin synthesis via arachidonic acid (from Davies, 2003).
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of mammaiy epithelial cells, fibroblasts, and osteoblasts. Indirectly, it may stimulate
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-Cyclooxygenase-derived prostanoids contribute to many normal physiological processes 
including haemostasis, platelet aggregation, kidney and gastric function, reproduction,
pain and fever (Howe et al., 2001; Howe and Dannenberg, 2003).
Despite the similar enzymatic activities of both enzymes, the COX-1 and COX-2 genes 
have distinct properties, and differing expression patterns. Both are 72-kDa proteins and 
localize to endoplasmic reticulum and nucleai’ envelope in the cell. COX-2 is glycosylated 
yielding an additional 74-kDa species. While COX-1 is constitutively expressed, COX-2 
‘the inducible isoenzyme’, is normally expressed in part of the kidney and brain but is 
over-expressed predominantly in various pathological status including cancer; in the I
tumour-epithelial cells, as well as, in the tumour-associated fibroblasts, vascular 
endothelial cells, and inflammatory mononuclear cells. Induction of COX-2 occurs by the i
upregulation of transcription and by the stabilization of COX-2 mRNA (Howe et ah, i
2001; Singh and Lucci, 2002; Howe and Dannenberg, 2003).
The exact mechanisms by which COX-2 expression is upregulated in breast carcinoma 
and contribute to carcinogenesis are still unclear, even though previous studies revealed 
that COX-2 is expressed in response to growth factors, tumour promoters, cytokines and 
several oncogenes such as HER~2/neu, Y-src, v-H a-ras, and Wnt genes (Howe et al., 
2001; Singh and Lucci, 2002; Howe and Dannenberg, 2003).
1
Mounting evidence suggests that COX-2 expression contributes to several processes 
during tumom- development and progression. Enhanced prostaglandins synthesis, the most 
obvious consequence of COX-2 overexpression, has been shown to stimulate mitogenesis
II■ :K"
mammary cellular proliferation and tumour growth, via stromal aromatase induction that 
lead to increased oestrogen biosynthesis. However, prostaglandins may have 
antiproliferative effects, which mediate immune suppression, by inhibiting T and B cell 
proliferation, dendritic cells development and function, cytokines synthesis, and 
diminishing the cytotoxic activity of natural killer cells, allowing tumours to avoid 
immune surveillance that might otherwise limit their growth. In addition, COX-2 
overexpression-related effects may result in inhibition of apoptosis, as well as, increased 
production of mutagens, such as malondialdehyde (MDA) that lead to DNA damage, 
thereby contributing to carcinogenesis. Also, it contributes to the production of several 
proangiogenic factors, including vascular endothelial growth factor (VEGF), basic 
fibroblast grov^th factor, transforming growth factor p-1, platelet-derived growth factor, 
and endothelin-1, leading to increased angiogenesis. COX-2 may enhance cancer cells 
invasion and metastasis by stimulating expression or activity of matrix metalloproteinases 
and by increasing adhesion to extracellular matrix. All of these characteristics may 
contribute to tumorigenicity, although the exact molecular mechanisms by which COX-2 
causes these effects are unknown (Howe et a l, 2001; Singh and Lucci, 2002; Howe and 
Dannenberg, 2003).
■The expression of COX-2 in human breast cancer has been evaluated in several studies 
using different methods of detection and different approaches, including reverse- 
transcriptase polymerise chain reaction (RT-PCR), western blot, and 
immunohistochemistry (IHC). Preliminary analyses, however, revealed conflicting data 
regarding the frequency of COX-2 expression and its possible prognostic significance in 
breast cancer, most probably reflecting different COX-2 expression techniques and
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smaller sample size (Costa et al., 2002; Half et al., 2002; Davies et a l, 2003; Yoshimura 
et al., 2003).
was especially apparent in a subgroup of patients with oestrogen positive receptor, low 
p53 expression, and no HER-2 amplification (Ristimaki et ah, 2002).
In another set of 221 primary breast carcinomas, Denkert and co-workers (2003) have 
investigated the expression of COX-1 and COX-2, using IHC with monoclonal antibody. 
COX-2 was found to be expressed in 36% of breast carcinoma, with a significant
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In contrast, laiger recent studies have investigated the role of COX-2 with focus on
associations of COX-2 overexpression with other clinico-pathological parameters and
possible prognostic role. In the majority, COX-2 positive tumours correlated with several
. . .poor prognostic characteristics and associated with an unfavourable outcome (Ristimaki 
et al., 2002; Denkert et ah, 2003; Spizzo et ah, 2003).
In a recent lai'ge-scale analysis of COX-2 expression in 1576 invasive breast cancer, using 
a monoclonal anti-COX-2 antibody immunohistochemistry, moderate to strong 
expression of COX-2 protein was observed in 37.4% of the tumour. COX-2
immunoreactivity localized exclusively to the cytoplasm of the tumour cells, and was not
elevated in stromal cells. Elevated COX-2 expression was associated with a large tumour 
.size, a high histological grade, a ductal histological type, with axillary node métastasés, a 
negative hormone receptor status, a high proliferation rate (identified by Ki-67), high p53 
expression, and the presence of HER-2 oncogene amplification, along with unfavourable
distant disease-free survival. Interestingly, the association with unfavourable outcomes
increased COX-2 expression in tumours > 20mm, in high-grade lesions, and in tumours
with lymph node metastasis and vascular invasion. COX-1 expression was observed in 
45% of tumour, but was significantly increased in smaller tumours (<20mm) and in 
tumours without lymph node metastasis. A significant association was obseiwed between 
COX-2 expression and decreased disease-free survival and overall survival in univariate 
analysis, with only borderline significance for disease-free survival in multivariate 
analysis. Elevated COX-1 expression, however, had no significant influence on patient 
prognosis.
Similarly, a moderate to strong cytoplasmic COX-2 staining was observed in 40.6% of 
breast cancer samples, using IHC teclinique with tissue microarry (TMA) and 
semiquantitative analysis in 600 samples of 200 patients. Increased COX-2 expression 
corresponded to higher tumour grade and stage, HER-2 amplification, lymphovascular 
invasion and a high Ki-67 proliferation index, with inverse relationship to oestrogen and 
progesterone receptor content of tumours. COX-2 overexpression, in contrast, had no 
significant association with disease-free survival or overall survival (Wulfing et a l, 
2003).
Witton and co-workers (2004) from our laboratory reported that COX-2 overexpression, 
which was observed in 21.2% of 179 patients with primary breast cancer, was not 
associated with tumour size, grade, high NPI, ER negativity, or HER 1-4 expression. 
High COX-2 expression was associated with reduced disease-fi-ee survival and disease- 
related survival in ER-negative but not ER-positive disease.
Together, these observations suggest that high COX-2 expression may serve as an 
additional unfavourable prognostic marker that may associate with adverse disease
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outcome in COX-2 positive breast cancer. However, the magnitude of the effect is likely 
to be relatively small.
Î É
117
1.5.6 Hypothesis and aims
It would appear from previous studies in patients with different stages of breast cancer 
that the information of the inter-relationship between the tmnour-based factors and the 
host-response and the relationship with disease outcome is limited.
It may be hypothesised that the local environment of cytokines, proteases, angiogenic and 
growth factors, and its subsequent systemic inflammatory response, may stimulate tumour 
growth, progression and metastasis, resulting in poor outcome.
Therefore, the aims of this thesis were to examine;
1. The prognostic significance of the systemic inflammatory response in patients 
with metastatic breast cancer.
2. The relationship between standard tumour-based clinico-pathological factors and 
the systemic inflammatory response, as evidenced by C-reactive protein and 
albumin concentrations, measured prior to surgery, and their prognostic 
significance in patients with invasive primary operable (loco-regional) breast 
cancer.
3. The inter-relationship between the local inflammatoiy response, as evidenced by 
tumour infiltration of T-lymphocyte sub-populations and macrophages, systemic 
inflammatory response, as evidenced by C-reactive protein and albumin 
concentrations measured prior to surgery, and tumour-based clinico-pathological
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factors, including tumour proliferative activity and microvessel density, and their 
prognostic significance in patients with invasive primary operable breast cancer.
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CHAPTER 2: EVALUATION OF AN INFLAMMATION-BASED PROGNOSTIC 
SCORE (GPS) IN PATIENTS WITH METASTATIC BREAST CANCER.
2.1 Introduction
Breast cancer is the second most common cause of cancer-related death among women in 
the Western world (CancerStats, www.cancenesearchuk.org; Jemal et a l, 2003). 
Approximately 10% of newly diagnosed breast cancer patients have locally advanced 
and/or metastatic disease at the time of presentation (Li et al., 2003; Sant, 2001). In 
addition, more than 40% of patients, who are diagnosed with eaily-stage breast 
carcinoma, will eventually experience later recurrence and/or metastatic disease (Early 
Breast Cancer Trialists' Collaborative Group, 1998b).
Metastatic breast carcinoma exhibits a great deal of variability in its clinical presentation 
and behaviour. The prognosis is generally poor with a median overall survival of 
approximately 2 to 3 years (Ali et ah, 2003; Bernard-Marty et a l, 2004). Current 
therapies are palliative, aiming at improving or maintaining quality of life, controlling 
symptoms, and prolonging survival. Nevertheless, specific subgroups of patients exist for 
which, depending on the site of metastasis and treatment given, survival may range from 
a few months to several years (Nomuia, 1998; Insa et a l, 1999). This prognostic I  
uncertainty has driven the search for well standar dised laboratory based parameters which 
have prognostic value.
Previous studies have established the prognostic importance of the systemic inflammatory 
response, as evidenced by an elevated circulating C-reactive protein concentration, in 
patients with advanced solid tumours (O’Gorman et a l, 2000; Mahmoud and Rivera,
120
2002; Maltoni et a l, 2005) including breast cancer (Albuquerque et a l, 1995; Zhang and 
Adachi, 1999). Recently, it has been shown that, using established cutoffs, a combination 
of an elevated C-reactive protein and hypoalbuminaemia, the Glasgow Prognostic score 
(GPS) has prognostic value, independent of stage and performance status, in patients with 
inoperable non-small cell lung cancer (Forrest et ah, 2003; 2004; 2005). However, there 
is no information on the prognostic value of this combination in patients with metastatic 
breast cancer.
The aim of the present study is to examine the relationship between the GPS and survival 
in patients with metastatic breast cancer.
121
2.2 Patients and methods
Breast cancer patients presenting, with metastatic relapse, to a single oncology clinic in 
the Beatson Oncology centre between February 2002 and November 2004 and who had a 
measurement of C-reactive protein and albumin undertaken were included in the study. 
At this time no patients showed clinical evidence of infection or other inflammatory 
conditions.
All patients had confiimed metastatic disease on the basis of either clinical findings or 
imaging. Patients were group according to whether they soft tissue and/ or bone 
métastasés, visceral métastasés and visceral and soft tissue and/ or bone métastasés. 
Oestrogen receptor (ER) status was considered as positive when nuclear staining was seen 
in > 10% of cancer cells.
Patients who developed other malignancies, and patients with C-reactive protein 
measur ed during a course of taxane therapy were excluded firom the study since they may 
produce a hypersensitivity reaction and elevated concentrations of interleukin-6 (Tsavaris 
et al., 2002; Williams et ah, 2003) which is a primary mediator of C-reactive protein 
(Gabay and Kushner, 1999). In total, 96 out of 295 (33%) patients with metastatic disease 
were eligible for the study.
The study was approved by the Research Ethics Committee of the North Glasgow NHS 
Trust.
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Routine laboratory measurements of C-reactive protein and albumin concentrations were 
carried out. The coefficient of variation was less than 5% as established by routine quality 
control procedures. The limit of detection of the assay is a C-reactive protein 
concentration of less than 6 mg/1,
The GPS was constmcted as previously described (Forrest et ah, 2003). Briefly, patients 
with both an elevated C-reactive protein (>10 mg/1) and hypoalbuminaemia (<35 g/1) 
were allocated a score of 2, Patients in whom only one of these biochemical abnormalities 
was present were allocated a score of 1. Patients in whom neither of these abnormalities 
was present were allocated a score of 0.
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Statistics
Grouping of the variables was carried out using standard thresholds. Survival (cancer- 
specific) analysis was performed using the Cox proportional hazard model. Deaths up to 
3D  ^ May 2005 have been included in the analysis. Multivariate survival analysis was 
performed using a stepwise backward procedure to derive a final model of the variables 
that had a significant independent relationship with survival. To remove a variable from 
the model, the corresponding f-value had to be greater than 0.10. Analysis was 
performed using SPSS software (SPSS Inc., Chicago, XL, USA).
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2.3 Results
The baseline clinicopathological characteristics of the patients with metastatic breast 
cancer (n=96) are shown in Table 2.1. The majority of patients were over 50 years of age 
(78%), and received active tieatment (96%). C-reactive protein and albumin 
concentrations were measured prior to systemic therapy in 35 patients and during 
systemic therapy in 61 patients. In all, 72 (75%) patients had not received cytotoxic 
chemotherapy for metastatic disease prior to the measurement of C-reactive protein and 
albumin concentrations.
In all, 92 (96%) patients received active treatment in the form of chemotherapy and/ or 
endocrine therapy. In those patients in whom Her-2 status was assessed, 14 out of 47 
patients were Her-2 positive and 11 of the 14 patients received Herceptin therapy. The 
majority of patients had C-reactive protein (53%) and albumin (94%) concentrations in 
the normal range; the GPS was elevated in 47% of patients. Of the 6 patients with 
hypoalbuminaemia, all had an elevated C-reactive protein concentration.
The minimum follow-up was 7 months; the median follow-up of the suivivors was 16 
months. During this period 51 patients died of their cancer. On univariate analysis, an 
elevated C-reactive protein (P<0.01), hypoalbuminaemia (P<0.05), the GPS (P<0.001) 
and treatment (P<0.05) were associated with poor cancer-specific survival. On 
multivariate analysis of the GPS and treatment, only the GPS (HR 2.26, 95% Cl 1.45- 
3.52, P<0.001) remained significantly associated with cancer-specific sui*vival.
The relationship between clinicopathological characteristics and an inflammation-based 
prognostic score (GPS) in patients witli metastatic breast cancer is shown in Table 2.2.
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The median survival in these patients was 24 months, 13 months and 1 month for a GPS 
of 0, 1 and 2 respectively (Figure 2.1).
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2.4 Discussion
In the present study, a simple inflammation-based prognostic score (GPS) based on 
standard laboratory measurements of C-reactive protein and albumin, was an independent 
predictor of survival in patients with metastatic breast cancer. This work is consistent 
with previous work in patients with inoperable non-small cell lung cancer (Forrest et aL, 
2003; 2004; 2005) and improves on the prediction of survival using an elevated C- 
reactive protein alone (Albuquerque et ah, 1995; Zhang and Adachi, 1999). If these 
results are confirmed in larger studies, the GPS may be useful in the assessment of 
advanced breast cancer patients at diagnosis and the stratification of patients entering 
randomised trials.
In the present study, performance status was not recorded in the majority of patients. 
However, almost all the patients received active treatment and this would suggest that 
they had similar’ good performance status. Moreover, performance status is subjective 
(Ando et al., 2002) and the GPS has been shown to be a prognostic factor, independent of 
performance status in patients with inoperahle non-small cell lung cancer (Forrest et al., 
2003; 2004). Other recognized prognostic factors, which have been shown to affect 
survival post relapse, such as oestrogen receptor status and disease free interval, did not 
reach statistical significance. This was probably due to the small number of patients in the 
present study. In contrast, an increasing GPS, (in particular 0 vs 1) was associated with a 
halving of survival. These results may point to the strength of the systemic inflammatory 
response (the GPS) in predicting survival in the patient with metastatic breast cancer.
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It has been previously shown that, in patients with inoperable non-small cell lung cancer 
at diagnosis, approximately three-quarters of patients had an abnormal GPS (1 or 2) and 
that these patients had a significantly poorer outcome (Forrest et ah, 2003; 2004). It was
of interest that, in the present study, although the proportion of patients with an abnormal
.GPS was less (47%), those metastatic breast cancer patients with a GPS of 2 had a isimilarly poorer survival. It may be that the prognostic value of the GPS is independent of 
tumour type in patients with advanced cancer (Elahi et al., 2004).
The mechanisms by which a systemic inflammatory response (the GPS) might impact on 
survival in advanced cancer patients are still not well defined. It may reflect the pro- 
inflammatory cytokine activity, in particular interleukin-6 (McKeown et ah, 2004), which 
not only stimulates breast tumour growth (Kurebayashi, 2000), but also produce profound 
catabolic effects on host metabolism (McMillan et al., 1998; Kotler, 2000). In this way,
the presence and magnitude of a clnonic systemic inflammatory response may produce 
progressive nutritional and functional decline, ultimately resulting in reduced survival. 
Indeed, this concept is consistent with the observation in the present study that all patients 
with hypoalbuminemia had an elevated elevated C-reactive protein concentration.
'I
At the time of diagnosis, there are well-established prognostic factors on which to base 
the prediction of likely survival in cancer patients. In contrast, predicting survival of 
patients with advanced disease is more problematic. As a result, clinicians often 
overestimate survival (Christakis and Lamont, 2000; Glare et ah, 2003). The results of the i f  
present study suggest that the GPS may be useful in the assessment of survival in patients 
with metastatic breast cancer. It is simple to use and based on routinely available, well- 
standardised measurements. i
:
îTable 2.1: Clinico-pathological characteristics in patients with metastatic breast 
cancer, univariate survival analysis.
Age (<50/ >50yeaxs)
Prior cytotoxic chemotherapies
Patients 
(n== 96) 
21/75
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Hazard ratio 
(95% Cl) 
0.70(0.38-1.31)
(0/> l)
Metastatic site
(Non-visceral/ visceral/ both) 43/14/ 39 1.08 (0.79-1.48)
Oestrogen receptor status 
(positive/ negative)
Disease free interval 
(>2/ <2 years)
White cell count 
(<11/>11x10%
Haemoglobin 
(>12/<12g/dl)
C- reactive protein 
(<10/>10 mg/1)
Albumin concentration 
(>35/<35 g/1)
GPS 
(0/ 1/ 2)
Treatment
(Herceptin/active/supportive) 11/81/4 2.29 (1.02-5.19)
P-value
0.266
72/24 1.42 (0.76-2.65) 0.266
0.625
63/27 1.17(0.65-2.12) 0.594
67/29 1.16(0.63-2.11) 0.633
74/3 1.13 (0.15-8.34) 0.904
46/30 1.75 (0.90-3.42) 0.100
51/45 2.50 (1.40-4.48) 0.002
90/6 3.41 (1.33-8.72) 0.011
51/39/6 2.26(1.45-3.52) <0.001
0.046
I
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Table 2.2: The relationship between clinico-pathological characteristics and an 
inflammation-based prognostic score (GPS) in patients with metastatic breast 
cancer.
GPSO GPS 1 GPS 2 P-value
(n= 51) (n=39) (n-6)
Age (<50/ >50years) 10/41 10/ 29 1/5 0.751
Prior cytotoxic chemotherapies
(0/> l) 36/15 32/7 4/2 0.409
Metastatic site
(Non-visceral/ visceral/ both) 24/9/18 16/ 5/18 3/0 /3 0.684
Oestrogen receptor status
(positive/ negative) 27/ 18 30/9 6/0 0.061
Disease free interval
(>2/ <2 years) 35/16 27/12 5/1 0.756
White cell count
(<11/>11x10% 40/1 28/2 6/0 0.580
Haemoglobin
(>12/ <12 g/dl) 26/14 18/12 2/4 0.334
Treatment
(Herceptin/ active/ supportive) 9/ 42/0 2/ 33/ 4 0 /6 /0 0.044
Survival (months) 23.8 12.7 1.2
(20.2- 27.5) (5.1-20.3) (0.7-10.4) <0.001
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Figure 2.1: The relationship between an inflammation-based prognostic score (GPS, 
0,1,2 from top to bottom) and survival in patients with metastatic breast cancer.
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CHAPTER 3: EVALUATION OF THE RELATIONSHIP BETWEEN THE 
SYSTEMIC INFLAMMATORY RESPONSE AND CANCER SPECIFIC 
SURVIVAL IN PATIENTS WITH PRIMARY OPERABLE BREAST CANCER.
3.1 Introduction
Breast cancer is the commonest female malignancy and is a major cause of morbidity and 
mortality in the Western World. For example, in the UK, there are approximately 42,000 
new patients each year and almost 13,000 deaths attributable to the disease (CancerStats, 
2003).
It is increasingly recognised that variations in outcome in cancer patients are not solely 
detennined by the characteristics of the tumour but also by the host-response factors 
(Balkwill and Mantovani, 2001; Coussens and Werb, 2002). However, the tumour-host 
interaction is complex and has yet to be fully understood. It is now accepted that the host 
systemic inflammatory response can be assessed by examining the changes in the 
concentrations of acute phase proteins, such as elevated circulating concentrations of C- 
reactive protein and low concentrations of albumin (Gabay and Kushner, 1999). It is of 
interest that, either singly or combined, these factors have been shown to be stage 
independent prognostic factors in patients with a variety of advanced cancers (McMillan 
et al., 2001b; Mahmoud and Rivera, 2002; Forrest et al., 2003; Crumley et al., 2006a).
There is also some evidence that the systemic inflammatory response has prognostic 
value in patients with metastatic breast cancer. For example, previous studies have 
reported that the presence of elevated circulating concentrations of C-reactive protein 
(Williams et al., 1990; Albuquerque et al., 1995; Zhang and Adachi, 1999; Chapter 2) and
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low concentrations of albumin (Heys et aL, 1998; Chapter 2) are associated with poorer 
survival.
However, few studies have examined the prognostic value of the systemic inflammatory 
response in patients with primary breast cancer (Mortensen and Rudczynski, 1982; Lis et 
aL, 2003). Those studies appear to have produced conflicting results with regard to 
whether C-reactive protein or albmnin concentrations have independent prognostic value. 
For example, Mortensen and Rudczynski (1982) studied almost 300 patients with a 
follow-up period of 3-48 months post-surgery and reported that the presence of an 
elevated C-reactive protein concentrations was not an independent prognostic factor. In 
contrast, Lis and coworkers (2003) reported that, in almost 200 patients with a follow-up 
period of 6-84 months, albumin was a stage independent prognostic factor. However, in 
both these studies the median follow-up was limited and approximately 20% of patients 
studied had advanced disease.
Therefore, the prognostic value of C-reactive protein and albumin in patients with 
primary operable breast cancer remains unclear. The aim of the present study was to 
examine the relationship between clinico-pathologic status, C-reactive protein and 
albumin concentrations, measured prior to surgery, and cancer specific survival in 
patients with invasive primary operable breast cancer.
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3.2 Patients and methods
Three hundred patients presenting with invasive primary operable breast cancer to two 
hospitals (Western Infirmary, Glasgow and Wishaw General Hospital, Lanarksliire) in the 
West of Scotland between June 2001- July 2003 were prospectively included in the study.
The extent of deprivation was derived from the 1991 census, using the postcode of 
residence at diagnosis (Carstairs and Morris, 1990; Carstairs and Morris, 1991). The 
results are presented by amalgamating the seven categories into three groups: affluent 
(categories 1 and 2), intermediate (categories 3-5) and deprived (categories 6 and 7).
Clinico-pathological data including age, deprivation category, histological type, tumour 
size, and grade, lymph node status, oestrogen (ER) and progesterone (PR) receptor status. 
The type of surgery and the use of adjuvant treatment (chemotherapy, hormonal therapy 
and radiotherapy) were recorded.
Routine pre-operative laboratory measurement of C-reactive protein, albumin and wliite 
cell count were carried out. At this time no patients showed clinical evidence of infection 
or other active chronic inflammatory conditions such as rheumatoid arthritis or crohn’s 
disease. The coefficient of variation for these measurements was less than 10% as 
established by routine quality control procedures. The limit of detection of C-reactive 
protein concentration assay was 6 mg/1, with the upper limit of normal values being <10 
mg/1.
The study was approved by the local Research Ethics committees.
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Statistics
As appropriate, data are presented as median and range, and comparisons between patient 
groups were carried out using the Chi-Square-test or Mami-Whitney U test. Statistical 
analysis was based on the seven individual deprivation categories. Grouping of the 
laboratory variables was carried out using standard thresholds (Goldwasser and Feldman, 
1997; O'Gorman et aL, 2000; McMillan et aL, 2001b; Maltoni et aL, 2005).
The correlation between C-reactive protein, white cell counts and albumin concentrations 
was performed using the Spearman’s Rank correlation. Relapse-free, cancer-specific, 
overall survival analyses of the group variables were performed using the Cox 
proportional hazard model. Deaths up to the end of May 2006 were included in the 
analysis. Multivariate survival analyses, including all covariates that were significant on 
univariate analysis, were performed using a stepwise backward procedure to derive a final 
model of the variables that had a significant independent relationship with survival. To 
remove a variable from the model, the corresponding F-value had to be greater than 0.10. 
Analysis was performed using SPSS software version 13.0 (SPSS Inc., Chicago, IL, 
USA).
'1Ï
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3.3 Results
The baseline clinico-pathological characteristics of the patients with primary operable 
breast cancer (n=300) are shown in Table 3.1. Two hundred and thirty three patients 
(78%) patients were over 50 years of age; 82 (27%) were in the most deprived categories 
6 and 7.
Of the 300 patients, 254 (85%) patients had ductal carcinoma, 122 (41%) had a tumour 
greater than 2 cm, and 130 (43%) had axillary lymph node involvement. The majority of 
patients had tumour grade II/ III (81%) disease. Sixty two (21%) had oestrogen receptor 
negative tumouis. Twenty out of 300 (7%) patients had evidence of pre-existing co­
morbidity, such as liver dysfunction, cardiovascular disease or diabetes mellitus. In one 
patient this was severe enough to interfere with planned adjuvant treatment. In all, 288 
(96%) patients received adjuvant treatment in the form of endocrine therapy and/or 
chemotherapy.
The majority had a wliite cell count, albumin and C-reactive protein concentrations in the 
normal range (96%, 100% and 88% respectively) prior to surgery. Wliite cell count was 
correlated with C-reactive protein 0.13, P=0.023) but not albumin concentration (rs= 
0.03, P=0.587). Albumin was correlated with C-reactive protein concentration (rg= -0.19, 
P=0.002).
The minimum follow-up was 35 months; the median follow-up of the suivivors was 46 
months. During this period, 37 patients relapsed and 25 died of their cancer; a fiirther 14 
patients died of intercurrent disease.
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On univariate survival analysis, age (P<0.10), tumour type (P<0.10), tumour size 
(F<0.0001), grade (F<0.01), lymph node involvement (F<0.01), hormone receptor status 
(P<0.0001), albumin (P<0.001), loco-regional treatment (P<0.0001) and systemic 
treatment (P<0.0001) were significantly associated with relapse-firee survival (Table 3.1). 
On multivariate analysis of these significant covariates, age (HR 5.02, 95% Cl 1.49- 
16.93, f=0.009), tumour size (HR 2.34, 95% Cl 1.18-4.62, P=0.015), albumin (HR 3.65, 
95% Cl 1.71-7.78 P=0.001), loco-regional treatment (HR 2.56, 95% Cl 1.17-5.59, 
f=0.019) and systemic treatment (HR 2.26, 95% Cl 1.54-3,32, P<0.0001) were 
significant independent predictors of relapse-free survival.
On univariate survival analysis, tumoui’ size (P<0.0001), grade (P<0.01), lymph node 
involvement (P<0.001), hormone receptor status (P<0.0001), albumin (P<0.01), loco- 
regional treatment (P<0.0001) and systemic treatment (P<0.0001) were significantly 
associated with cancer-specific survival (Table 3.1). On multivariate analysis of these 
significant covariates, tumour size (HR 2.53, 95% Cl 1.15-5.55, P=0.021), albumin (HR 
4.44, 95% Cl 1.60-12.28, P=0.004), loco-regional treatment (HR 3.55, 95% Cl 1.30-9.67, 
P-0.013) and systemic treatment (HR 2.67, 95% Cl 1.56-4.57, P<0.0001) were 
significant independent predictors of cancer-specific survival.
On univariate survival analysis, age (P<0.10), tumour size (P<0.0001), grade (P<0.05), 
lymph node involvement (P<0.05), hormone receptor status (P<0.01), albumin 
(P<0.001), loco-regional treatment (P<0.01) and systemic treatment (P<0.001) were 
significantly associated with overall smvival (Table 3.1). On multivariate analysis of 
these significant covariates, age (HR 4.19, 95% Cl 1.26-13.91, P=0.019), albumin (HR 
3.33, 95% Cl 1.60-6.90, P-0.001), tumour size (HR 2.48, 95% Cl 1.36-4.55, P=0.003)
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and systemic treatment (HR 2.10, 95% Cl 1.45-3.05, P<0.0001) were significant 
independent predictors of overall survival.
Patients were then grouped according to albumin concentrations (>43/ <43g/1) as shown 
in Table 3.2. A lower serum albumin concentiation (<43g/1) was associated with 
deprivation (P<0.05), hormonal receptor negative tumours (P<0.01) and significantly 
poorer 3-year relapse free (85% vs 93%, P=0.001) cancer specific (87% vs 97%, 
P<0.0001) and overall survival (84% vs 94%, P=0.001) rates.
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3.4 Discussion
Predicting recurrence and survival following potentially curative surgical resection for 
primary operable breast cancer, is conventionally based on standard clinico-pathological 
criteria such as age, tumour size and grade, nodal status and hormonal receptor status. 
However, it was of interest that other host-related factors, such as the systemic 
inflammatory response, have previously been shown to be associated with poor survival 
following a potentially curative resection for a variety of cancers including gastro- 
oesophageal, pancreatic, colorectal, and urinary bladder cancers (McMillan et ah, 2003; 
Hilmy et ah, 2005; Jamieson et ah, 2005; Crumley et ah, 2006b).
In the present study, albumin but not C-reactive protein was a significant, stage 
independent, predictor of survival in patients with primary operable breast cancer. The 
relationship between albumin concentrations and outcome are tlierefore consistent with 
those previously reported in patients with advanced breast cancer (Heys et ah, 1998; 
Chapter 2).
Previous studies have shown that elevated C-reactive protein concentrations have 
prognostic value in patients with a variety of primary operable tumours (Ikeda et ah, 
2003; McMillan et ah, 2003; Hilmy et ah, 2005; Jamieson et ah, 2005) and also in 
patients with advanced breast cancer (Williams et ah, 1990; Albuquerque et ah, 1995; 
Zhang and Adachi, 1999; Chapter 2). It was therefore was unexpected that C-reactive 
protein, either as a continuous or categorical variable, was not a significant prognostic 
factor in the present study.
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The basis of this observation is not clear. However, an elevated C-reactive protein 
concentration (>10mg/l) was seen in only 12% of patients, a lower proportion than 
previously seen in both primary operable disease (approximately 20-40%) and in 
advanced cancer (approximately 40-80%). This may, in part, reflect the relatively small 
number of events relating to relapse-ffee survival, cancer specific and overall survival in 
the present study.
It was of interest that, of the two acute phase proteins examined in the present study, 
albumin, generally considered to be a relatively insensitive measure of the systemic 
inflammatory response, had independent prognostic value, even with values within the 
normal range. It has been previously shown that small reduction in albumin 
concentrations are associated with certain comorbid conditions such as liver dysfunction, 
cardiovascular disease or diabetes mellitus and poorer survival in the general population 
(Goldwasser and Feldman, 1997). In the present study only 7% of patients had such 
comorbidity; only one patient had plaimed adjuvant treatment altered, and therefore this 
would suggest that there may be an interaction between breast cancer and albumin 
concentrations which might impact on the smvival of these patients.
The mechanism by which a low serum albumin might impact on relapse-free, cancer- 
specific and overall survival is not clear. It may reflect the biological functions of 
circulating albumin including binding and transporting of hormones and giowth factors, 
inhibition of platelet function and tlrrombosis (Margarson and Soni, 1998). Furthermore, 
albumin in the breast cancer cell cytosol may inhibit tumour growth (Soreide et aL, 1991), 
and tumour cell proliferation by modulating the activities of autocrine growth regulatory 
factors (Laursen et aL, 1990).
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In the present study, conventional prognostic factors, including tumour size, histological 
grade, nodal status and hormonal receptor status were significant on univariate analysis. 
However, including potentially curative loco-regional treatment and systemic treatment 
that based on hormonal-receptor status in the multivariate analysis, nodal status was not 
independently significant. This probably reflects the close association between nodal 
status and the treatment received and their relative impact on relapse and survival.
Nevertheless, lower albumin concentrations prior to surgery, even those within the normal 
range, may be a sensitive measure of those patients likely to recur and therefore be used 
to identify high risk patients and alter their treatment accordingly. Furthermore, a follow- 
up measure of albumin, after the systemic inflammatory response of treatment has 
resolved, may be of a value to establish whether treatment of the primaiy tumour has 
resulted in recovery of albumin concentrations (McMillan et aL, 2003; Hilmy et aL, 2005; 
Jamieson et aL, 2005). Clearly, further studies are required to establish the prognostic 
value of pre-operative albumin concentrations and to determine whether longitudinal 
albumin concentrations may also be of value.
In summary, the results of the present study suggest that pre-operative albumin 
concentration predicts survival, independent of tumour-based factors, in patients 
undergoing potentially curative surgery for primary operable breast cancer.
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Table 3.2; The clinico-pathological characteristics of patients with invasive primary 
operable breast cancer according to albumin concentrations.
Albumin >43 g/1 Albumin <43 g/1 (P-value)
Age (<50/ >50 years) 
Deprivation (1-2/ 3-5/ 6-7)*
(n= 155) 
35/120 
26/ 90/ 39
(n= 114) 
26/88 
13/68/33
0.965
0.011
Type (Special type/ Lobular/ Ductal)
Size (<20/ 21-50/ >50 mm)
Grade ( I /I I /I I I )
Involved lymph node (0/1-3/ >3) 
Hormonal-receptor status 
(ER+ PR4-/ ER+ PR- or unknown / ER- PR- 
or unknown)
8/17/130 
96/ 57/ 2 
31/72/ 52 
93/47/ 15
80/ 47/ 28
3/15/ 96 
62/49/3 
18/ 65/30 
60/35/ 18
35/ 54/25
0.524
0.384
0.201
0.269
0.002
White cell count (1071)** 6.8 (3.6-13.9) 7.0 (3.4-17.4) 0.920
White cell count (<8.5/ 8.5-11/ >11 xlO %  127/ 18/ 8 83/ 27/ 3 0.281
C- reactive protein (mg/1)** <6 (<6-57) <6 (<6-66) 0.138
C-reactive protein (<10/>10 mg/1) 136/ 19 102/12 0.660
Loco-regional tieatment 
(Mastectomy or conservation surgery + 
radiotherapy/ mastectomy + radiotherapy) 
Systemic treatment (ER-based treatment) 
(Hormonal/ hormonal + chemotherapy/ 
chemotherapy/ none)
120/35
74/ 52/25/3
78/36
64/25/21/4
0.098
0.185
3 years relapse-free survival rate***
3 years cancer-specific survival rate*** 
3 years overall survival rate***
93(2)
97 (1) 
94(2)
85 (3)
87 (3) 
84 (3)
0.001
<0.0001
0.001
*: Individual deprivation categories were used in the statistical analysis, **: median 
(range), ***: 3 year survival rate (SE).
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CHAPTER 4; THE RELATIONSHIP BETWEEN THE SYSTEMIC 
INFLAMMATORY RESPONSE, TUMOUR PROLIFERATIVE ACTIVITY, T-
4.1 Introduction
It is now recognised that the development of cancer and its progression is dependent on a 
complex interaction of the tumour and the host inflammatory response (Balkwill and 
Mantovani, 2001; Coussens and Werb 2002; Vakkila and Lotze 2004). Recently, the 
systemic inflammatory response, as evidenced by elevated circulating concentrations of 
C-reactive protein and hypoalbuminaemia, has been shown to be independently 
associated with poorer survival in patients with advanced disease (McMillan et aL,
1
LYMPHOCYTIC AND MACROPHAGE INFILTRATION, MICROVESSEL 
DENSITY AND SURVIVAL IN PATIENTS WITH PRIMARY OPERABLE 
BREAST CANCER.
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2001b; Forrest et aL, 2003; Maltoni et aL, 2005) including breast cancer (Albuquerque et If
aL, 1995; Zhang and Adachi, 1999; Chapter 2). There is also some evidence that these 
acute phase proteins have independent prognostic value in primary operable disease 
(McMillan et aL, 2003; Jamieson et aL, 2005; McMillan et aL, 2007) including breast
:
cancer (Lis et aL, 2003; Chapter 3). 7
In animal models, at least, it would appear that the cell-mediated immune response is 
more important than humoural immunity in preventing the progression of cancer and 
there is some evidence that cell-mediated immunity can bring about tumour regression. 
The principal cells involved in the cell-mediated response are T-lymphocytes and 
macrophages (O’Sullivan and Lewis, 1994; Lee et aL, 1996; Ogmundsdottir, 2001;
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Whiteside, 2003; Lee et aL, 2006). However, this immune response, in particular the local 
environment of cytokines, proteases, angiogenic/ growth factors, and the resulting 
systemic inflammatory response, may, in turn, stimulate tumour growth and metastasis 
(O’Sullivan and Lewis, 1994; Lewis et aL, 1995; Leek et aL, 1996; Leek and Harris, 
2002; Yu and Rak, 2003; Lewis and Pollai’d, 2006),
A number of studies have observed that, in breast tumours, there is a difflise infiltrate of 
T-lymphocytes and macrophages (Lee et aL, 1996; Lee et aL, 2006). Also, that there is an 
association with better outcome in patients with a moderate or marked diffuse 
inflammatory pattern in the subgroup of high grade cases (Pupa et aL, 1996; Lee et aL, 
2006). Recently, the use of immunohistochemical techniques to reliably identify and 
assess tumour-infiltrating T-lymphocytes subsets and macrophages has led to renewed 
interest in the relationship between the tmnour inflammatory infiltrate and cancer specific 
survival in a variety of common solid tumours. With reference to tumour CD4+ T- 
lymphocytic infiltration a significant association with survival has been shown in renal 
(Bromwich et aL, 2003), prostate (McArdle et aL, 2004) colorectal (Caima et al., 2005) 
and head and neck cancers (Badoual et aL, 2006). However, few studies have examined 
the association between tumour CD4+/ CD8+ T-lymphocytic infiltration and/or CD68+ 
macrophage infiltration and survival in patients with primary operable breast cancer 
(Griffith et aL, 1990; Wintzer et aL, 1991; Leek et aL, 1996; Toi et aL, 1999; Tsutsui et 
aL, 2005).
Griffith and coworkers (1990), as well as, Wintzer and coworkers (1991) have both 
reported that disease-free survival and overall survival in breast cancer patients were not 
influenced by the tumour' infiltration of any lymphocyte subset. However, these were
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relatively small studies of less than 80 patients. In contrast, different monocyte subsets Ai:
appeared to either be associated with good or poor disease-free survival (Toi et aL, 1999). 
Furthermore, in studies between 100 -250 cases, there was conflicting evidence as to 
whether or not CD68+ macrophage infiltration was superior to microvessel density in
■Ipredicting disease-free survival (Leek et aL, 1996; Tsutsui et aL, 2005).
1
1:
Therefore, the inter-relationship between local and systemic inflammatory responses and 
its prognostic significance in patients with primary operable breast cancer remains 
unclear. The aim of the present study was to examine the relationship between circulating 
concentrations of C-reactive protein and albumin, tumour infiltration of T-lymphocyte 
subpopulations and macrophages and survival in patients who had undergone potentially 
curative surgical resection for invasive primary operable breast cancer.
I
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4.2 Patients and methods
Lanarkshire) in the West of Scotland between June 2001- December 2002 were studied 
prospectively.
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A
One hundred and sixty eight patients presenting with invasive primary operable breast 
.cancer to two hospitals (Western Infirmary, Glasgow and Wishaw General Hospital, If
ii
Clinico-pathological data included the age, deprivation category, histological type and 
grade (Figure: 4.1 - 4.14), tumour size, lymph node status, and oestrogen (ER) and
progesterone (PR) receptor status. The type of surgery and the use of adjuvant treatment 
(chemotherapy, hormonal therapy and radiotherapy) were recorded.
The extent of deprivation was derived from the 1991 census, using the postcode of 
residence at diagnosis (Carstairs and Morris, 1990; Carstairs and Morris, 1991). The
'-.iresults are presented by amalgamating the seven categories into three groups: affluent 
(categories 1 and 2), intermediate (categories 3-5) and deprived (categories 6 and 7).
Routine pre-operative laboratory measurement of C-reactive protein, albumin and white 
cell count were carried out. At this time no patients showed clinical evidence of infection 
or other inflammatory conditions. The coefficient of variation for these measurements 
was less than 10% as established by routine quality control procedures. The limit of 
detection of C-reactive protein concentration assay was 6 mg/1, with the upper limit of 
normal values being < lOmg/I.
■
rr ;
■The study was approved by the local Research Ethics committees.
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'Immunohistochemistrv
Slides were dewaxed in xylene for 4 minutes twice and rehydrated through graded 
alcohols then rinsed with water.
The following mouse monoclonal antibodies were used: CD4 (Vector, Peterborough, UK) 
at dilution of 1:10, CDS (Dako, Cambridgeshire, UK) at dilution of 1:1000, CD68 (Dako, 
Cambridgeshire, UK) at dilution of 1:200, Ki-67 (Dako, Cambridgeshire, UK) at dilution 
of 1:500 and CD34 (Novocastra, Newcastle upon Tyne, UK) at dilution of 1:50.
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For the immuno-histochemistry of CD4+ and CD8+ (T-lymphocytes), CD68+ (tumour
associated macrophages), Ki-67 (proliferative index) and CD34+ (microvessel density), 
.blocks from the primary tumour were fixed in 10% buffered formalin in saline and 
embedded in paraffin wax. One representative block of tumour was selected for each
patient. Serial individual sections (4pm) were cut and mounted on slides coated with 
aminopropyltriethoxysilane and placed in oven at 56 °C for 40 minutes.
'
.Antigen retrieval for CD4, CDS, CD68 and Ki-67 was earned out by microwaving in Tris
EDTA buffer solution (0.555g Sodium EDTA, 0.825g Trisma base in 1.5 litre distilled
water; PH: 8) for 5 minutes under full pressure in a plastic pressure cooker m a 850W 
.microwave on full power. For CD34, antigen retrivel was carried out using 1 % trypsin in 
1% CaCl2 solution (0.1 g CaCH, 0.1 g trypsin in 100ml H2O) at 37°C for 25 minutes.
'  " i #
Staining method for CD4, CDS, CD68 and Ki-67 was as follows:
1. 5% Normal Goat Serum 20 minutes.
2. Primary antibody 30 minutes.
3. Wash in Tris Buffered Saline (TBS),
4. Hydrogen Peroxide blocking agent (Dako S2023).
5. Wash in TBS.
6. Envision (Dako, Cambridgeshire, UK) 30 minutes.
7. Wash in TBS.
8. DAB (Dako, Cambridgeshire, UK) 10 minutes.
9. Wash in water.
Staining method for CD34 was as follows:
1. Blocking solution (ISjil horse serum per 1ml TBS) 20 minutes.
2. Primary antibody 60 minutes.
3. Wash in TBS for 5 minutes.
4. Envision (Dako, Cambridgeshire, UK) 30-60 minutes.
5. Wash in TBS for 5 minutes.
6. DAB (Dako, Cambridgeshire, UK) 2-10 minutes.
7. Wash in water for 10 minutes.
Appropriate positive controls were included in each run. Negative controls were stained 
using antibody diluting fluid alone.
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Tissues were counter-stained with haematoxylin for 15 seconds then wash with water, |  
followed by scotts water for another 30 seconds before washing them with water. Then, 
copper enhancement for CD4, CDS, CD68 and Ki-67 was carried out for 5 minutes then 
wash with water. Finally, Slides were dehydrated through graded alcohols 70%, 90% and 
100% and then xylene. The slides were cleared, mounted with Pertex and appropriate 
slide covers applied.
lL-6 staining
I
I
Previous attempts to reliably identify regions of IL-6 expression in colorectal and bladder 
cancers were unsuccessful. Different methods of antigen retrieval and staining, with the 
use of negative and positive controls, have been tried. However, the background staining 
precluded accurate scoring of IL-6 positive cells in the tumour tissue sections. The 
reasons for this poor quality of IL-6 immunostaining are unclear. On inspection of 
previous equivalent IL-6 staining in colorectal carcinoma by Kinoshita and co-workers S
(1999), it would appear likely that non-specific binding by the primary antibodies was a 
problem. Therefore, the unsuccessful results of IL-6 immunostaining have precluded
further attempts to be undertaken, including this study on breast tumours. I
■I
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Morphometry
CD4+, CD8+ and CD68+
CD34+
Quantitative analysis of the microvessel density was performed by selecting the three 
most vascular areas (hot spots), where the highest numbers of discrete microvessels were 
stained, at low power (x40 and xlOO). Counting of discrete vessels was performed with a 
magnification of x 200, using a 25- point Chalkley grid as described by Hansen et al. 
(2000a,b; Figure: 4.23 and 4.24).
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Quantitative analysis of the lymphoid infiltrate (CD4+ and CD8+) and tumour associated 
macrophages (CD68+) were performed using a point counting method (Anderson and 
Dunnill, 1965) with a random sampling technique. With this method, the volume 
occupied by any given component (volume density) is expressed as a percentage of the 
total volume of the tissue. A 100-point ocular grid was used at x 400 magnification and 
30 fields were counted per case for CD4+, CD8+ and CD68+ immunopositive cells 
(Figure: 4.15-4.20).
I
.1 ,5
Ki-67
a;The percentages of Ki-67-reactive tumour cells were evaluated at x 400 magnification by 
scoring a minimum of 1000 tumour cells in randomly selected fields (Ki-67 labelling 
index; Figure: 4,21 and 4.22). I
■li
■a:
Only fields containing tumour (including tumour nest and surroimding tissues stroma) 
were counted. Any normal tissue on the slide was excluded from the analysis. All cases 
were counted by the author (AA). For the purpose of assessing inter-observer 
reproducibility, a second observer (JB) and (MH) independently scored the slides for T- 
lymphocytes (CD4+ and CD8+), and the tumour associated macrophages (CD68+) and 
CD34+ respectively. The intra-observer intraclass correlation coefficients (ICCC) were as 
follow; CD4+ = 0.71, CD8+ = 0.93, CD68+ -  0.79, Ki67 -  0.98 and CD34+ = 0.93. The 
inter-observers ICCC were as follow; CD4+ = 0.69, CD8+ = 0.78, CD68+ = 0.67, and 
CD34+ = 0.94 (ICCC values > 0.6 were considered acceptable and ICCC > 0.9 were 
considered excellent). The observers were blinded to the clinical outcome of the patient.
151
Figure 4.1: Invasive ductal carcinoma- Grade I (xlOO).
Figure 4.2: Invasive ductal carcinoma- Grade I (x200).
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Figure 4.3: Invasive ductal carcinoma- Grade II (xlOO).
¥
Figure 4.4: Invasive ductal carcinoma- Grade II (x200).
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Figure 4.5: Invasive ductal carcinoma- Grade III (xlOO).
Figure 4.6: Invasive ductal carcinoma- Grade III (x200).
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Figure 4.7: Invasive lobular carcinoma- Grade I (xlOO)
m
Figure 4.8: Invasive lobular carcinoma- Grade I (x200).
155
Figure 4.9: Invasive lobular carcinoma- Grade II (xlOO).
Figure 4.10: Invasive lobular carcinoma- Grade II (x200).
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Figure 4.11: Invasive lobular carcinoma- Grade III (xlOO).
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Figure 4.12: Invasive lobular carcinoma- Grade III (x200).
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#Figure 4.13: Invasive mucinous carcinoma- Grade I (xlOO).
Figure 4.14: Invasive mucinous carcinoma- Grade I (x200).
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Figure 4.15: CD4+ immunohistochemical staining in invasive breast 
cancer (x200).
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Figure 4.16: CD4+ immunohistochemical staining in invasive breast
cancer (x400).
159
Figure 4.17: CD8+ immunohistochemical staining in invasive breast 
cancer (x200).
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f tFigure 4.18: CD8+ immunohistochemical staining in invasive breast
cancer (x400).
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Figure 4.19: CD68+ immunohistochemical staining in invasive breast 
cancer (x400).
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wÈm.Figure 4.20: CD68+ immunohistochemical staining in invasive breast
cancer (x400).
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Figure 4.21: Ki67 immunohistochemical staining in invasive breast cancer 
(x200).
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Figure 4.22: Ki67 immunohistochemical staining in invasive breast cancer
(x400).
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Figure 4.23: CD34+ immunohistochemical staining in invasive breast 
cancer (x200).
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Figure 4.24: CD34+ immunohistochemical staining in invasive breast 
cancer (x200).
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Statistics
Data ai e presented as median and range. Grouping of the laboratory variables was carried 
out using standard thresholds (Goldwasser and Feldman, 1997; O’Gorman et ah, 2000; 
McMillan et ah, 2001b; Maltoni et ah, 2005). For the purpose of analysis, the tumour 
Ki67 proliferative index, and T-lymphocytes subset populations (CD4+ and CD8+) and 
tumour associated macrophages (CD68+) were grouped by tertiles, and microvessel 
density (CD34+) was grouped by vascular' grade; based on Chalkley mean count with cut­
off points at 5 and 7 as described by (Hansen et ah, 2000a,b). The relationships between 
these and other variables were analysed using the Mantel-Haenszel (X^) test for trend and 
Spearman rank correlation as appropriate.
Survival analysis was performed using the Cox proportional hazard model. Multivariate 
survival analysis was performed using stepwise backwai'd procedure to derive a final 
model of the variables that had a significant independent relationship with survival. To 
remove a variable fi*om the model, the corresponding P-value had to be a greater than 
0.10. Deaths up to the end of March 2007 were included in the analysis. Analysis was 
performed using SPSS software (SPSS Inc., Chicago, IL, USA).
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4.3 Results
The baseline clinico-pathological characteristics of the patients with primary operable 
breast cancer (n=168) are shown in Table 4.1. One hundred and thirty six (81%) patients 
were over 50 years of age, and 49 (29%) were in the most deprived categories 6 and 7.
Of the 168 patients, one hundred and forty two (85%) patients had ductal carcinoma, 100 
(60%) had a tumour less than 2 cm and 139 (83%) had a grade 11/ III tumour. Ninety four 
(56%) patients had no axillary lymph node involvement. Thirty five patients (21%) had 
oestrogen receptor negative tumorrrs.
Prior to surgery the majority had a white cell count, albumin and C-reactive protein 
concentrations in the normal range (96%, 100% and 85% respectively). C-reactive protein 
concentration was correlated with albumin concentration (rs= -0.24, F~0.003) but not 
white cell count (rs= 0.13, P=0.100).
In all, 162 (97%) patients received adjuvant treatment in the form of endocrine therapy 
and/or chemotherapy. The minimum follow-up was 52 months; the median follow-up of 
the survivors was 60 months. During this period, 20 patients relapsed and 15 died of their 
cancer. On univariate survival analysis, lymph node involvement (f<0.0001), hormone 
receptor status (f<0.05), albumin (P<0.01), Ki-67 (P<0.05), microvessel density CD34+ 
(P<0.05), loco-regional treatment (f<0.0001) and systemic treatment (f<0.01) were 
significantly associated with relapse-free survival (Table 4.1). On multivariate analysis of 
these significant covariates, albumin (HR 3.55, 95% Cl 1.15-11.00, P=0.028), loco- 
regional treatment (HR 5.00, 95% Cl 1.71-14.60, R-0.003) and systemic treatment (HR 
1.76, 95% Cl 1.03-3.02, P=0.038) were significant independent predictors of relapse-firee
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survival. When albumin was excluded from the multivaiiate analysis, only hoimone 
receptor status (HR 1.80, 95% Cl 0.96-3.39, f=0.068), and loco-regional treatment (HR 
6.79, 95% Cl 2.57-17.98, P<0.0001) were independently associated with poorer relapse- 
free survival.
On univariate survival analysis, lymph node involvement (P<0.01), hormone receptor 
status (P<0.05), albumin (P<0.01), Ki-67 (R<0.05), microvessel density CD34+ (P<0.05), 
loco-regional treatment (P<0.0001) and systemic treatment (P<0.01) were significantly 
associated with cancer-specific survival (Table 4.1). On multivariate analysis of these 
significant covariates, albumin (HR 5.67, 95% Cl 1.24-25.88, P=0.025), loco-regional 
treatment (HR 6.07, 95% Cl 1.63-22.54, P=0.007) and systemic treatment (HR 2.22, 95% 
Cl 1.22-4.07, P=0.010) were significant independent predictors of cancer-specific 
survival. When albumin was excluded from the multivariate analysis, only loco-regional 
treatment (HR 8.70, 95% Cl 2.41-31.42, P=0.001) and systemic treatment (HR 2.47, 95% 
Cl 1.30-4.71, P=0.006) were independently associated with poorer cancer-specific 
survival.
The inter-relationships between clinico-pathological characteristics are shown in Table 
4.2. In all patients, high tumour grade was positively associated with negative hormonal- 
receptors tumours (P<0.001), high Ki-67 labelling index (P<0.001) and high expression 
of CD34+ (P<0.01), CD68+ (P<0.05), CD4+ (P<0.05) and CD8+ (P<0.05). Similarly, 
Ki-67 labelling index was positively associated with CD34+ (P<0.001), CD68+ 
(P<0.001), CD4+ (P<0.001) and CD8+ (P<0.01) T-lymphocytes. Negative hormonal- 
receptors tumours were directly associated with lower albumin concentrations (P<0.05), 
high Ki-67 labelling index (P<0.001) and the presence of CD68+ (P<0.05) and CD8+
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II(P<0.05). An elevated C-reactive protein concentration was positively associated with the 
expression of CD34+ (P=0.05) and the presence of CD4+ T-lymphocytes (P<0.05).
■1-
i
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Microvessel density CD34+ was positively associated with the presence of CD68+ 
(P<0.01) and CD4+ T-lymphocytes (P<0.05). Tumour associated macrophages CD68+ 
were positively correlated with tumour CD4+ (P<0.01) and CD8+ (P<0.001) T- 
lymphocytes. Tumour CD4+ T-lymphocytes were also positively associated with CD8+ 
T-lymphocytes (P<0.001).
■3
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4.4 Discussion
!
111 the present study, increased tumour grade and Ki-67 labelling index were associated 
with increased infiltration by CD68+ tumour associated macrophages, CD4+ and CD8+ 
T-lymphocytes and increased tumour micro vessel density in patients with primary
.operable breast cancer. Furthermore, increased Ki-67 labelling index and micro vessel 
density were associated with poorer relapse hree and cancer survival. These results may 
be consistent with the concept that there is an active immune response to poor tumour cell 
differentiation and increased proliferative activity in these patients which results in 
increased angiogenesis (Pupa et al., 1996; Tsutsui et ah, 2005; Lee et al., 2006). 
Alternatively, it may reflect a more passive consequence of increased cytokine excretion 
from high grade proliferating tumours that attracts macrophages and T lymphocytes and 
increases microvessel density. Irrespective, these results together with previous studies 
suggest that these tumour immune-cellular infiltrates, in particular of macrophages, may 
in fact promote angiogenesis and disease progression (Leek et ah, 1996; Tsutsui et a l,
■ il:.,2005).
Previous studies have shown that tumour CD4+ T-lymphocyte infiltration was associated 
with poor outcome, independent of grade or stage, in patients with a variety of cancer 
including renal and prostate cancer (Bromwich et ah, 2003; McAi'dle et al., 2004). 
However, in the present study, the extent of tumour lymphocytes and macrophages 
infiltration was not a significant prognostic marker in determining disease-outcome,
consistent with previous studies (Griffith et al., 1990; Wintzer et al., 1991; Vgenopoulou 
et al., 2003).
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Recently, Lee and coworkers (2006) in 700 patients with stage 1 and 2 breast cancer and a 
median follow-up period of nearly 10 years reported that, on simple staining with 
haematoxylin and eosin, there was a significant relationship between the extent of both 
macrophage and lymphocytic infiltration and cancer specific survival. Although, 
moderate or marked diffuse inflammation was present in only 10% of tumoui's, only 
moderate or dense tumour inflammatory infiltrates were associated with a better 
prognosis in the subset of patients with grade 3 carcinomas.
The apparent discrepancies in the results of the present study and those of Lee and his co­
workers (2006) and some other previous studies may reflect methodological differences, 
including the subsets of immune-cellular infiltrates examined and the way in which the 
inflammatory infiltrates were assessed. In the present study, the subsets of the tumour 
cellular infiltrates were identified by immunoliistochemistiy and the density was assessed 
using a point counting technique. This approach provided a more objective assessment 
and circumvents the problem of variation in distribution within an individual tumour. In 
addition, some previous studies have not included the type of surgery and/ or the adjuvant 
treatment received in their survival analysis. However, the relatively limited number of 
events and the relatively short follow-up period in our study should also be taken into 
account.
In the present study, also consistent with previous works, increased tumour grade, Ki-67 
labelling index (Veronese et ah, 1993; Scholzen and Gerdes, 2000; Trihia et aL, 2003; 
Tsutsui et al., 2005) and microvessel density (Hansen et al., 2000a,b; Uzzan et al., 2004; 
Tsutsui et al., 2005) were significantly associated with poorer relapse hee and cancer- 
specific survival. However, none of tumour-based prognostic factors, including
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histological grade, nodal status, hormonal receptor status, Ki67 proliferative index, and 
CD34+ microvessel density, were independently significant when potentially curative 
loco-regional and systemic treatment based on hormonal-receptor status, were included in 
the multivariate survival analysis. This probably reflects the close association between the 
risk-assessment and the treatment received and their relative impact on relapse and 
survival. Also, adjuvant chemotherapy, in addition to its direct cytotoxic effect on cancer 
cells, might attenuate surgery-stimulated tumour cell proliferation and tumour growth 
possibly occurring at distant dormant or indolent micrometastases, which might follow 
the excision of primary tumour with its subsequent angiogenic surge that result from the 
removal of the inhibitors secreted by or in response to the primary tumour, or to 
appearance of stimulators or growth factors in response to surgical wounding (Retsky et 
ah, 2004). Furthermore, adjuvant chemo-radiotherapy may be effective by virtue of its 
cellular-immune suppression and modification of specific host-immune related 
mechanisms, which may persist for few years after adjuvant treatment (Reizenstein et al., 
1985; Stewart and Tasi, 1993).
In contrast, the systemic inflammatory response, as evidenced by lower albumin 
concentrations, was significant on both univariate and multivariate survival analysis. 
Therefore, the present study examines, for the first time in patients with primary operable 
breast cancer, the relationship between the preoperative systemic inflammatory response, 
tumour-based factors and outcome, and suggests that the systemic inflammatory response 
is more closely related to cancer specific relapse and survival.
In the present study it was of interest that albumin but not C-reactive protein, which are 
relatively insensitive and sensitive measure of the systemic inflammatory response
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respectively (Gabay and Kushner, 1999), had independent prognostic value in patients 
with primary operable breast cancer. This relationship between albumin, tumour 
recurrence and cancer specific survival was present even in patients with values within 
the normal range.
The basis of this observation is not clear but it may be that chronic illness, reflected by a 
lower albumin (Goldwasser and Feldman, 1997), also impacts on cancer survival. 
Alternatively, since a lower albumin concentration was directly associated with hormone 
receptor negative tumours, an unfavourable prognostic sign, it may, in part, reflect the 
biological functions of circulating albumin that include binding and transporting of 
hormones and growth factors (Margarson and Soni, 1998), inhibiting growth in the breast 
tumour-cell cytosol (Soreide et aL, 1991) and tumour proliferation by modulating the 
activities of autocrine growth regulatory factors (Laursen et al., 1990).
Other intracellular signalling systems may play important roles in regulating cancer-cell 
survival and progression pathways during different tumour stages. For example, growing 
evidences suggest that the Nuclear Factor- k B  with its associated pathways may represent 
the key cellular mediators that modulate poor genes expression and prognostic markers 
within the tumour, as well as, the host-cellular immune response in a variety of malignant 
diseases including breast cancer (Haffher et al., 2006).
In summary, the results of the present study show the interrelationships between systemic 
and tumour-based factors and cancer specific outcome in patients with primary operable 
breast cancer. The host inflammatory responses appear to be closely related to poor 
tumour differentiation and malignant disease progression in primary invasive operable
171
disease. Only pre-operative albumin concentration, loco-regional and systemic treatments 
were independent predictors of relapse-free and cancer-specific survival.
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CHAPTERS; CONCLUSION
In the present studies, the results suggest a potential independent prognostic value of the 
systemic inflammatory response, as evidenced by lowered albumin concentrations witli/ 
without elevated circulating C-reactive protein concentrations, particularly in patients 
with advanced metastatic disease, and early-staged breast cancer. Also, the local host- 
inflammatory response in eaily-staged invasive disease appears to be closely related to 
poor tumour differentiation and malignant disease progression.
In patients with advanced metastatic breast cancer, the mechanisms by which a systemic 
inflammatory response, as evidenced by higher inflammatory-based score (GPS), might 
impact on survival may reflect the underlying activities of pro-inflammatory cytokines, in 
particular interleukin-6 (McKeown et ah, 2004), which not only stimulate tumour growth 
(Kurebayashi, 2000), but also produce profoimd catabolic effects on host metabolism 
(McMillan et al., 1998; Kotler, 2000). The presence and magnitude of a chronic systemic 
inflammatory response may result in progressive nutritional and functional decline that 
ultimately result in reduced survival, consistent with tlie observation of this study which 
showed that all patients with metastatic breast cancer who had hypoalbuminemia had an 
elevated C-reactive protein concentration.
Therefore, the potential value of the systemic inflammatory-based score (GPS) in 
predicting the advanced breast cancer patient’s suivival is encouraging but clearly 
requires to be validated on an independent set of patients with a larger sample size. In 
addition to, head-to-head direct comparisons with other scoring systems that are used to 
predict survival in advanced metastatic breast cancer such as performance status.
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Furthermore, a combination of tliese clinico-pathological factors together with the GPS 
may allow more accurate prognostication (Chang et aL, 2003; Maltoni et al., 2005; 
Kattan, 2006). Also, the systemic inflammatory-based score may be used to identify 
patients most likely to benefit from the systemic immune-modulation using anti­
inflammatory agents.
In those patients with early-staged breast cancer, there are well-established prognostic 
factors at the time of diagnosis on which to base the prediction of likely suiwival. It was 
of interest that the GPS does not appear to have value in primary operable disease, 
primarily due to majority of patients having C-reactive protein and albumin 
concentrations in the normal range (< 1 0  mg/1 and > 3 5  g/1, respectively). However, 
albumin as a continuous or categorical variable (split at 43 g/1) did have prognostic value 
in early-staged invasive breast cancer, and was superior to tumour-based factors including 
angiogenesis. Therefore, the addition of these simple well-standardised measurements 
that reflect the ongoing host-tumom* interaction in the routine management of early-staged 
disease at initial presentation may be useful in identifying those high-risk patients that are 
likely to relapse and, therefore, adjust or alter their treatment accordingly. Clearly, further 
studies with large cohort and against conventional prognostic factors and established 
scores; either in comparison or added to a prognostic score such as the Nottingham 
Prognostic Index (Hansen et al., 2000b), are required to establish the prognostic value of 
pre-operative, as well as, post operative (longitudinal) measures of circulating albumin 
and C-reactive protein concentrations.
Within the tumour microenvironment of primary early-staged invasive breast cancer, 
increased tumour grade and proliferative activity (Ki-67 labelling index) were associated
17.
with increased tumour cell-mediated immune infiltrations (CD68+ tumour associated 
macrophages, CD4+ and CD8+ T-lymphocytes) and increased tumour angiogenesis 
(microvessel density). These results may be consistent with the concept that there is an 
active immune response to poor tumour cell differentiation and increased proliferative 
activity, which may result in increased angiogenesis (Pupa et al., 1996; Tsutsui et ah, 
2005; Lee et ah, 2006). Alternatively, it may reflect a more passive consequence of 
increased cytokine excretion from high grade proliferating tumours that attracts 
macrophages and T-lymphocytes and increases microvessel density. Irrespectively, these 
results together with previous studies suggest that these immune-cellular infiltrates, in 
particular of macrophages, may in fact promote angiogenesis and disease progression 
(Leek et ah, 1996; Tsutsui et ah, 2005) and, therefore, may represent an important target 
for selective immuno-modulation or immuno-inhibitoiy therapy in breast cancer.
The results of the present studies, therefore, emphasize the inter-relationship between the 
tumour-host inflammatory responses and other conventional prognostic factors with 
outcomes in breast cancer. However, the exact underlying molecular mechanisms of this 
intimate association are poorly understood.
These findings parallel recent findings in animal models of human cancer. These have 
established that inflammation is a critical component of both tumour-promotion and 
tumour-progression (Balkwill et ah, 2005; Karin, 2006).
At the biological level, it appears to involve complex network interactions of intracellular 
and extracellular signals that contiol multiple underlying processes. In recent years the 
transcription factor, Nuclear Factor- kappaB (NF-kB), and associated pathways have
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emerged as a critical mediators for the inflammation-associated tumour growth and 
progression, as well as, an important modulator of the immune response and tumour 
surveillance that associated with high cell proliferation, poor differentiation and 
unfavourable prognosis (Rayet and Gelinas, 1999; Hagemann et ah, 2005; Wu and Krai, 
2005).
Nuclear Factor-KB transcription factor is a key cellular regulatory molecule of the human 
immune stress response and of the cell survival pathway, which mediates a wide variety 
of target genes expression that influence developmental, cell-cycle progression and 
physiological processes; such as cellular proliferation, differentiation and apoptosis, as 
well as, immunity, inflammation, and acute phase responses, and also other diseases 
processes including tumour survival pathways; such as tumour growth, invasion, 
angiogenesis and metastasis (Pahl, 1999; Rayet and Gelinas, 1999; Li and Verma, 2002; 
Wu and Krai, 2005).
Different signal-transduction pathways selectively activate different NF-kB complexes in 
a coordinated manner, however, it is not known how these pathways integrate the diverse 
extracellular signals and maintain specificity in the context of gene transcription. 
Pleiotropic extracellular stimuli including various physiological, physical, and oxidative 
stress stimuli, as well as, cytokines, interleukins, growth factors and chemotherapeutic 
agents interact with cell surface receptors. The intracellular signalling pathways are then 
transmitted in either a linear or a network manner leading to the activation of NF-kB, 
mostly through IkB kinase (IKK)-dependent phosphorylation with subsequent 
degradation and release of its inhibitor (the IkB family of proteins) that result in nuclear 
translocation of NF-kB and its binding to DNA at specific kB sites which are then
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followed by a rapid induction and modulation of expression of variety of encoding genes 
involved in normal cell survival and physiological pathways and diseases processes (Pahl, 
1999; Chen et al., 2001 ; Wu and Krai, 2005).
Previous studies have implicated deregulation and/or sustained activation of the 
transcription Nuclear Factor-KB family and its associated pathways in a variety of 
malignant diseases in which NF-kB is overexpressed (Rayet and Gelinas, 1999). 
Activation of NF-kB does not appear to be confined to a unique stage during tumour 
development and progression, and has been postulated to be required for the regulation of 
different characteristics of the tumour (Hafhier et ah, 2006). In addition, there is an 
increasing body of evidence which delineates the role of the Nuclear Factor-KB in linking 
inflammation and cancer. However, the mechanisms underlying their association remain 
unclear (Rayet and Gelinas, 1999; Hagemann et al., 2005; Hafhier et al., 2006).
In particular, it is still unclear whether the increased production of the pro-inflammatory 
cytokines is the cause or the result of NF-kB activation, and whether NF-KB activation in 
the immune system influences mammary cancer (Li and Verma, 2002; Lin and Karin, 
2007).
Recent studies in human breast cancer cell lines and animal models of breast cancer have 
implicated the NF-kB transcription factors signalling systems in mammaiy cai'cinogenesis 
and progression via a number of target genes and mechanisms that are linked to breast 
tumoui* cell proliferation, growth, differentiation and pro-survival pathways (cyclin D l, 
BRCA2, tumour necrosis factor-a), tissue invasion (matrix metalloproteinase, urokinase 
plasminogen activator, cell adhesion molecules such as ICAM-1), tumoui* angiogenesis
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and metastasis (VEGF, cyclooxygenase-2, inducible nitric-oxide synthase), resistance to 
anticancer chemotherapeutic agents and ionizing radiation, such as doxorubicin, taxols, 
topoisomerase inhibitors, and with y-radiation (Figure 5.1; Rayet and Gelinas, 1999; Wu 
and Krai, 2005; Haffner et al., 2006). Furthermore, molecular approaches have 
documented antagonistic cross-talk between the NF-kB and ER pathways by 1
Î
%./A'
demonstrating the ability of oestrogen-activated ER to inhibit NF-kB signals. In a specific 
subclass, NF-kB activity may be implicated in the conversion to less differentiated and 
hormone-independent tumours; a characteristic of more aggressive and metastatic 
tumours. For example, a positive correlation has been observed between NF-kB activation 
and over-expression of epidermal growth factor receptor family members (erbB-2), 
especially in oestrogen receptor negative tumours (Biswas et al., 2005; Zhou et al., 2005; 
Biswas and Iglehart, 2006; Haffiier et ah, 2006). Therefore, it would be of interest to re­
examine the prognostic value of the acute-phase proteins (C-reactive protein and albumin) 
in a cohort of patients with primary operable ER-negative tumours.
At present, there is little evidence of a prominent role of active immunosui’veillance in 
breast cancer. Instead, tumour-cellular infiltrate may be subverted to promote tumour 
progression and metastasis. For example, tumour-associated macrophages secrete 
cytokines, such as IL-6 and IL-10, which act on proliferation, survival and metastasis of 
tumour cells and promote angiogenesis (Haffiier et al., 2006). The in-vitro interaction of 
tumour cells with macrophages, in a JNKII- and NF-kB-dependent manner, induces 
macrophages to release matrix metalloproteinases and so support tumour cell invasion 
(Hagemann et al., 2005). Furthermore, NF-kB inhibitors have been found to blunt the 
action of some of these cytokines in tumour cells. Whether NF-kB inhibitors could also 
act on tumour-associated macrophages and prevent the secretion of tumoui* growth and
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invasion promoting cytokines remain to be shown (Haffiier et ah, 2006). On the other 
hand, reduced NF-kB signalling in immune cells fiom patients with cancer may also 
contribute to tumour progression (Rayet and Gelinas, 1999).
TUMOUR INITIATION
METASTASIS PROLIFERATION
r
IL-10
NF-KB
Acute-phase proteins
CHEMO-RESISTANCE ANTI-APOPTOSIS
ANGIOGENESIS
Figure 5.1: Possible link and relationship between NF-kB, cytokines (IL-6 & IL-10), 
acute-phase proteins and breast cancer promotion/ progression (Balkwill et aL, 
2005; Wu and Krai, 2005; Lin and Karin, 2007).
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The determination of the transcriptional outcome of Nuclear Factor-KB activation remains 
.a challenging task, because the detection of nuclear’ localization and DNA binding does 
not always predict which NF-kB target genes are actually transcribed. These target genes 
are also dependent on its post-transcriptional modifications, as well as, the cell type. 
Thereby, the analysis of the downstream genes that are regulated by the NF-kB, in 
addition, is likely to provide important insight into its function. This should be integrated 
with clinical information on outcomes to establish the prognostic and predictive 
significance of NF-kB in breast cancer (Li and Verma, 2002; Wu and Krai, 2005; Haffner 
et al., 2006).
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